U.S. patent application number 10/795482 was filed with the patent office on 2006-01-26 for interleukin-8 homologous polypeptides and therapeutic uses thereof.
This patent application is currently assigned to GENENTECH, INC.. Invention is credited to Dan L. Eaton, Dorothy French, J. Christopher Grimaldi, Kenneth J. Hillan, Maria Teresa Pisabarro, Kerstin N. Schmidt, Victoria Smith, Daniel Tumas, Richard Vandlen, Colin K. Watanabe, P. Mickey Williams, William I. Wood.
Application Number | 20060019307 10/795482 |
Document ID | / |
Family ID | 27108223 |
Filed Date | 2006-01-26 |
United States Patent
Application |
20060019307 |
Kind Code |
A1 |
Eaton; Dan L. ; et
al. |
January 26, 2006 |
Interleukin-8 homologous polypeptides and therapeutic uses
thereof
Abstract
The present invention is directed to novel polypeptides having
structural homology to IL-8 and to nucleic acid molecules encoding
those polypeptides. Also provided herein are vectors and host cells
comprising those nucleic acid sequences, chimeric polypeptide
molecules comprising the polypeptides of the present invention
fused to heterologous polypeptide sequences, antibodies which bind
to the polypeptides of the present invention and to methods for
producing the polypeptides of the present invention. Further
provided herein are methods for treatment and diagnosis of
inflammatory diseases.
Inventors: |
Eaton; Dan L.; (San Rafael,
CA) ; French; Dorothy; (Redwood City, CA) ;
Grimaldi; J. Christopher; (San Francisco, CA) ;
Hillan; Kenneth J.; (San Francisco, CA) ; Pisabarro;
Maria Teresa; (Dresden, DE) ; Schmidt; Kerstin
N.; (San Francisco, CA) ; Smith; Victoria;
(Burlingame, CA) ; Tumas; Daniel; (Orinda, CA)
; Vandlen; Richard; (Hillsborough, CA) ; Watanabe;
Colin K.; (Moraga, CA) ; Williams; P. Mickey;
(Half Moon Bay, CA) ; Wood; William I.;
(Hillsborough, CA) |
Correspondence
Address: |
SIDLEY AUSTIN BROWN & WOOD LLP;ATTN: DC PATENT DOCKETING
1501 K STREET, N.W.
WASHINGTON
DC
20005
US
|
Assignee: |
GENENTECH, INC.
|
Family ID: |
27108223 |
Appl. No.: |
10/795482 |
Filed: |
March 9, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10015967 |
Dec 7, 2001 |
|
|
|
10795482 |
Mar 9, 2004 |
|
|
|
09941992 |
Aug 28, 2001 |
|
|
|
10015967 |
Dec 7, 2001 |
|
|
|
PCT/US01/06520 |
Feb 28, 2001 |
|
|
|
10015967 |
Dec 7, 2001 |
|
|
|
09709238 |
Nov 8, 2000 |
|
|
|
10015967 |
Dec 7, 2001 |
|
|
|
PCT/US00/23328 |
Aug 24, 2000 |
|
|
|
10015967 |
Dec 7, 2001 |
|
|
|
PCT/US00/08439 |
Mar 30, 2000 |
|
|
|
10015967 |
Dec 7, 2001 |
|
|
|
09380137 |
|
|
|
|
10015967 |
Dec 7, 2001 |
|
|
|
PCT/US99/12252 |
Jun 2, 1999 |
|
|
|
10015967 |
Dec 7, 2001 |
|
|
|
60090696 |
Jun 25, 1998 |
|
|
|
Current U.S.
Class: |
435/7.1 ;
435/320.1; 435/325; 435/348; 435/456; 435/69.52; 530/351;
536/23.5 |
Current CPC
Class: |
C07K 14/52 20130101;
C12Q 2600/158 20130101; G01N 33/6863 20130101; G01N 33/6869
20130101; C12Q 1/6883 20130101; G01N 33/564 20130101; C07K 14/47
20130101; C12Q 2600/136 20130101; C07K 14/5421 20130101; G01N
33/6893 20130101; C07K 14/705 20130101 |
Class at
Publication: |
435/007.1 ;
435/069.52; 435/320.1; 435/325; 530/351; 435/348; 435/456;
536/023.5 |
International
Class: |
G01N 33/53 20060101
G01N033/53; C07H 21/04 20060101 C07H021/04; C12P 21/04 20060101
C12P021/04; C12N 5/06 20060101 C12N005/06; C07K 14/54 20060101
C07K014/54 |
Claims
1-32. (canceled)
33. A method of diagnosing an immune related disease in a mammal
comprising providing a test sample of tissue cells from said mammal
detecting the presence or absence of a PRO842 polypeptide in said
test sample of tissue cells, wherein the presence or absence of the
PRO842 polypeptide in said test sample is indicative of the
presence of an immune related disease in said mammal.
34. A method of diagnosing an immune related disease in a mammal
comprising providing a test sample of tissue cells from said mammal
contacting an anti-PRO842 antibody with said test sample of tissue
cells and detecting the presence or absence of the formation of a
complex between said antibody and said PRO842 polypeptide, wherein
formation of said complex indicates the presence of an immune
related disease in said mammal from which said test sample of
tissue cells were obtained.
35. The method of claim 34 wherein said immune related disease is
an immune-mediated inflammatory disease.
36. The method of claim 34 wherein said immune related disease is a
non-immune-mediated inflammatory disease.
37. The method of claim 34 wherein said immune related disease is
an infectious disease.
38. The method of claim 34 wherein said immune related disease is
an immunodeficiency disease.
39. The method of claim 34 wherein said immune related disease is a
neoplasia.
40. The method of claim 34 wherein said immune related disease is
selected from the group consisting of: systemic lupus
erythematosis, rheumatoid arthritis, juvenile chronic arthritis,
spondyloarthropathies, systemic sclerosis, idiopathic inflammatory
myopathies, Sjogren's syndrome, systemic vasculitis, sarcoidosis,
autoimmune hemolytic anemia, autoimmune thrombocytopenia,
thyroiditis, diabetes mellitus, immune-mediated renal disease,
demyelinating diseases of the central nervous systems,
demyelinating diseases of the peripheral nervous system,
hepatobiliary diseases, inflammatory bowel disease,
gluten-sensitive enteropathy, and Whipple's disease, autoimmune or
immune-mediated skin diseases, psoriasis, allergic diseases,
immunologic diseases of the ovaries, immunologic diseases of the
lung, transplantation associated diseases, viral diseases, AIDS,
herpes, bacterial infections, fungal infections, protozoal
infections, parasitic infections, infectious diseases,
immunodeficiency disease and neoplasia.
41. The method claim 40 wherein said idiopathic inflammatory
myopathy is selected from the group consisting of dermatomyositis
and polymyositis.
42. The method of claim 40 wherein said autoimmune hemolytic anemia
is selected from the group consisting of immune pancytopenia and
paroxysmal nocturnal hemoglobinuria.
43. The method of claim 40 wherein said autoimmune thrombocytopenia
is selected from the group consisting of idiopathic
thrombocytopenic purpura and immune-mediated thrombocytopenia.
44. The method of claim 40 wherein said thyroiditis is selected
from the group consisting of Grave's disease, Hashimoto's
thyroiditis, juvenile lymphocytic thyroiditis and atrophic
thyroiditis.
45. The method of claim 40 wherein said immune-mediated renal
disease is selected from the group consisting of glomerulonephritis
and tubulointerstitial nephritis.
46. The method of claim 40 wherein said demyelinating disease is
selected from the group consisting of multiple sclerosis,
idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome,
and chronic inflammatory demyelinating polyneuropathy.
47. The method of claim 40 wherein said hepatobiliary disease is
selected from the group consisting of hepatitis A, hepatitis B,
hepatitis C, hepatitis D, hepatitis E, autoimmune chronic active
hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and
sclerosing cholangitis.
48. The method of claim 40 wherein said inflammatory bowel disease
is selected from the group consisting of ulcerative colitis and
Crohn's disease.
49. The method of claim 40 wherein said autoimmune or
immune-mediated skin disease is selected from the group consisting
of bullous skin diseases, erythema multiforme and contact
dermatitis.
50. The method of claim 40 wherein said allergic disease is
selected from the group consisting of asthma, allergic rhinitis,
atopic dermatitis, food hypersensitivity and urticaria.
51. The method of claim 40 wherein said allergic disease is
selected from the group consisting of eosinophilic pneumonia,
idiopathic pulmonary fibrosis and hypersensitivity pneumonitis.
52. The method of claim 40 wherein said transplantation associated
disease is selected from the group consisting of graft rejection
and graft-versus-host-disease.
53. The method of claim 40 wherein said immune related disease is
lupus erythematosis.
54. The method claim 53 wherein said antibody is a monoclonal
antibody.
55. The method of claim 40 wherein said immune related disease is
rheumatoid arthritis.
56. The method claim 55 wherein said antibody is a monoclonal
antibody.
57. The method of claim 40 where in said neoplasia is a breast
neoplasia.
58. The method claim 57 wherein said antibody is a monoclonal
antibody.
59. The method of claim 40 wherein the neoplasia is a lung
neoplasia.
60. The method claim 59 wherein said antibody is a monoclonal
antibody.
61. The method of claim 40 wherein the neoplasia is a colon
neoplasia.
62. The method claim 61 wherein said antibody is a monoclonal
antibody.
63. The method of claim 34 wherein said anti-PRO842 antibody
further comprises a detectable label.
64. The method of claim 34 wherein said antibody is selected from
the group consisting of a monoclonal antibody, a humanized
antibody, an antibody fragment, a single-chain antibody and an
anti-idiotypic antibody.
65. The method of claim 34 wherein said antibody is a monoclonal
antibody comprising nonhuman complementary determining region
residues and human framework region residues.
66. The method of claim 34 wherein said antibody is an agonist
antibody.
67. The method of claim 34 wherein said antibody is an antagonist
antibody.
68. The method of claim 34 wherein said antibody is immobilized on
a solid support.
69. The method of claim 34 wherein said anti-PRO842 antibody is in
admixture with a pharmaceutically acceptable carrier.
70. The method of claim 34 wherein said detection of the formation
of a complex is carried out by a process selected from the group
consisting of light microscopy, flow cytometry and flourimetry.
Description
[0001] This application is a continuing application (filed under 35
U.S.C. .sctn. 120) which application claims priority to U.S.
Provisional Application No. 60/090,696, filed on Jun. 25, 1998; and
to which U.S. Provisional Application claims priority under 35
U.S.C. .sctn.119; and also claims priority to International PCT
Application Nos.: PCT/US99/12252, filed on Jun. 2, 1999;
PCT/US00/08439, filed on Mar. 30, 2000; PCT/US00/23328, filed on
Aug. 24, 2000; and PCT/US01/06520, filed on Feb. 28, 2001; to which
International PCT Applications claim priority under 35 U.S.C.
.sctn.120; and also claims priority to U.S. patent application Ser.
No. 09/380,137, filed on Aug. 25, 1999; Ser. No. 09/709,238, filed
on Nov. 8, 2000; and Ser. No. 09/941,992, filed on Aug. 28, 2001;
to which U.S. patent applications claim priority under 35 U.S.C.
.sctn.120 the entire disclosures of which are hereby incorporated
by reference.
FIELD OF THE INVENTION
[0002] The present invention relates generally to the
identification and isolation of novel DNA and to the recombinant
production of novel polypeptides having structural homology to the
chemokine interleukin-8.
BACKGROUND OF THE INVENTION
[0003] Extracellular proteins play important roles in, among other
things, the formation, differentiation and maintenance of
multicellular organisms. The fate of many individual cells, e.g.,
proliferation, migration, differentiation, or interaction with
other cells, is typically governed by information received from
other cells and/or the immediate environment. This information is
often transmitted by secreted polypeptides (for instance, mitogenic
factors, survival factors, cytotoxic factors, differentiation
factors, neuropeptides, and hormones) which are, in turn, received
and interpreted by diverse cell receptors or membrane-bound
proteins. These secreted polypeptides or signaling molecules
normally pass through the cellular secretory pathway to reach their
site of action in the extracellular environment.
[0004] Secreted proteins have various industrial applications,
including as pharmaceuticals, diagnostics, biosensors and
bioreactors. Most protein drugs available at present, such as
thrombolytic agents, interferons, interleukins, erythropoietins,
colony stimulating factors, and various other cytokines, are
secretory proteins. Their receptors, which are membrane proteins,
also have potential as therapeutic or diagnostic agents.
[0005] Membrane-bound proteins and receptors can play important
roles in, among other things, the formation differentiation and
maintenance of multicellular organisms. The fate of many individual
cells, e.g., proliferation migration, differentiation, or
interaction with other cells, is typically governed by information
received from other cells and/or the immediate environment. This
information is often transmitted by secreted polypeptides (for
instance, mitogenic factors, survival factors, cytotoxic factors,
differentiation factors, neuropeptides, and hormones) which are, in
turn, received and interpreted by diverse cell receptors or
membrane-bound proteins. Such membrane-bound proteins and cell
receptors include, but are not limited to, cytokine receptors,
receptor kinases, receptor phosphatases, receptors involved in
cell-cell interactions, and cellular adhesin molecules like
selectins and integrins. For instance, transduction of signals that
regulate cell growth and differentiation is regulated in part by
phosphorylation of various cellular proteins. Protein tyrosine
kinases, enzymes that catalyze that process, can also act as growth
factor receptors. Examples include fibroblast growth factor
receptor and nerve growth factor receptor.
[0006] Similarly to secreted proteins, membrane-bound proteins and
receptor molecules have various industrial applications, including
as pharmaceutical and diagnostic agents. Receptor immunoadhesins,
for instance, can be employed as therapeutic agents to block
receptor-ligand interactions. The membrane-bound proteins can also
be employed for screening of potential peptide or small molecule
inhibitors of the relevant receptor/ligand interaction.
[0007] Efforts are being undertaken by both industry and academia
to identify new, native secreted proteins and native receptor or
membrane-bound proteins. Many efforts are focused on the screening
of mammalian recombinant DNA libraries to identify the coding
sequences for novel secreted proteins. Examples of screening
methods and techniques are described in the literature [see, for
example, Klein et al., Proc. Natl. Acad. Sci., 93:7108-7113 (1996);
U.S. Pat. No. 5,536,637)].
[0008] In this regard, the present invention relates to identifying
novel secreted polypeptides of the interleukin-8 (IL-8) family
which have been shown to be related to immune-mediated and
inflammatory disease. Immune related and inflammatory diseases are
the manifestation or consequence of fairly complex, often multiple
interconnected biological pathways which in normal physiology are
critical to respond to insult or injury, initiate repair from
insult or injury, and mount innate and acquired defense against
foreign organisms. Disease or pathology occurs when these normal
physiological pathways cause additional insult or injury either as
directly related to the intensity of the response, as a consequence
of abnormal regulation or excessive stimulation, as a reaction to
self, or as a combination of these.
[0009] Though the genesis of immune-related diseases often involves
multi-step pathways and often multiple different biological
systems/pathways, intervention at critical points in one or more of
these pathways can have an ameliorative or therapeutic effect.
Therapeutic intervention can occur by either antagonism of a
detrimental process/pathway or stimulation of a beneficial
process/pathway.
[0010] Many immune related diseases are known and have been
extensively studied. Such diseases include immune-mediated
inflammatory diseases (such as rheumatoid arthritis, immune
mediated renal disease, hepatobiliary diseases, inflammatory bowel
disease (IBD), psoriasis, and asthma), non-immune-mediated
inflammatory diseases, infectious diseases, immunodeficiency
diseases, neoplasia, etc.
[0011] Immune related diseases could be treated by suppressing the
immune response. Using neutralizing antibodies that inhibit
molecules having immune stimulatory activity would be beneficial in
the treatment of immune-mediated and inflammatory diseases.
Molecules which inhibit the immune response can be utilized
(proteins directly or via the use of antibody agonists) to inhibit
the immune response and thus ameliorate immune related disease.
[0012] The present invention concerns the identification a novel
chemokine which has structural homology to interleukin-8 (IL-8).
The amino acid sequence between the two proteins is low, however
they both have a CXC motif, which classifies IL-8 as a member of
the CXC chemokine family. Interleukin-8 has been shown to play a
role in the acute inflammatory response. This response is mediated
primarily by TNF-.alpha., IL-1 and IL-6. Localized effects include
increased adherence of circulating white blood cells to vascular
endothelial cells and their extravasation into tissue spaces. Both
IL-1 and TNF-.alpha. induce increased expression of cell-adhesion
molecules (CAMs) on endothelial cells. These two cytokines also
induce production of interleukin-8 by macrophages and endothelial
cells. IL-8 chemotactically attracts neutrophils and promotes their
adherence to endothelial cells. Specifically, IL-8 chemoattracts
monocytes and dendritic cells. Both cell types play an important
role in the initiation of an immune response.
[0013] Since the discovery 13 years ago of interleukin-8 (IL-8) as
a potent neutrophil chemotactic factor, accumulating evidence has
established it as a crucial mediator in neutrophil-dependent acute
inflammation. In fact, leukocyte infiltration is a hallmark of
inflammation. Numerous observations have demonstrated that various
types of cells can produce a large amount of IL-8, either in
response to various stimuli or constitutively, after malignant
transformation (Mukaida, N., International Journal of Hematology,
72(4):391-398 (2000)). The release of IL-8 is triggered by
inflammatory signals from a variety of cells. The diversity in the
cellular source indicates pleiotrophy of its functions. IL-8 plays
a key role in host defense mechanism through its effects on
neutrophiI activation, but a continued presence of IL-8 in
circulation in response to inflammatory conditions may lead to a
variable degree of tissue damage. The presence of IL-8 in various
pathophysiological conditions implies that blockade of its actions
could be exploited for therapeutic purposes (Atta-ur-Rahman et al.,
Current Pharmaceutical Design, 5(4):241-253 (1999)). Recently, IL-8
has been shown to be an autocrine growth factor for human ovarian
cancer. IL-8 appears to play a direct role in the progressive
growth of ovarian cancer cells (Xu, L. and Fidler, I. J., Oncology
Research, 12(2):97-106 (2000)). In addition, increased levels of
IL-8 have been found in bronchoalveolar lavage (BAL) fluids from
patient's with acute respiratory distress syndrome (ARDS). The
presence of anti-IL-8:IL-8 complexes in BAL fluids of patients with
ARDS is an important prognostic indicator for the development and
outcome of ARDS (Kurdowska, A. et al., American Journal of
Respiratory & Critical Care Medicine, 163(2):463-468
(2001)).
[0014] As discussed above, the class of molecules known as
chemokines are a family of proinflammatory cytokines of low
molecular mass (8-11 kDa) characterized by a structurally conserved
motif and their ability to mediate leukocyte chemotaxis, thus
playing an important role in leukocyte trafficking as well as
function in regulation. It is now clear that these small cytokines
play a role in a variety of homostatic and disease processes,
including development, hematopoiesis, allergies, angiogenesis, and
oncogenesis (see Broxmeyer, H. E. et al., J. Exp. Med., 170:1583
(1989); Cao, Y. et al., J. Exp. Med., 182:2069 (1995); and
Strieter, R. M. et al., J. Biol. Chem., 270:27348 (1995)). The
majority of chemokines are expressed in response to some stimuli,
but several are constitutively expressed (Wang, J. M. et al., J.
Immunol. Methods, 220:1-17 (1998); Baggiolini, M. Annu. Rev.
Immunol. 15:675-705 (1997); and Gale, L. M., and McColl, S. R.,
Bioessays, 21:17-28 (1999)). In addition, several CC chemokines,
including RANTES, macrophage inflammatory protein
(MIP).sup.4-1.alpha., and MIP-10, have been found to be capable of
inhibiting HIV infection (Cocchi. F. et al. Science, 270:1811
(1995)).
[0015] The chemokine family can be divided into four major
subfamilies based on the positions of amino-terminal cysteine
residues. In the CXC chemokines, the first two cysteines are
separated by a non-conserved amino acid, while in the CC chemokine
subfamily, these two cysteines are adjacent to each other. The C
chemokine subfamily with the only member of lymphotactin lacks the
second and fourth cysteines, which are conserved in the CXC and CC
chemokines. The CX.sub.3C membrane-bound chemokines have 3 amino
acids between the first two cysteines, a long mucin-like stalk, and
a short transmembrane domain (Bazan, J. F. et al., Nature, 385:640
(1997); Pan, Y. et al., Nature, 387:611 (1997)). In general, the
CXC chemokines primarily recruit neutrophils, while the CC
chemokines primarily attract monocytes and also lymphocytes,
basophils, and/or eosinophils with variable selectivity. The C
chemokine of lymphotactin seems to act specifically on T
lymphocytes and NK cells (Kelner, G. S. et al., Science, 266:1395
(1994) and Kennedy, J. G. et al., J. Immunol., 155:203 (1995)).
[0016] Dendritic cells (DC) are the uniquely potent APCs involved
in immune responses (Banchereau, J., and Steinman, R. M., Nature,
392:245 (1998)). As adjuvants for Ag delivery, immature dendritic
cells pick up Ags in the periphery and carry them to the T cell
area in lymphoid organs to prime the immune responses, meanwhile
undergoing maturation. Thus, chemokines play a vital role in
dendritic trafficking, maturation, and function.
[0017] In addition, numerous cytokines play a role in generating a
delayed-type hypersensitivity (DTH) response. The pattern of
cytokines implicated in a DTH response suggest that activated T
cells may be primarily of the Th1 subset. IL-2 functions in an
autocrine manner to amplify the population of cytokine-producing T
cells. Among the cytokines produced by these cells are a number
that serve to activate and attract macrophages to the site of Th1
activation. IL-3 and GM-CSF induce localized hematopoiesis of the
granulocyte-monocyte lineage. IFN-.gamma. and TNF-0 (together with
macrophage-derived TNF-.alpha. and IL-1) act on nearby endothelial
cells, inducing a number of changes that facilitate extravasation
of monocytes and other nonspecific inflammatory cells. Among the
changes induced are increases in the expression of
cellular-adhesion molecules including ICAMs, VCAMs, and ELAMSs;
changes in the shape of the vascular endothelial cells to
facilitate extravasation; and secretion of IL-8 and monocyte
chemotactic factor. Circulating neutrophils and monocytes adhere to
the adhesion molecules displayed on the vascular endothelial cells
and extravasate into the tissue spaces. Neutrophils appear early in
the reaction, whereas the monocyte infiltration occurs later. (See
Immunology, Second Edition, Chapter 15, pgs. 363-364 (copyright
1994) W.H. Freeman and Company publishers).
[0018] Interest in this family of molecules has increased as it has
become apparent that chemokines may contribute to a number of
important medical conditions related to immune function: including
rheumatoid arthritis, immune mediated renal diseases, hepatobiliary
diseases, inflammatory bowel disease, psoriasis, asthma, multiple
sclerosis, atherosclerosis, promotion of tumor growth, or
degenerative joint disease. Given the potential of chemokine
related molecules to occupy important roles in the control of
immune function, there is an interest in the identification of
other members of this family and the receptors that direct the
actions of these molecules through particular target cell
populations. In this respect, the present invention describes the
cloning and characterization of novel proteins (designated herein
as "PRO842" polypeptides) that are structurally similar to IL-8,
and active variants thereof.
SUMMARY OF THE INVENTION
A. Embodiments
[0019] The present invention concerns compositions and methods
useful for the diagnosis and treatment of immune related disease in
mammals, including humans. The present invention is based on the
identification of proteins (including agonist and antagonist
antibodies) which either stimulate or inhibit the immune response
in mammals. Immune related diseases can be treated by suppressing
or enhancing the immune response. Molecules that enhance the immune
response stimulate or potentiate the immune response to an antigen.
Molecules which stimulate the immune response can be used
therapeutically where enhancement of the immune response would be
beneficial. Alternatively, molecules that suppress the immune
response attenuate or reduce the immune response to an antigen
(e.g., neutralizing antibodies) can be used therapeutically where
attenuation of the immune response would be beneficial (e.g.,
inflammation). Accordingly, the PRO842 polypeptides of the present
invention and agonists and antagonists thereof are also useful to
prepare medicines and medicaments for the treatment of
immune-related and inflammatory diseases. In a specific aspect,
such medicines and medicaments comprise a therapeutically effective
amount of a PRO842 polypeptide, agonist or antagonist thereof with
a pharmaceutically acceptable carrier. Preferably, the admixture is
sterile.
[0020] In a further embodiment, the invention concerns a method of
identifying agonists of or antagonists to a PRO842 polypeptide
which comprises contacting the PRO842 polypeptide with a candidate
molecule and monitoring a biological activity mediated by said
PRO842 polypeptide. Preferably, the PRO842 polypeptide is a native
sequence PRO842 polypeptide. In a specific aspect, the PRO842
agonist or antagonist is an anti-PRO842 antibody.
[0021] In another embodiment, the invention concerns a composition
of matter comprising a PRO842 polypeptide or an agonist or
antagonist antibody which binds the polypeptide in admixture with a
carrier or excipient. In one aspect, the composition comprises a
therapeutically effective amount of the polypeptide or antibody. In
another aspect, when the composition comprises an immune
stimulating molecule, the composition is useful for: (a) enhancing
infiltration of inflammatory cells into a tissue of a mammal in
need thereof, (b) stimulating or enhancing an immune response in a
mammal in need thereof, (c) increasing the proliferation of
T-lymphocytes in a mammal in need thereof in response to an
antigen, (d) stimulating the activity of T-lymphocytes or (e)
increasing the vascular permeability. In a further aspect, when the
composition comprises an immune inhibiting molecule, the
composition is useful for: (a) decreasing infiltration of
inflammatory cells into a tissue of a mammal in need thereof, (b)
inhibiting or reducing an immune response in a mammal in need
thereof, (c) decreasing the activity of T-lymphocytes or (d)
decreasing the proliferation of T-lymphocytes in a mammal in need
thereof in response to an antigen. In another aspect, the
composition comprises a further active ingredient, which may, for
example, be a further antibody or a cytotoxic or chemotherapeutic
agent. Preferably, the composition is sterile.
[0022] In another embodiment, the invention concerns a method of
treating an immune related disorder in a mammal in need thereof,
comprising administering to the mammal a therapeutically effective
amount of a PRO842 polypeptide, an agonist thereof, or an
antagonist thereto. In a preferred aspect, the immune related
disorder is selected form the group consisting of: systemic lupus
erythematosis, rheumatoid arthritis, osteoarthritis, juvenile
chronic arthritis, spondyloarthropathies, systemic sclerosis,
idiopathic inflammatory myopathies. Sjogren's syndrome, systemic
vasculitis, sarcoidosis, autoimmune hemolytic anemia, autoimmune
thrombocytopenia, thyroiditis, diabetes mellirus, immune-mediated
renal disease, demyelinating diseases of the central and peripheral
nervous systems such as multiple sclerosis, idiopathic
demyelinating polyneuropathy or Guillain-Barre syndrome, and
chronic inflammatory demyelinating polyneuropathy, hepatobiliary
diseases such as infectious, autoimmune chronic active hepatitis,
primary biliary cirrhosis, granulomatous hepatitis, and sclerosing
cholangitis, inflammatory bowel disease, gluten-sensitive
enteropathy, and Whipple's disease, autoimmune or immune-mediated
skin diseases including bullous skin diseases, erythema multiforme
and contact dermatitis, psoriasis, allergic diseases such as
asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity
and urticaria, immunologic diseases of the lung such as
eosinophilic pneumonia, idiopathic pulmonary fibrosis and
hypersensitivity pneumonitis, transplantation associated diseases
including graft rejection and graft-versus-host-disease.
[0023] In another embodiment, the invention provides an antibody
which specifically binds to any of the above or below described
polypeptides. Optionally, the antibody is a monoclonal antibody,
humanized antibody, antibody fragment or single-chain antibody. In
one aspect, the present invention concerns an isolated antibody
which binds a PRO842 polypeptide. In another aspect, the antibody
mimics the activity of a PRO842 polypeptide (an agonist antibody)
or conversely the antibody inhibits or neutralizes the activity of
a PRO842 polypeptide (an antagonist antibody). In another aspect,
the antibody is a monoclonal antibody, which preferably has
nonhuman complementarity determining region (CDR) residues and
human framework region (FR) residues. The antibody may be labeled
and may be immobilized on a solid support. In a further aspect, the
antibody is an antibody fragment, a monoclonal antibody, a
single-chain antibody, or an anti-idiorypic antibody.
[0024] In yet another embodiment, the present invention provides a
composition comprising an anti-PRO842 antibody in admixture with a
pharmaceutically acceptable carrier. In one aspect, the composition
comprises a therapeutically effective amount of the antibody.
Preferably, the composition is sterile. The composition may be
administered in the form of a liquid pharmaceutical formulation,
which may be preserved to achieve extended storage stability.
Alternatively, the antibody is a monoclonal antibody, an antibody
fragment, a humanized antibody, or a single-chain antibody.
[0025] In a further embodiment, the invention concerns an article
of manufacture, comprising: [0026] (a) a composition of matter
comprising a PRO842 polypeptide or agonist, antagonist, or an
antibody that specifically binds to said polypeptide thereof;
[0027] (b) a container containing said composition; and [0028] (c)
a label affixed to said container, or a package insert included in
said container referring to the use of said PRO842 polypeptide or
agonist or antagonist thereof in the treatment of an immune related
disease. The composition may comprise a therapeutically effective
amount of the PRO842 polypeptide or the agonist or antagonist
thereof.
[0029] In yet another embodiment, the present invention concerns a
method of diagnosing an immune related disease in a mammal,
comprising detecting the level of expression of a gene encoding a
PRO842 polypeptide (a) in a test sample of tissue cells obtained
from the mammal, and (b) in a control sample of known normal tissue
cells of the same cell type, wherein a higher or lower expression
level in the test sample as compared to the control sample
indicates the presence of immune related disease in the mammal from
which the test tissue cells were obtained.
[0030] In another embodiment, the present invention concerns a
method of diagnosing an immune disease in a mammal, comprising (a)
contacting an anti-PRO842 antibody with a test sample of tissue
cells obtained from the mammal, and (b) detecting the formation of
a complex between the antibody and a PRO842 polypeptide, in the
test sample; wherein the formation of said complex is indicative of
the presence or absence of said disease. The detection may be
qualitative or quantitative, and may be performed in comparison
with monitoring the complex formation in a control sample of known
normal tissue cells of the same cell type. A larger quantity of
complexes formed in the test sample indicates the presence or
absence of an immune disease in the mammal from which the test
tissue cells were obtained. The antibody preferably carries a
detectable label. Complex formation can be monitored, for example,
by light microscopy, flow cytometry, fluorimetry, or other
techniques known in the art. The test sample is usually obtained
from an individual suspected of having a deficiency or abnormality
of the immune system.
[0031] In another embodiment, the invention provides a method for
determining the presence of a PRO842 polypeptide in a sample
comprising exposing a test sample of cells suspected of containing
the PRO842 polypeptide to an anti-PRO842 antibody and determining
the binding of said antibody to said cell sample. In a specific
aspect, the sample comprises a cell suspected of containing the
PRO842 polypeptide and the antibody binds to the cell. The antibody
is preferably detectably labeled and/or bound to a solid
support.
[0032] In another embodiment, the present invention concerns an
immune-related disease diagnostic kit, comprising an anti-PRO842
antibody and a carrier in suitable packaging. The kit preferably
contains instructions for using the antibody to detect the presence
of the PRO842 polypeptide. Preferably the carrier is
pharmaceutically acceptable.
[0033] In another embodiment, the present invention concerns a
diagnostic kit, containing an anti-PRO842 antibody in suitable
packaging. The kit preferably contains instructions for using the
antibody to detect the PRO842 polypeptide.
[0034] In another embodiment, the invention provides a method of
diagnosing an immune-related disease in a mammal which comprises
detecting the presence or absence or a PRO842 polypeptide in a test
sample of tissue cells obtained from said mammal, wherein the
presence or absence of the PRO842 polypeptide in said test sample
is indicative of the presence of an immune-related disease in said
mammal.
[0035] In another embodiment, the present invention concerns a
method for identifying an agonist of a PRO842 polypeptide
comprising: (a) contacting cells and a test compound to be screened
under conditions suitable for the induction of a cellular response
normally induced by a PRO842 polypeptide; and (b) determining the
induction of said cellular response to determine if the test
compound is an effective agonist, wherein the induction of said
cellular response is indicative of said test compound being an
effective agonist.
[0036] In another embodiment, the invention concerns a method for
identifying a compound capable of inhibiting the activity of a
PRO842 polypeptide comprising contacting a candidate compound with
a PRO842 polypeptide under conditions and for a time sufficient to
allow these two components to interact and determining whether the
activity of the PRO842 polypeptide is inhibited. In a specific
aspect, either the candidate compound or the PRO842 polypeptide is
immobilized on a solid support. In another aspect, the
non-immobilized component carries a detectable label. In a
preferred aspect, this method comprises the steps of: (a)
contacting cells and a test compound to be screened in the presence
of a PRO842 polypeptide under conditions suitable for the induction
of a cellular response normally induced by a PRO842 polypeptide;
and (b) determining the induction of said cellular response to
determine if the test compound is an effective antagonist.
[0037] In another embodiment, the invention provides a method for
identifying a compound that inhibits the expression of a PRO842
polypeptide in cells that normally express the polypeptide, wherein
the method comprises contacting the cells with a test compound and
determining whether the expression of the PRO842 polypeptide is
inhibited. In a preferred aspect, this method comprises the steps
of: (a) contacting cells and a test compound to be screened under
conditions suitable for allowing expression of the PRO842
polypeptide; and (b) determining the inhibition of expression of
said polypeptide.
[0038] In yet another embodiment, the present invention concerns a
method for treating an immune-related disorder in a mammal that
suffers therefrom comprising administering to the mammal a nucleic
acid molecule that codes for either (a) a PRO842 polypeptide, (b)
an agonist of a PRO842 polypeptide or (c) an antagonist of a PRO842
polypeptide, wherein said agonist or antagonist may be an
anti-PRO842 antibody. In a preferred embodiment, the mammal is
human. In another preferred embodiment, the nucleic acid is
administered via ex vivo gene therapy. In a further preferred
embodiment, the nucleic acid is comprised within a vector, more
preferably an adenoviral, adeno-associated viral, lentiviral or
retroviral vector.
[0039] In yet another aspect, the invention provides a recombinant
viral particle comprising a viral vector consisting essentially of
a promoter, nucleic acid encoding (a) a PRO842 polypeptide, (b) an
agonist polypeptide of a PRO842 polypeptide, or (c) an antagonist
polypeptide of a PRO842 polypeptide, and a signal sequence for
cellular secretion of the polypeptide, wherein the viral vector is
in association with viral structural proteins. Preferably, the
signal sequence is from a mammal, such as from a native PRO842
polypeptide.
[0040] In a still further embodiment, the invention concerns an ex
vivo producer cell comprising a nucleic acid construct that
expresses retroviral structural proteins and also comprises a
retroviral vector consisting essentially of a promoter, nucleic
acid encoding (a) a PRO842 polypeptide, (b) an agonist polypeptide
of a PRO842 polypeptide or (c) an antagonist polypeptide of a
PRO842 polypeptide, and a signal sequence for cellular secretion of
the polypeptide, wherein said producer cell packages the retroviral
vector in association with the structural proteins to produce
recombinant retroviral particles.
[0041] In a still further embodiment, the invention provides a
method for enhancing the infiltration of inflammatory cells from
the vasculature into a tissue of a mammal comprising administering
to said mammal (a) a PRO842 polypeptide, (b) an agonist of a PRO842
polypeptide, or (c) an antagonist of a PRO842 polypeptide, wherein
the infiltration of inflammatory cells from the vasculature in the
mammal is enhanced.
[0042] In a still further embodiment, the invention provides a
method for decreasing the infiltration of inflammatory cells from
the vasculature into a tissue of a mammal comprising administering
to said mammal (a) a PRO842 polypeptide, (b) an agonist of a PRO842
polypeptide, or (c) an antagonist of a PRO842 polypeptide, wherein
the infiltration of inflammatory cells from the vasculature in the
mammal is decreased.
[0043] In a still further embodiment, the invention provides a
method of increasing the activity of T-lymphocytes in a mammal
comprising administering to said mammal (a) a PRO842 polypeptide,
(b) an agonist of a PRO842 polypeptide, or (c) an antagonist of a
PRO842 polypeptide, wherein the activity of T-lymphocytes in the
mammal is increased.
[0044] In a still further embodiment, the invention provides a
method of decreasing the activity of T-lymphocytes in a mammal
comprising administering to said mammal (a) a PRO842 polypeptide,
(b) an agonist of a PRO842 polypeptide, or (c) an antagonist of a
PRO842 polypeptide, wherein the activity of T-lymphocytes in the
mammal is decreased.
[0045] In a still further embodiment, the invention provides a
method of increasing the proliferation of T-lymphocytes in a mammal
comprising administering to said mammal (a) a PRO842 polypeptide,
(b) an agonist of a PRO842 polypeptide, or (c) an antagonist of a
PRO842 polypeptide, wherein the proliferation of T-lymphocytes in
the mammal is increased.
[0046] In a still further embodiment, the invention provides a
method of decreasing the proliferation of T-lymphocytes in a mammal
comprising administering to said mammal (a) a PRO842 polypeptide,
(b) an agonist of a PRO842 polypeptide, or (c) an antagonist of a
PRO842 polypeptide, wherein the proliferation of T-lymphocytes in
the mammal is decreased.
[0047] In still a further embodiment, the invention relates to a
kit comprising a composition comprising a PRO842, or an agonist or
antagonist thereof, in admixture with a pharmaceutically acceptable
carrier; a container containing said composition; and a label
affixed to said container, referring to the use of said
composition, in the treatment of a degenerative cartilaginous
disorder.
B. Additional Embodiments
[0048] In other embodiments of the present invention, the invention
provides an isolated nucleic acid molecule comprising a nucleotide
sequence that encodes a PRO842 polypeptide.
[0049] In one aspect, the isolated nucleic acid molecule comprises
a nucleotide sequence having at least about 80% nucleic acid
sequence identity, alternatively at least about 81% nucleic acid
sequence identity, alternatively at least about 82% nucleic acid
sequence identity, alternatively at least about 83% nucleic acid
sequence identity, alternatively at least about 84% nucleic acid
sequence identity, alternatively at least about 85% nucleic acid
sequence identity, alternatively at least about 86% nucleic acid
sequence identity, alternatively at least about 87% nucleic acid
sequence identity, alternatively at least about 88% nucleic acid
sequence identity, alternatively at least about 89% nucleic acid
sequence identity, alternatively at least about 90% nucleic acid
sequence identity, alternatively at least about 91% nucleic acid
sequence identity, alternatively at least about 92% nucleic acid
sequence identity, alternatively at least about 93% nucleic acid
sequence identity, alternatively at least about 94% nucleic acid
sequence identity, alternatively at least about 95% nucleic acid
sequence identity, alternatively at least about 96% nucleic acid
sequence identity, alternatively at least about 97% nucleic acid
sequence identity, alternatively at least about 98% nucleic acid
sequence identity and alternatively at least about 99% nucleic acid
sequence identity to (a) a DNA molecule encoding a PRO842
polypeptide having a full-length amino acid sequence as disclosed
herein, an amino acid sequence lacking the signal peptide as
disclosed herein, an extracellular domain of a transmembrane
protein, with or without the signal peptide, as disclosed herein or
any other specifically defined fragment of the full-length amino
acid sequence as disclosed herein, or (b) the complement of the DNA
molecule of (a).
[0050] In other aspects, the isolated nucleic acid molecule
comprises a nucleotide sequence having at least about 80% nucleic
acid sequence identity, alternatively at least about 81% nucleic
acid sequence identity, alternatively at least about 82% nucleic
acid sequence identity, alternatively at least about 83% nucleic
acid sequence identity, alternatively at least about 84% nucleic
acid sequence identity, alternatively at least about 85% nucleic
acid sequence identity, alternatively at least about 86% nucleic
acid sequence identity, alternatively at least about 87% nucleic
acid sequence identity, alternatively at least about 88% nucleic
acid sequence identity, alternatively at least about 89% nucleic
acid sequence identity, alternatively at least about 90% nucleic
acid sequence identity, alternatively at least about 91% nucleic
acid sequence identity, alternatively at least about 92% nucleic
acid sequence identity, alternatively at least about 93% nucleic
acid sequence identity, alternatively at least about 94% nucleic
acid sequence identity, alternatively at least about 95% nucleic
acid sequence identity, alternatively at least about 96% nucleic
acid sequence identity, alternatively at least about 97% nucleic
acid sequence identity, alternatively at least about 98% nucleic
acid sequence identity and alternatively at least about 99% nucleic
acid sequence identity to (a) a DNA molecule comprising the coding
sequence of a full-length PRO842 polypeptide cDNA as disclosed
herein, the coding sequence of a PRO842 polypeptide lacking the
signal peptide as disclosed herein, the coding sequence of an
extracellular domain of a transmembrane PRO842 polypeptide, with or
without the signal peptide, as disclosed herein or the coding
sequence of any other specifically defined fragment of the
full-length amino acid sequence as disclosed herein, or (b) the
complement of the DNA molecule of (a).
[0051] In a further aspect, the invention concerns an isolated
nucleic acid molecule comprising a nucleotide sequence having at
least about 80% nucleic acid sequence identity, alternatively at
least about 81% nucleic acid sequence identity, alternatively at
least about 82% nucleic acid sequence identity, alternatively at
least about 83% nucleic acid sequence identity, alternatively at
least about 84% nucleic acid sequence identity, alternatively at
least about 85% nucleic acid sequence identity, alternatively at
least about 86% nucleic acid sequence identity, alternatively at
least about 87% nucleic acid sequence identity, alternatively at
least about 88% nucleic acid sequence identity, alternatively at
least about 89% nucleic acid sequence identity, alternatively at
least about 90% nucleic acid sequence identity, alternatively at
least about 91% nucleic acid sequence identity, alternatively at
least about 92% nucleic acid sequence identity, alternatively at
least about 93% nucleic acid sequence identity, alternatively at
least about 94% nucleic acid sequence identity, alternatively at
least about 95% nucleic acid sequence identity, alternatively at
least about 96% nucleic acid sequence identity, alternatively at
least about 97% nucleic acid sequence identity, alternatively at
least about 98% nucleic acid sequence identity and alternatively at
least about 99% nucleic acid sequence identity to (a) a DNA
molecule that encodes the same mature polypeptide encoded by any of
the human protein cDNAs deposited with the ATCC as disclosed
herein, or (b) the complement of the DNA molecule of (a).
[0052] Another aspect of the present invention provides an isolated
nucleic acid molecule comprising a nucleotide sequence encoding a
PRO842 polypeptide which is either transmembrane domain-deleted or
transmembrane domain-inactivated, or is complementary to such
encoding nucleotide sequence, wherein the transmembrane domain(s)
of such polypeptide are disclosed herein. Therefore, soluble
extracellular domains of the herein described PRO842 polypeptides
are contemplated.
[0053] Another embodiment is directed to fragments of a PRO842
polypeptide coding sequence, or the complement thereof, that may
find use as, for example, hybridization probes, for encoding
fragments of a PRO842 polypeptide that may optionally encode a
polypeptide comprising a binding site for an anti-PRO842 antibody
or as antisense oligonucleotide probes. Such nucleic acid fragments
are usually at least about 20 nucleotides in length, alternatively
at least about 30 nucleotides in length, alternatively at least
about 40 nucleotides in length, alternatively at least about 50
nucleotides in length, alternatively at least about 60 nucleotides
in length, alternatively at least about 70 nucleotides in length,
alternatively at least about 80 nucleotides in length,
alternatively at least about 90 nucleotides in length,
alternatively at least about 100 nucleotides in length,
alternatively at least about 110 nucleotides in length,
alternatively at least about 120 nucleotides in length,
alternatively at least about 130 nucleotides in length,
alternatively at least about 140 nucleotides in length,
alternatively at least about 150 nucleotides in length,
alternatively at least about 160 nucleotides in length,
alternatively at least about 170 nucleotides in length,
alternatively at least about 180 nucleotides in length,
alternatively at least about 190 nucleotides in length,
alternatively at least about 200 nucleotides in length,
alternatively at least about 250 nucleotides in length,
alternatively at least about 300 nucleotides in length,
alternatively at least about 350 nucleotides in length,
alternatively at least about 400 nucleotides in length,
alternatively at least about 450 nucleotides in length,
alternatively at least about 500 nucleotides in length,
alternatively at least about 600 nucleotides in length,
alternatively at least about 700 nucleotides in length,
alternatively at least about 800 nucleotides in length,
alternatively at least about 900 nucleotides in length and
alternatively at least about 1000 nucleotides in length, wherein in
this context the term "about" means the referenced nucleotide
sequence length plus or minus 10% of that referenced length. It is
noted that novel fragments of a PRO842 polypeptide-encoding
nucleotide sequence may be determined in a routine manner by
aligning the PRO842 polypeptide-encoding nucleotide sequence with
other known nucleotide sequences using any of a number of well
known sequence alignment programs and determining which PRO842
polypeptide-encoding nucleotide sequence fragment(s) are novel. All
of such PRO842 polypeptide-encoding nucleotide sequences are
contemplated herein. Also contemplated are the PRO842 polypeptide
fragments encoded by these nucleotide molecule fragments,
preferably those PRO842 polypeptide fragments that comprise a
binding site for an anti-PRO842 antibody.
[0054] In another embodiment, the invention provides an isolated
PRO842 polypeptide encoded by any of the isolated nucleic acid
sequences hereinabove identified.
[0055] In a certain aspect, the invention concerns an isolated
PRO842 polypeptide, comprising an amino acid sequence having at
least about 80% amino acid sequence identity, alternatively at
least about 81% amino acid sequence identity, alternatively at
least about 82% amino acid sequence identity, alternatively at
least about 83% amino acid sequence identity, alternatively at
least about 84% amino acid sequence identity, alternatively at
least about 85% amino acid sequence identity, alternatively at
least about 86% amino acid sequence identity, alternatively at
least about 87% amino acid sequence identity, alternatively at
least about 88% amino acid sequence identity, alternatively at
least about 89% amino acid sequence identity, alternatively at
least about 90% amino acid sequence identity, alternatively at
least about 91% amino acid sequence identity, alternatively at
least about 92% amino acid sequence identity, alternatively at
least about 93% amino acid sequence identity, alternatively at
least about 94% amino acid sequence identity, alternatively at
least about 95% amino acid sequence identity, alternatively at
least about 96% amino acid sequence identity, alternatively at
least about 97% amino acid sequence identity, alternatively at
least about 98% amino acid sequence identity and alternatively at
least about 99% amino acid sequence identity to a PRO842
polypeptide having a full-length amino acid sequence as disclosed
herein, an amino acid sequence lacking the signal peptide as
disclosed herein, an extracellular domain of a transmembrane
protein, with or without the signal peptide, as disclosed herein or
any other specifically defined fragment of the full-length amino
acid sequence as disclosed herein.
[0056] In a further aspect, the invention concerns an isolated
PRO842 polypeptide comprising an amino acid sequence having at
least about 80% amino acid sequence identity, alternatively at
least about 81% amino acid sequence identity, alternatively at
least about 82% amino acid sequence identity, alternatively at
least about 83% amino acid sequence identity, alternatively at
least about 84% amino acid sequence identity, alternatively at
least about 85% amino acid sequence identity, alternatively at
least about 86% amino acid sequence identity, alternatively at
least about 87% amino acid sequence identity, alternatively at
least about 88% amino acid sequence identity, alternatively at
least about 89% amino acid sequence identity, alternatively at
least about 90% amino acid sequence identity, alternatively at
least about 91% amino acid sequence identity, alternatively at
least about 92% amino acid sequence identity, alternatively at
least about 93% amino acid sequence identity, alternatively at
least about 94% amino acid sequence identity, alternatively at
least about 95% amino acid sequence identity, alternatively at
least about 96% amino acid sequence identity, alternatively at
least about 97% amino acid sequence identity, alternatively at
least about 98% amino acid sequence identity and alternatively at
least about 99% amino acid sequence identity to an amino acid
sequence encoded by any of the human protein cDNAs deposited with
the ATCC as disclosed herein.
[0057] In a further aspect, the invention concerns an isolated
PRO842 polypeptide comprising an amino acid sequence scoring at
least about 80% positives, alternatively at least about 81%
positives, alternatively at least about 82% positives,
alternatively at least about 83% positives, alternatively at least
about 84% positives, alternatively at least about 85% positives,
alternatively at least about 86% positives, alternatively at least
about 87% positives, alternatively at least about 88% positives,
alternatively at least about 89% positives, alternatively at least
about 90% positives, alternatively at least about 91% positives,
alternatively at least about 92% positives, alternatively at least
about 93% positives, alternatively at least about 94% positives,
alternatively at least about 95% positives, alternatively at least
about 96% positives, alternatively at least about 97% positives,
alternatively at least about 98% positives and alternatively at
least about 99% positives when compared with the amino acid
sequence of a PRO842 polypeptide having a full-length amino acid
sequence as disclosed herein, an amino acid sequence lacking the
signal peptide as disclosed herein, an extracellular domain of a
transmembrane protein, with or without the signal peptide, as
disclosed herein or any other specifically defined fragment of the
full-length amino acid sequence as disclosed herein.
[0058] In a specific aspect, the invention provides an isolated
PRO842 polypeptide without the N-terminal signal sequence and/or
the initiating methionine and is encoded by a nucleotide sequence
that encodes such an amino acid sequence as hereinbefore described.
Processes for producing the same are also herein described, wherein
those processes comprise culturing a host cell comprising a vector
which comprises the appropriate encoding nucleic acid molecule
under conditions suitable for expression of the PRO842 polypeptide
and recovering the PRO842 polypeptide from the cell culture.
[0059] Another aspect of the invention provides an isolated PRO842
polypeptide which is either transmembrane domain-deleted or
transmembrane domain-inactivated. Processes for producing the same
are also herein described, wherein those processes comprise
culturing a host cell comprising a vector which comprises the
appropriate encoding nucleic acid molecule under conditions
suitable for expression of the PRO842 polypeptide and recovering
the PRO842 polypeptide from the cell culture.
[0060] In yet another embodiment, the invention concerns agonists
and antagonists of a native PRO842 polypeptide as defined herein.
In a particular embodiment, the agonist or antagonist is an
anti-PRO842 antibody or a small molecule.
[0061] In a further embodiment, the invention concerns a method of
identifying agonists or antagonists to a PRO842 polypeptide which
comprise contacting the PRO842 polypeptide with a candidate
molecule and monitoring a biological activity mediated by said
PRO842 polypeptide. Preferably, the PRO842 polypeptide is a native
PRO842 polypeptide.
[0062] In a still further embodiment, the invention concerns a
composition of matter comprising a PRO842 polypeptide, or an
agonist or antagonist of a PRO842 polypeptide as herein described,
or an anti-PRO842 antibody, in combination with a carrier.
Optionally, the carrier is a pharmaceutically acceptable
carrier.
[0063] Another embodiment of the present invention is directed to
the use of a PRO842 polypeptide, or an agonist or antagonist
thereof as hereinbefore described, or an anti-PRO842 antibody, for
the preparation of a medicament useful in the treatment of a
condition which is responsive to the PRO842 polypeptide, an agonist
or antagonist thereof or an anti-PRO842 antibody.
[0064] In additional embodiments of the present invention, the
invention provides vectors comprising DNA encoding any of the
herein described polypeptides. Host cell comprising any such vector
are also provided. By way of example, the host cells may be CHO
cells, E. coli, yeast, or Baculovirus-infected insect cells. A
process for producing any of the herein described polypeptides is
further provided and comprises culturing host cells under
conditions suitable for expression of the desired polypeptide and
recovering the desired polypeptide from the cell culture.
[0065] In other embodiments, the invention provides chimeric
molecules comprising any of the herein described polypeptides fused
to a heterologous polypeptide or amino acid sequence. Example of
such chimeric molecules comprise any of the herein described
polypeptides fused to an epitope tag sequence or a Fc region of an
immunoglobulin.
[0066] In yet another embodiment, the invention provides an
antibody which specifically binds to any of the above or below
described polypeptides. Optionally, the antibody is a monoclonal
antibody, humanized antibody, antibody fragment or single-chain
antibody.
[0067] In yet other embodiments, the invention provides
oligonucleotide probes useful for isolating genomic and cDNA
nucleotide sequences or as antisense probes, wherein those probes
may be derived from any of the above or below described nucleotide
sequences.
BRIEF DESCRIPTION OF THE DRAWINGS
[0068] FIG. 1 shows a nucleotide sequence (SEQ ID NO:1) of a native
sequence PRO842 cDNA, wherein SEQ ID NO:1 is a clone designated
herein as "DNA56855-1447".
[0069] FIG. 2 shows the amino acid sequence (SEQ ID NO:2) derived
from the coding sequence of SEQ ID NO:1 shown in FIG. 1.
[0070] FIG. 3 shows the tissue expression pattern of DNA56855
(CK27) as demonstrated by hybridization to a human multiple tissue
expression array. Significant expression was observed in lung (A8),
stomach (B5), and trachea (H7). In ovary, prostate, colon and fetal
lung weak expression of CK27 was detected.
[0071] FIG. 4 shows the tissue expression pattern of DNA56855
(CK27) as shown by hybridization of a 150 bp probe to a human
multiple tissue Northern Blot. Significant expression was observed
in the stomach, thyroid, lymph node and trachea.
[0072] FIG. 5 shows the tissue expression pattern of murine CK27 in
a mouse RNA Blot. Significant expression was observed in the lung
(A4), thyroid (C2), submaxillary gland (C4) and uterus (D5).
[0073] FIG. 6 demonstrates that PRO842 (CK27) specifically attracts
dendritic cells (CD11c+cells) as compared with CD3.sup.+ cells or
CD16.sup.+ cells.
[0074] FIG. 7 shows that different lots of PRO842 (CK27) show
similar chemoattractant activity.
[0075] FIG. 8 demonstrates that heat-treatment of PRO842 (CK27)
reduces the chemoattraction of dendritic cells (CD11c.sup.+ cells)
and monocytic cells (CD14.sup.+ cells) to PRO842 (CK27).
[0076] FIG. 9 demonstrates the formation of ovarian cysts in human
DNA56855 (C127) transgenic mice. The top left image corresponds to
the control (normal ovary in non-transgenic mice); the bottom left
image shows cystic degeneration and hemosiderin in CK27 transgenic
mice; the top right image shows the ovary with hemosiderin changes
which extend into adjacent adipose tissue in CK27 transgenic mice;
and the bottom right high power image shows the presence of pigment
laden macrophages.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
I. Definitions
[0077] The terms "PRO polypeptide" and "PRO" as used herein and
when immediately followed by a numerical designation refer to
various polypeptides, wherein the complete designation (i.e.,
PRO/number) refers to specific polypeptide sequences as described
herein. The terms "PRO/number polypeptide" and "PRO/number" wherein
the term "number" is provided as an actual numerical designation as
used herein encompass native sequence polypeptides and polypeptide
variants (which are further defined herein). The PRO polypeptides
described herein may be isolated from a variety of sources, such as
from human tissue types or from another source, or prepared by
recombinant or synthetic methods. The term "PRO polypeptide" refers
to each individual PRO/number polypeptide disclosed herein. All
disclosures in this specification which refer to the "PRO
polypeptide" refer to each of the polypeptides individually as well
as jointly. For example, descriptions of the preparation of,
purification of, derivation of, formation of antibodies to or
against, administration of, compositions containing, treatment of a
disease with, etc. pertain to each polypeptide of the invention
individually. The term "PRO polypeptide" also includes variants of
the PRO/number polypeptides disclosed herein.
[0078] A "native sequence PRO842 polypeptide" comprises a
polypeptide having the same amino acid sequence as the
corresponding PRO842 polypeptide derived from nature. Such native
sequence PRO842 polypeptides can be isolated from nature or can be
produced by recombinant or synthetic means. The term "native
sequence PRO842 polypeptide" specifically encompasses
naturally-occurring truncated or secreted forms of the specific
PRO842 polypeptide (e.g., an extracellular domain sequence),
naturally-occurring variant forms (e.g., alternatively spliced
forms) and naturally-occurring allelic variants of the polypeptide.
In various embodiments of the invention, the native sequence PRO842
polypeptides disclosed herein are mature or full-length native
sequence polypeptides comprising the full-length amino acid
sequences shown in the accompanying figures. Start and stop codons
are shown in bold font and underlined in the figures. However,
while the PRO842 polypeptide disclosed in the accompanying figures
are shown to begin with methionine residues designated herein as
amino acid position I in the figures, it is conceivable and
possible that other methionine residues located either upstream or
downstream from the amino acid position I in the figures may be
employed as the starting amino acid residue for the PRO842
polypeptides.
[0079] The PRO842 polypeptide "extracellular domain" or "ECD"
refers to a form of the PRO842 polypeptide which is essentially
free of the transmembrane and cytoplasmic domains. Ordinarily, a
PRO842 polypeptide ECD will have less than 1% of such transmembrane
and/or cytoplasmic domains and preferably, will have less than 0.5%
of such domains. It will be understood that any transmembrane
domains identified for the PRO842 polypeptides of the present
invention are identified pursuant to criteria routinely employed in
the art for identifying that type of hydrophobic domain. The exact
boundaries of a transmembrane domain may vary but most likely by no
more than about 5 amino acids at either end of the domain as
initially identified herein. Optionally, therefore, an
extracellular domain of a PRO842 polypeptide may contain from about
5 or fewer amino acids on either side of the transmembrane
domain/extracellular domain boundary as identified in the Examples
or specification and such polypeptides, with or without the
associated signal peptide, and nucleic acid encoding them, are
contemplated by the present invention.
[0080] The approximate location of the "signal peptides" of the
various PRO842 polypeptides disclosed herein are shown in the
present specification and/or the accompanying figures. It is noted,
however, that the C-terminal boundary of a signal peptide may vary,
but most likely by no more than about 5 amino acids on either side
of the signal peptide C-terminal boundary as initially identified
herein, wherein the C-terminal boundary of the signal peptide may
be identified pursuant to criteria routinely employed in the art
for identifying that type of amino acid sequence element (e.g.,
Nielsen et al., Prot. Eng., 10:1-6 (1997) and von Heinje et al.,
Nucl. Acids. Res., 14:4683-4690 (1986)). Moreover, it is also
recognized that, in some cases, cleavage of a signal sequence from
a secreted polypeptide is not entirely uniform, resulting in more
than one secreted species. These mature polypeptides, where the
signal peptide is cleaved within no more than about 5 amino acids
on either side of the C-terminal boundary of the signal peptide as
identified herein, and the polynucleotides encoding them, are
contemplated by the present invention.
[0081] "PRO842 polypeptide variant" means an active PRO842
polypeptide as defined above or below having at least about 80%
amino acid sequence identity with a full-length native sequence
PRO842 polypeptide sequence as disclosed herein, a PRO842
polypeptide sequence lacking the signal peptide as disclosed
herein, an extracellular domain of a PRO842 polypeptide, with or
without the signal peptide, as disclosed herein or any other
fragment of a full-length PRO842 polypeptide sequence as disclosed
herein. Such PRO842 polypeptide variants include, for instance,
PRO842 polypeptides wherein one or more amino acid residues are
added, or deleted, at the- or C-terminus of the full-length native
amino acid sequence. Ordinarily, a PRO842 polypeptide variant will
have at least about 80% amino acid sequence identity, alternatively
at least about 81% amino acid sequence identity, alternatively at
least about 82% amino acid sequence identity, alternatively at
least about 83% amino acid sequence identity, alternatively at
least about 84% amino acid sequence identity, alternatively at
least about 85% amino acid sequence identity, alternatively at
least about 86% amino acid sequence identity, alternatively at
least about 87% amino acid sequence identity, alternatively at
least about 88% amino acid sequence identity, alternatively at
least about 89% amino acid sequence identity, alternatively at
least about 90% amino acid sequence identity, alternatively at
least about 91% amino acid sequence identity, alternatively at
least about 92% amino acid sequence identity, alternatively at
least about 93% amino acid sequence identity, alternatively at
least about 94% amino acid sequence identity, alternatively at
least about 95% amino acid sequence identity, alternatively at
least about 96% amino acid sequence identity, alternatively at
least about 97% amino acid sequence identity, alternatively at
least about 98% amino acid sequence identity and alternatively at
least about 99% amino acid sequence identity to a full-length
native sequence PRO842 polypeptide sequence as disclosed herein, a
PRO842 polypeptide sequence lacking the signal peptide as disclosed
herein, an extracellular domain of a PRO842 polypeptide, with or
without the signal peptide, as disclosed herein or any other
specifically defined fragment of a full-length PRO84-2 polypeptide
sequence as disclosed herein. Ordinarily, PRO842 variant
polypeptides are at least about 10 amino acids in length,
alternatively at least about 20 amino acids in length,
alternatively at least about 30 amino acids in length,
alternatively at least about 40 amino acids in length,
alternatively at least about 50 amino acids in length,
alternatively at least about 60 amino acids in length,
alternatively at least about 70 amino acids in length,
alternatively at least about 80 amino acids in length,
alternatively at least about 90 amino acids in length,
alternatively at least about 100 amino acids in length,
alternatively at least about 150 amino acids in length,
alternatively at least about 200 amino acids in length,
alternatively at least about 300 amino acids in length, or
more.
[0082] "Percent (%) amino acid sequence identity" with respect to
the PRO842 polypeptide sequences identified herein is defined as
the percentage of amino acid residues in a candidate sequence that
are identical with the amino acid residues in the specific PRO842
polypeptide sequence, after aligning the sequences and introducing
gaps, if necessary, to achieve the maximum percent sequence
identity, and not considering any conservative substitutions as
part of the sequence identity. Alignment for purposes of
determining percent amino acid sequence identity can be achieved in
various ways that are within the skill in the art, for instance,
using publicly available computer software such as BLAST, BLAST-2.
ALIGN or Megalign (DNASTAR) software. Those skilled in the art can
determine appropriate parameters for measuring alignment, including
any algorithms needed to achieve maximal alignment over the full
length of the sequences being compared. For purposes herein,
however, % amino acid sequence identity values are generated using
the sequence comparison computer program ALIGN-2, wherein the
complete source code for the ALIGN-2 program is provided in Table 1
below. The ALIGN-2 sequence comparison computer program was
authored by Genentech, Inc. and the source code shown in Table 1
below has been filed with user documentation in the U.S. Copyright
Office, Washington D.C., 20559, where it is registered under
U.S.Copyright Registration No. TXU510087. The ALIGN-2 program is
publicly available through Genentech, Inc., South San Francisco,
Calif. or may be compiled from the source code provided in Table 1
below. The ALIGN-2 program should be compiled for use on a UNIX
operating system, preferably digital UNIX V4.0D. All sequence
comparison parameters are set by the ALIGN-2 program and do not
vary.
[0083] In situations where ALIGN-2 is employed for amino acid
sequence comparisons, the % amino acid sequence identity of a given
amino acid sequence A to, with, or against a given amino acid
sequence B (which can alternatively be phrased as a given amino
acid sequence A that has or comprises a certain % amino acid
sequence identity to, with, or against a given amino acid sequence
B) is calculated as follows: 100 times the fraction X/Y where X is
the number of amino acid residues scored as identical matches by
the sequence alignment program ALIGN-2 in that program's alignment
of A and B, and where Y is the total number of amino acid residues
in B. It will be appreciated that where the length of amino acid
sequence A is not equal to the length of amino acid sequence B, the
% amino acid sequence identity of A to B will not equal the % amino
acid sequence identity of B to A. As examples of % amino acid
sequence identity calculations using this method, Tables 2 and 3
demonstrate how to calculate the % amino acid sequence identity of
the amino acid sequence designated "Comparison Protein" to the
amino acid sequence designated "PRO", wherein "PRO" represents the
amino acid sequence of a hypothetical PRO polypeptide of interest,
"Comparison Protein" represents the amino acid sequence of a
polypeptide against which the "PRO" polypeptide of interest is
being compared, and "X, "Y" and "Z" each represent different
hypothetical amino acid residues.
[0084] Unless specifically stated otherwise, all % amino acid
sequence identity values used herein are obtained as described in
the immediately preceding paragraph using the ALIGN-2 computer
program. However, % amino acid sequence identity values may also be
obtained as described below by using the WU-BLAST-2 computer
program (Altschul et al., Methods in Enzymology 266:460-480
(1996)). Most of the WU-BLAST-2 search parameters are set to the
default values. Those not set to default values, i.e., the
adjustable parameters, are set with the following values: overlap
span=1, overlap fraction=0.125, word threshold (T)=11, and scoring
matrix=BLOSUM62. When WU-BLAST-2 is employed, a % amino acid
sequence identity value is determined by dividing (a) the number of
matching identical amino acid residues between the amino acid
sequence of the PRO polypeptide of interest having a sequence
derived from the native PRO polypeptide and the comparison amino
acid sequence of interest (i.e., the sequence against which the PRO
polypeptide of interest is being compared which may be a PRO
variant polypeptide) as determined by WU-BLAST-2 by (b) the total
number of amino acid residues of the PRO polypeptide of interest.
For example, in the statement "a polypeptide comprising an the
amino acid sequence A which has or having at least 80% amino acid
sequence identity to the amino acid sequence B", the amino acid
sequence A is the comparison amino acid sequence of interest and
the amino acid sequence B is the amino acid sequence of the PRO
polypeptide of interest.
[0085] Percent amino acid sequence identity may also be determined
using the sequence comparison program NCBI-BLAST2 (Altschul et al.,
Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence
comparison-program may be downloaded from
http://www.ncbi.nim.nih.gov or otherwise obtained from the National
Institute of Health, Bethesda, Md. NCBI-BLAST2 uses several search
parameters, wherein all of those search parameters are set to
default values including, for example, unmask yes, strand=all,
expected occurrences=10, minimum low complexity length=15/5,
multi-pass e-value=0.01, constant for multi-pass=25, dropoff for
final gapped alignment=25 and scoring matrix=BLOSUM62.
[0086] In situations where NCBI-BLAST2 is employed for amino acid
sequence comparisons, the % amino acid sequence identity of a given
amino acid sequence A to, with, or against a given amino acid
sequence B (which can alternatively be phrased as a given amino
acid sequence A that has or comprises a certain % amino acid
sequence identity to, with, or against a given amino acid sequence
B) is calculated as follows: 100 times the fraction X/Y where X is
the number of amino acid residues scored as identical matches by
the sequence alignment program NCBI-BLAST2 in that program's
alignment of A and B, and where Y is the total number of amino acid
residues in B. It will be appreciated that where the length of
amino acid sequence A is not equal to the length of amino acid
sequence B, the % amino acid sequence identity of A to B will not
equal the % amino acid sequence identity of B to A.
[0087] "PRO842 variant polynucleotide" or "PRO842 variant nucleic
acid sequence" means a nucleic acid molecule which encodes an
active PRO842 polypeptide as defined below and which has at least
about 80% nucleic acid sequence identity with a nucleotide acid
sequence encoding a full-length native sequence PRO842 polypeptide
sequence as disclosed herein, a full-length native sequence PRO842
polypeptide sequence lacking the signal peptide as disclosed
herein, an extracellular domain of a PRO842 polypeptide, with or
without the signal peptide, as disclosed herein or any other
fragment of a full-length PRO842 polypeptide sequence as disclosed
herein. Ordinarily, a PRO842 variant polynucleotide will have at
least about 80% nucleic acid sequence identity, alternatively at
least about 81% nucleic acid sequence identity, alternatively at
least about 82% nucleic acid sequence identity, alternatively at
least about 83% nucleic acid sequence identity, alternatively at
least about 84% nucleic acid sequence identity, alternatively at
least about 85% nucleic acid sequence identity, alternatively at
least about 86% nucleic acid sequence identity, alternatively at
least about 87% nucleic acid sequence identity, alternatively at
least about 88% nucleic acid sequence identity, alternatively at
least about 89% nucleic acid sequence identity, alternatively at
least about 90% nucleic acid sequence identity, alternatively at
least about 91% nucleic acid sequence identity, alternatively at
least about 92% nucleic acid sequence identity, alternatively at
least about 93% nucleic acid sequence identity, alternatively at
least about 94% nucleic acid sequence identity, alternatively at
least about 95% nucleic acid sequence identity, alternatively at
least about 96% nucleic acid sequence identity, alternatively at
least about 97% nucleic acid sequence identity, alternatively at
least about 98% nucleic acid sequence identity and alternatively at
least about 99% nucleic acid sequence identity with a nucleic acid
sequence encoding a full-length native sequence PRO842 polypeptide
sequence as disclosed herein, a full-length native sequence PRO842
polypeptide sequence lacking the signal peptide as disclosed
herein, an extracellular domain of a PRO842 polypeptide, with or
without the signal sequence, as disclosed herein or any other
fragment of a full-length PRO842 polypeptide sequence as disclosed
herein. Variants do not encompass the native nucleotide
sequence.
[0088] Ordinarily, PRO842 variant polynucleotides are at least
about 30 nucleotides in length, alternatively at least about 60
nucleotides in length, alternatively at least about 90 nucleotides
in length, alternatively at least about 120 nucleotides in length,
alternatively at least about 150 nucleotides in length,
alternatively at least about 180 nucleotides in length,
alternatively at least about 210 nucleotides in length,
alternatively at least about 240 nucleotides in length,
alternatively at least about 270 nucleotides in length,
alternatively at least about 300 nucleotides in length,
alternatively at least about 450 nucleotides in length,
alternatively at least about 600 nucleotides in length,
alternatively at least about 900 nucleotides in length, or
more.
[0089] "Percent (%) nucleic acid sequence identity" with respect to
PRO-encoding nucleic acid sequences identified herein is defined as
the percentage of nucleotides in a candidate sequence that are
identical with the nucleotides in the PRO nucleic acid sequence of
interest, after aligning the sequences and introducing gaps, if
necessary, to achieve the maximum percent sequence identity.
Alignment for purposes of determining percent nucleic acid sequence
identity can be achieved in various ways that are within the skill
in the art, for instance, using publicly available computer
software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR)
software. For purposes herein, however, % nucleic acid sequence
identity values are generated using the sequence comparison
computer program ALIGN-2, wherein the complete source code for the
ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence
comparison computer program was authored by Genentech, Inc. and the
source code shown in Table 1 below has been filed with user
documentation in the U.S. Copyright Office, Washington D.C., 20559,
where it is registered under U.S. Copyright Registration No.
TXU510087. The ALIGN-2 program is publicly available through
Genentech, Inc., South San Francisco, Calif. or may be compiled
from the source code provided in Table 1 below. The ALIGN-2 program
should be compiled for use on a UNIX operating system, preferably
digital UNIX V4.0D. All sequence comparison parameters are set by
the ALIGN-2 program and do not vary.
[0090] In situations where ALIGN-2 is employed for nucleic acid
sequence comparisons, the % nucleic acid sequence identity of a
given nucleic acid sequence C to, with, or against a given nucleic
acid sequence D (which can alternatively be phrased as a given
nucleic acid sequence C that has or comprises a certain % nucleic
acid sequence identity to, with, or against a given nucleic acid
sequence D) is calculated as follows: 100 times the fraction W/Z
where W is the number of nucleotides scored as identical matches by
the sequence alignment program ALIGN-2 in that program's alignment
of C and D, and where Z is the total number of nucleotides in D. It
will be appreciated that where the length of nucleic acid sequence
C is not equal to the length of nucleic acid sequence D, the %
nucleic acid sequence identity of C to D will not equal the %
nucleic acid sequence identity of D to C. As examples of % nucleic
acid sequence identity calculations, Tables 4 and 5, demonstrate
how to calculate the % nucleic acid sequence identity of the
nucleic acid sequence designated "Comparison DNA" to the nucleic
acid sequence designated "PRO-DNA", wherein "PRO-DNA" represents a
hypothetical PRO-encoding nucleic acid sequence of interest,
"Comparison DNA" represents the nucleotide sequence of a nucleic
acid molecule against which the "PRO-DNA" nucleic acid molecule of
interest is being compared, and "N", "L" and "V" each represent
different hypothetical nucleotides.
[0091] Unless specifically stated otherwise, all % nucleic acid
sequence identity values used herein are obtained as described in
the immediately preceding paragraph using the ALIGN-2 computer
program. However, % nucleic acid sequence identity values may also
be obtained as described below by using the WU-BLAST-2 computer
program (Altschul et al., Methods in Enzymology 266:460-480
(1996)). Most of the WU-BLAST-2 search parameters are set to the
default values. Those not set to default values, i.e., the
adjustable parameters, are set with the following values: overlap
span=1, overlap fraction=0.125, word threshold (T)=11, and scoring
matrix=BLOSUM62. When WU-BLAST-2 is employed, a % nucleic acid
sequence identity value is determined by dividing (a) the number of
matching identical nucleotides between the nucleic acid sequence of
the PRO polypeptide-encoding nucleic acid molecule of interest
having a sequence derived from the native sequence PRO
polypeptide-encoding nucleic acid and the comparison nucleic acid
molecule of interest (i.e., the sequence against which the PRO
polypeptide-encoding nucleic acid molecule of interest is being
compared which may be a variant PRO polynucleotide) as determined
by WU-BLAST-2 by (b) the total number of nucleotides of the PRO
polypeptide-encoding nucleic acid molecule of interest. For
example, in the statement "an isolated nucleic acid molecule
comprising a nucleic acid sequence A which has or having at least
80% nucleic acid sequence identity to the nucleic acid sequence B",
the nucleic acid sequence A is the comparison nucleic acid molecule
of interest and the nucleic acid sequence B is the nucleic acid
sequence of the PRO polypeptide-encoding nucleic acid molecule of
interest.
[0092] Percent nucleic acid sequence identity may also be
determined using the sequence comparison program NCBI-BLAST2
(Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The
NCBI-BLAST2 sequence comparison program may be downloaded from
http://www.ncbi.nim.nih.gov or otherwise obtained from the National
Institute of Health, Bethesda, Md. NCBI-BLAST2 uses several search
parameters, wherein all of those search parameters are set to
default values including, for example, unmask=yes, strand=all,
expected occurrences=10, minimum low complexity length=1515,
multi-pass e-value=0.01, constant for multi-pass=25, dropoff for
final gapped alignment=25 and scoring matrix=BLOSUM62.
[0093] In situations where NCBI-BLAST2 is employed for sequence
comparisons, the % nucleic acid sequence identity of a given
nucleic acid sequence C to, with, or against a given nucleic acid
sequence D (which can alternatively be phrased as a given nucleic
acid sequence C that has or comprises a certain % nucleic acid
sequence identity to, with, or against a given nucleic acid
sequence D) is calculated as follows: 100 times the fraction W/Z
where W is the number of nucleotides scored as identical matches by
the sequence alignment program NCBI-BLAST2 in that program's
alignment of C and D, and where Z is the total number of
nucleotides in D. It will be appreciated that where the length of
nucleic acid sequence C is not equal to the length of nucleic acid
sequence D, the % nucleic acid sequence identity of C to D will not
equal the % nucleic acid sequence identity of D to C.
[0094] In other embodiments, PRO842 variant polynucleotides are
nucleic acid molecules that encode an active PRO842 polypeptide and
which are capable of hybridizing, preferably under stringent
hybridization and wash conditions, to nucleotide sequences encoding
a full-length PRO842 polypeptide as disclosed herein. PRO842
variant polypeptides may be those that are encoded by a PRO842
variant polynucleotide.
[0095] "Isolated," when used to describe the various polypeptides
disclosed herein, means polypeptide that has been identified and
separated and/or recovered from a component of its natural
environment. Contaminant components of its natural environment are
materials that would typically interfere with diagnostic or
therapeutic uses for the polypeptide, and may include enzymes,
hormones, and other proteinaceous or non-proteinaceous solutes. In
preferred embodiments, the polypeptide will be purified (1) to a
degree sufficient to obtain at least 15 residues of N-terminal or
internal amino acid sequence by use of a spinning cup sequenator,
or (2) to homogeneity by SDS-PAGE under non-reducing or reducing
conditions using Coomassie blue or, preferably, silver stain.
Isolated polypeptide includes polypeptide in situ within
recombinant cells, since at least one component of the PRO842
polypeptide natural environment will not be present. Ordinarily,
however, isolated polypeptide will be prepared by at least one
purification step.
[0096] An "isolated" PRO842 polypeptide-encoding nucleic acid or
other polypeptide-encoding nucleic acid is a nucleic acid molecule
that is identified and separated from at least one contaminant
nucleic acid molecule with which it is ordinarily associated in the
natural source of the polypeptide-encoding nucleic acid. An
isolated polypeptide-encoding nucleic acid molecule is other than
in the form or setting in which it is found in nature. Isolated
polypeptide-encoding nucleic acid molecules therefore are
distinguished from the specific polypeptide-encoding nucleic acid
molecule as it exists in natural cells. However, an isolated
polypeptide-encoding nucleic acid molecule includes
polypeptide-encoding nucleic acid molecules contained in cells that
ordinarily express the polypeptide where, for example, the nucleic
acid molecule is in a chromosomal location different from that of
natural cells.
[0097] The term "control sequences" refers to DNA sequences
necessary for the expression of an operably linked coding sequence
in a particular host organism. The control sequences that are
suitable for prokaryotes, for example, include a promoter,
optionally an operator sequence., and a ribosome binding site.
Eukaryotic cells are known to utilize promoters, polyadenylation
signals, and enhancers.
[0098] Nucleic acid is "operably linked" when it is placed into a
functional relationship with another nucleic acid sequence. For
example, DNA for a presequence or secretory leader is operably
linked to DNA for a polypeptide if it is expressed as a preprotein
that participates in the secretion of the polypeptide; a promoter
or enhancer is operably linked to a coding sequence if it affects
the transcription of the sequence; or a ribosome binding site is
operably linked to a coding sequence if it is positioned so as to
facilitate translation. Generally, "operably linked" means that the
DNA sequences being linked are contiguous, and, in the case of a
secretory leader, contiguous and in reading phase. However,
enhancers do not have to be contiguous. Linking is accomplished by
ligation at convenient restriction sites. If such sites do not
exist, the synthetic oligonucleotide adaptors or linkers are used
in accordance with conventional practice.
[0099] The term "antibody" is used in the broadest sense and
specifically covers, for example, single anti-PRO842 monoclonal
antibodies (including agonist, antagonist, and neutralizing
antibodies), anti-PRO842 antibody compositions with polyepitopic
specificity, single chain anti-PRO842 antibodies, and fragments of
anti-PRO842 antibodies (see below). The term "monoclonal antibody"
as used herein refers to an antibody obtained from a population of
substantially homogeneous antibodies, i.e., the individual
antibodies comprising the population are identical except for
possible naturally-occurring mutations that may be present in minor
amounts.
[0100] "Stringency" of hybridization reactions is readily
determinable by one of ordinary skill in the art, and generally is
an empirical calculation dependent upon probe length, washing
temperature, and salt concentration. In general, longer probes
require higher temperatures for proper annealing, while shorter
probes need lower temperatures. Hybridization generally depends on
the ability of denatured DNA to reanneal when complementary strands
are present in an environment below their melting temperature. The
higher the degree of desired homology between the probe and
hybridizable sequence, the higher the relative temperature which
can be used. As a result, it follows that higher relative
temperatures would tend to make the reaction conditions more
stringent, while lower temperatures less so. For additional details
and explanation of stringency of hybridization reactions, see
Ausubel et al., Current Protocols in Molecular Biology, Wiley
Interscience Publishers, (1995).
[0101] "Stringent conditions" or "high stringency conditions", as
defined herein, may be identified by those that: (1) employ low
ionic strength and high temperature for washing, for example 0.015
M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl
sulfate at 50.degree. C.; (2) employ during hybridization a
denaturing agent, such as formamide, for example, 50% (v/v)
formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1%
polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with
750 mM sodium chloride, 75 mM sodium citrate at 42.degree. C.; or
(3) employ 50% formamide, 5.times.SSC (0.75 M NaCl, 0.075 M sodium
citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium
pyrophosphate, 5.times. Denhardt's solution, sonicated salmon sperm
DNA (50 .mu.g/ml), 0.1% SDS, and 10% dextran sulfate at 42.degree.
C., with washes at 42.degree. C. in 0.2.times.SSC (sodium
chloride/sodium citrate) and 50% formamide at 55.degree. C.,
followed by a high-stringency wash consisting of 0.1.times.SSC
containing EDTA at 55.degree. C.
[0102] "Moderately stringent conditions" may be identified as
described by Sambrook et al., Molecular Cloning: A Laboratory
Manual, New York: Cold Spring Harbor Press, 1989, and include the
use of washing solution and hybridization conditions (e.g.,
temperature, ionic strength and % SDS) less stringent that those
described above. An example of moderately stringent conditions is
overnight incubation at 37.degree. C. in a solution comprising: 20%
formamide, 5.times.SSC (150 mM NaCl, 15 mM trisodium citrate), 50
mM sodium phosphate (pH 7.6), 5.times. Denhardt's solution, 10%
dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA,
followed by washing the filters in 1.times.SSC at about
37-50.degree. C. The skilled artisan will recognize how to adjust
the temperature, ionic strength, etc. as necessary to accommodate
factors such as probe length and the like.
[0103] The term "epitope tagged" when used herein refers to a
chimeric polypeptide comprising a PRO842 polypeptide fused to a
"tag polypeptide". The tag polypeptide has enough residues to
provide an epitope against which an antibody can be made, yet is
short enough such that it does not interfere with activity of the
polypeptide to which it is fused. The tag polypeptide preferably
also is fairly unique so that the antibody does not substantially
cross-react with other epitopes. Suitable tag polypeptides
generally have at least six amino acid residues and usually between
about 8 and 50 amino acid residues (preferably, between about 10
and 20 amino acid residues).
[0104] As used herein, the term "immunoadhesin" designates
antibody-like molecules which combine the binding specificity of a
heterologous protein (an "adhesin") with the effector functions of
immunoglobulin constant domains. Structurally, the immunoadhesins
comprise a fusion of an amino acid sequence with the desired
binding specificity which is other than the antigen recognition and
binding site of an antibody (i.e., is "heterologous"), and an
immunoglobulin constant domain sequence. The adhesin part of an
immunoadhesin molecule typically is a contiguous amino acid
sequence comprising at least the binding site of a receptor or a
ligand. The immunoglobulin constant domain sequence in the
immunoadhesin may be obtained from any immunoglobulin, such as
IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and
IgA-2), IgE, IgD or IgM.
[0105] The term "antagonist" is used in the broadest sense, and
includes any molecule that partially or fully blocks, inhibits, or
neutralizes a biological activity of a native PRO842 polypeptide
disclosed herein. In a similar manner, the term "agonist" is used
in the broadest sense and includes any molecule that mimics a
biological activity of a native PRO842 polypeptide disclosed
herein. Suitable agonist or antagonist molecules specifically
include agonist or antagonist antibodies or antibody fragments,
fragments or amino acid sequence variants of native PRO842
polypeptides, peptides, antisense oligonucleotides, small organic
molecules, etc. Methods for identifying agonists or antagonists of
a PRO842 polypeptide may comprise contacting a PRO842 polypeptide
with a candidate agonist or antagonist molecule and measuring a
detectable change in one or more biological activities normally
associated with the PRO842 polypeptide.
[0106] "Treatment" refers to both therapeutic treatment and
prophylactic or preventative measures, wherein the object is to
prevent or slow down (lessen) the targeted pathologic condition or
disorder. Those in need of treatment include those already with the
disorder as well as those prone to have the disorder or those in
whom the disorder is to be prevented.
[0107] "Chronic" administration refers to administration of the
agent(s) in a continuous mode as opposed to an acute mode, so as to
maintain the initial therapeutic effect (activity) for an extended
period of time. "Intermittent" administration is treatment that is
not consecutively done without interruption, but rather is cyclic
in nature.
[0108] "Mammal" for purposes of treatment refers to any animal
classified as a mammal, including humans, domestic and farm
animals, and zoo, sports, or pet animals, such as dogs, cats,
cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the
mammal is human.
[0109] Administration "in combination with" one or more further
therapeutic agents includes simultaneous (concurrent) and
consecutive administration in any order.
[0110] "Carriers" as used herein include pharmaceutically
acceptable carriers, excipients, or stabilizers which are nontoxic
to the cell or mammal being exposed thereto at the dosages and
concentrations employed. Often the physiologically acceptable
carrier is an aqueous pH buffered solution. Examples of
physiologically acceptable carriers include buffers such as
phosphate, citrate, and other organic acids; antioxidants including
ascorbic acid; low molecular weight (less than about 10 residues)
polypeptide; proteins, such as serum albumin, gelatin, or
immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone,
amino acids such as glycine, glutamine, asparagine, arginine or
lysine; monosaccharides, disaccharides, and other carbohydrates
including glucose, mannose, or dextrins; chelating agents such as
EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming
counterions such as sodium; and/or nonionic surfactants such as
TWEEN.TM., polyethylene glycol (PEG), and PLURONICS.TM..
[0111] "Antibodyfragments" comprise a portion of an intact
antibody, preferably the antigen binding or variable region of the
intact antibody. Examples of antibody fragments include Fab, Fab',
F(ab').sub.2, and Fv fragments; diabodies; linear antibodies
(Zapata et al., Protein Eng., 8(10):1057-1062 [1995]); single-chain
antibody molecules; and multispecific antibodies formed from
antibody fragments.
[0112] Papain digestion of antibodies produces two identical
antigen-binding fragments, called "Fab" fragments, each with a
single antigen-binding site, and a residual "Fc" fragment, a
designation reflecting the ability to crystallize readily. Pepsin
treatment yields an F(ab').sub.2 fragment that has two
antigen-combining sites and is still capable of cross-linking
antigen.
[0113] "Fv" is the minimum antibody fragment which contains a
complete antigen-recognition and binding site. This region consists
of a dimer of one heavy- and one light-chain variable domain in
tight, non-covalent association. It is in this configuration that
the three CDRs of each variable domain interact to define an
antigen-binding site on the surface of the V.sub.H-V.sub.L dimer.
Collectively, the six CDRs confer antigen-binding specificity to
the antibody. However, even a single variable domain (or half of an
Fv comprising only three CDRs specific for an antigen) has the
ability to recognize and bind antigen, although at a lower affinity
than the entire binding site.
[0114] The Fab fragment also contains the constant domain of the
light chain and the first constant domain (CH1) of the heavy chain.
Fab fragments differ from Fab' fragments by the addition of a few
residues at the carboxy terminus of the heavy chain CH 1 domain
including one or more cysteines from the antibody hinge region.
Fab'-SH is the designation herein for Fab' in which the cysteine
residue(s) of the constant domains bear a free thiol group.
F(ab').sub.2 antibody fragments originally were produced as pairs
of Fab' fragments which have hinge cysteines between them. Other
chemical couplings of antibody fragments are also known.
[0115] The "light chains" of antibodies (immunoglobulins) from any
vertebrate species can be assigned to one of two clearly distinct
types, called kappa and lambda, based on the amino acid sequences
of their constant domains.
[0116] Depending on the amino acid sequence of the constant domain
of their heavy chains, irrununoglobulins can be assigned to
different classes. There are five major classes of immunoglobulins:
IgA, IgD, IgE, IgG, and IgM, and several of these may be further
divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4,
IgA, and IgA2.
[0117] "Single-chain Fv" or "sFv" antibody fragments comprise the
V.sub.H and V.sub.L domains of antibody, wherein these domains are
present in a single polypeptide chain. Preferably, the Fv
polypeptide further comprises a polypeptide linker between the
V.sub.H and V.sub.L domains which enables the sFv to form the
desired structure for antigen binding. For a review of sFv, see
Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113,
Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315
(1994).
[0118] The term "diabodies" refers to small antibody fragments with
two antigen-binding sites, which fragments comprise a heavy-chain
variable domain (V.sub.H) connected to a light-chain variable
domain (V.sub.L) in the same polypeptide chain (V.sub.H-V.sub.L).
By using a linker that is too short to allow pairing between the
two domains on the same chain, the domains are forced to pair with
the complementary domains of another chain and create two
antigen-binding sites. Diabodies are described more fully in, for
example. EP 404,097; WO 93/11161: and Hollinger et al., Proc. Natl.
Acad. Sci. USA, 90:6444-6448 (1993).
[0119] An "isolated" antibody is one which has been identified and
separated and/or recovered from a component of its natural
environment. Contaminant components of its natural environment are
materials which would interfere with diagnostic or therapeutic uses
for the antibody, and may include enzymes, hormones, and other
proteinaceous or nonproteinaceous solutes. In preferred
embodiments, the antibody will be purified (1) to greater than 95%
by weight of antibody as determined by the Lowry method, and most
preferably more than 99% by weight, (2) to a degree sufficient to
obtain at least 15 residues of N-terminal or internal amino acid
sequence by use of a spinning cup sequenator, or (3) to homogeneity
by SDS-PAGE under reducing or nonreducing conditions using
Coomassie blue or, preferably, silver stain. Isolated antibody
includes the antibody in situ within recombinant cells since at
least one component of the antibody's natural environment will not
be present. Ordinarily, however, isolated antibody will be prepared
by at least one purification step.
[0120] An antibody that "specifically binds to" or is "specific
for" a particular polypeptide or an epitope on a particular
polypeptide is one that binds to that particular polypeptide or
epitope on a particular polypeptide without substantially binding
to any other polypeptide or polypeptide epitope.
[0121] The word "label" when used herein refers to a detectable
compound or composition which is conjugated directly or indirectly
to the antibody so as to generate a "labeled" antibody. The label
may be detectable by itself (e.g. radioisotope labels or
fluorescent labels) or, in the case of an enzymatic label, may
catalyze chemical alteration of a substrate compound or composition
which is detectable.
[0122] By "solid phase" is meant a non-aqueous matrix to which the
antibody of the present invention can adhere. Examples of solid
phases encompassed herein include those formed partially or
entirely of glass (e.g., controlled pore glass), polysaccharides
(e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol
and silicones. In certain embodiments, depending on the context,
the solid phase can comprise the well of an assay plate; in others
it is a purification column (e.g., an affinity chromatography
column). This term also includes a discontinuous solid phase of
discrete particles, such as those described in U.S. Pat. No.
4,275,149.
[0123] A "liposome" is a small vesicle composed of various types of
lipids, phospholipids and/or surfactant which is useful for
delivery of a drug (such as a PRO842 polypeptide or antibody
thereto) to a mammal. The components of the liposome are commonly
arranged in a bilayer formation, similar to the lipid arrangement
of biological membranes.
[0124] A "small molecule" is defined herein to have a molecular
weight below about 500 Daltons.
[0125] The term "modulate" means to affect (e.g., either
upregulate, downregulate or otherwise control) the level of a
signaling pathway. Cellular processes under the control of signal
transduction include, but are not limited to, transcription of
specific genes, normal cellular functions, such as metabolism,
proliferation, differentiation, adhesion, apoptosis and survival,
as well as abnormal processes, such as transformation, blocking of
differentiation and metastasis.
[0126] "Active" or "activity" for the purposes herein refers to
form(s) of a PRO842 polypeptide which retain a biological and/or an
immunological activity of native or naturally-occurring PRO842
polypeptides, wherein "biological" activity refers to a biological
function (either inhibitory or stimulatory) caused by a native or
naturally-occurring PRO842 polypeptide other than the ability to
induce the production of an antibody against an antigenic epitope
possessed by a native or naturally-occurring PRO842 polypeptide and
an "immunological" activity refers to the ability to induce the
production of an antibody against an antigenic epitope possessed by
a native or naturally-occurring PRO842 polypeptide.
[0127] An "immunological" activity refers only to the ability to
induce the production of an antibody against an antigenic epitope
possessed by a native or naturally-occurring PRO842
polypeptide.
[0128] The term "immune related disease" means a disease in which a
component of the immune system of a mammal causes, mediates or
otherwise contributes to a morbidity in the mammal. Also included
are diseases in which stimulation or intervention of the immune
response has an ameliorative effect on progression of the disease.
Included within this term are immune-mediated inflammatory
diseases, non-immune-mediated inflammatory diseases, infectious
diseases, immunodeficiency diseases, neoplasia, etc.
[0129] The term "T cell mediated disease" means a disease in which
T cells directly or indirectly mediate or otherwise contribute to a
morbidity in a mammal. The T cell mediated disease may be
associated with cell mediated effects, lymphokine mediated effects,
etc., and even effects associated with B cells if the B cells are
stimulated, for example, by the lymphokines secreted by T
cells.
[0130] Examples of immune-related and inflammatory diseases, some
of which are immune or T cell mediated, which can be treated
according to the invention include systemic lupus erythematosis,
rheumatoid arthritis, juvenile chronic arthritis,
spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic
inflammatory myopathies (dermatomyositis, polymyositis), Sjogren's
syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic
anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria),
autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura,
immune-mediated thrombocytopenia), thyroiditis (Grave's disease,
Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic
thyroiditis), diabetes mellitus, immune-mediated renal disease
(glomerulonephritis, tubulointerstitial nephritis), demyelinating
diseases of the central and peripheral nervous systems such as
multiple sclerosis, idiopathic demyelinating polyneuropathy or
Guillain-Barre syndrome, and chronic inflammatory demyelinating
polyneuropathy, hepatobiliary diseases such as infectious hepatitis
(hepatitis A, B, C, D, E and other non-hepatotropic viruses),
autoimmune chronic active hepatitis, primary biliary cirrhosis,
granulomatous hepatitis, and sclerosing cholangitis, inflammatory
bowel disease (ulcerative colitis: Crohn's disease),
gluten-sensitive enteropathy, and Whipple's disease, autoimmune or
immune-mediated skin diseases including bullous skin diseases,
erythema multiforme and contact dermatitis, psoriasis, allergic
diseases such as asthma, allergic rhinitis, atopic dermatitis, food
hypersensitivity and urticaria, immunologic diseases of the
ovaries, immunologic diseases of the lung such as eosinophilic
pneumonia, idiopathic pulmonary fibrosis and hypersensitivity
pneumonitis, transplantation associated diseases including graft
rejection and graft-versus-host-disease. Infectious diseases
including viral diseases such as AIDS (HIV infection), hepatitis A,
B, C, D, and E, herpes, etc., bacterial infections, fungal
infections, protozoal infections and parasitic infections.
[0131] The term "effective amount" is a concentration or amount of
a PRO842 polypeptide and/or agonist/antagonist which results in
achieving a particular stated purpose. An "effective amount" of a
PRO842 polypeptide or agonist or antagonist thereof may be
determined empirically. Furthermore, a "therapeutically effective
amount" is a concentration or amount of a PRO842 polypeptide and/or
agonist/antagonist which is effective for achieving a stated
therapeutic effect. This amount may also be determined
empirically.
[0132] The term "cytotoxic agent" as used herein refers to a
substance that inhibits or prevents the function of cells and/or
causes destruction of cells. The term is intended to include
radioactive isotopes (e.g., I.sup.131, I.sup.125, Y.sup.90 and
Re.sup.186), chemotherapeutic agents, and toxins such as
enzymatically active toxins of bacterial, fungal, plant or animal
origin, or fragments thereof.
[0133] A "chemotherapeutic agent" is a chemical compound useful in
the treatment of cancer. Examples of chemotherapeutic agents
include adriamycin, doxorubicin, epirubicin, 5-fluorouracil,
cytosine arabinoside ("Ara-C"), cyclophosphamide, thiotepa,
busulfan, cytoxin, taxoids, e.g., paclitaxel (Taxol, Bristol-Myers
Squibb Oncology, Princeton, N.J.), and doxetaxel (Taxotere,
Rhone-Poulenc Rorer, Antony, France), toxotere, methotrexate,
cisplatin, melphalan, vinblastine, bleomycin, etoposide,
ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine,
carboplatin, teniposide, daunomycin, carminomycin, aminopterin,
dactinomycin, mitomycins, esperamicins (see U.S. Pat. No.
4,675,187), melphalan and other related nitrogen mustards. Also
included in this definition are hormonal agents that act to
regulate or inhibit hormone action on tumors such as tamoxifen and
onapristone.
[0134] A "growth inhibitory agent" when used herein refers to a
compound or composition which inhibits growth of a cell, especially
cancer cell overexpressing any of the genes identified herein,
either in vitro or in vivo. Thus, the growth inhibitory agent is
one which significantly reduces the percentage of cells
overexpressing such genes in S phase. Examples of growth inhibitory
agents include agents that block cell cycle progression (at a place
other than S phase), such as agents that induce G1 arrest and
M-phase arrest. Classical M-phase blockers include the vincas
(vincristine and vinblastine), taxol, and topo II inhibitors such
as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin.
Those agents that arrest G1 also spill over into S-phase arrest,
for example, DNA alkylating agents such as tamoxifen, prednisone,
dacarbazine, mechlorethamine, cisplatin, methotrexate,
5-fluorouracil, and ara-C. Further information can be found in The
Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1,
entitled "Cell cycle regulation, oncogens, and antineoplastic
drugs" by Murakami et al., (W B Saunders: Philadelphia, 1995),
especially p. 13.
[0135] The term "cytokine" is a generic term for proteins released
by one cell population which act on another cell as intercellular
mediators. Examples of such cytokines are lymphokines, monokines,
and traditional polypeptide hormones. Included among the cytokines
are growth hormone such as human growth hormone, N-methionyl human
growth hormone, and bovine growth hormone; parathyroid hormone;
thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein
hormones such as follicle stimulating hormone (FSH), thyroid
stimulating hormone (TSH), and luteinizing hormone (LH); hepatic
growth factor; fibroblast growth factor; prolactin; placental
lactogen; tumor necrosis factor-.alpha. and -.beta.;
mullerian-inhibiting substance; mouse gonadotropin-associated
peptide; inhibin; activin; vascular endothelial growth factor;
integrin; thrombopoietin (TPO); nerve growth factors such as NGF-P;
platelet-growth factor; transforming growth factors (TGFs) such as
TGF-.alpha. and TGF-.beta.; insulin-like growth factor-I and -II;
erythropoietin (EPO); osteoinductive factors; interferons such as
interferon-.alpha., -.beta., and -.gamma.; colony stimulating
factors (CSFs) such as macrophage-CSF (M-CSF);
granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF);
interleukins (I Ls) such as IL-1, IL-1a, IL-2. IL-3. IL-4, IL-5.
IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, or IL-17: a tumor
necrosis factor such as TNF-.alpha. or TNF-.beta.: and other
polypeptide factors including leukemia inhibitory factor (LIF) and
kit ligand (KL). As used herein, the term cytokine includes
proteins from natural sources or from recombinant cell culture and
biologically active equivalents of the native sequence
cytokines.
[0136] The term "chemokine" refers to a class of molecules
belongiong to the family of proinflammatory cytokines of low
molecular mass (8-11 kDa) characterized by a structurally conserved
motif and their ability to mediate leukocyte chemotaxis, thus
playing a role in leukocyte trafficking as well as playing a role
in leukocyte regulation. TABLE-US-00001 TABLE 2 PRO XXXXXXXXXXXXXXX
(Length = 15 amino acids) Comparison XXXXXYYYYYYY (Length = 12
amino acids) Protein % amino acid sequence identity = (the number
of identically matching amino acid residues between the two
polypeptide sequences as determined by ALIGN-2) divided by (the
total number of amino acid residues of the PRO polypeptide) = 5
divided by 15 = 33.3%
[0137] TABLE-US-00002 TABLE 3 PRO XXXXXXXXXX (Length = 10 amino
acids) Comparison XXXXXYYYYYYZZYZ (Length = 15 amino acids) Protein
% amino acid sequence identity = (the number of identically
matching amino acid residues between the two polypeptide sequences
as determined by ALIGN-2) divided by (the total number of amino
acid residues of the PRO polypeptide) = 5 divided by 10 = 50%
[0138] TABLE-US-00003 TABLE 4 PRO-DNA NNNNNNNNNNNNNN (Length = 14
nucleotides) Comparison NNNNNNLLLLLLLLLL (Length = 16 nucleotides)
DNA % nucleic acid sequence identity = (the number of identically
matching nucleotides between the two nucleic acid sequences as
determined by ALIGN-2) divided by (the total number of nucleotides
of the PRO-DNA nucleic acid sequence) = 6 divided by 14 = 42.9%
[0139] TABLE-US-00004 TABLE 5 PRO-DNA NNNNNNNNNNNN (Length = 12
nucleotides) Comparison DNA NNNNLLLVV (Length = 9 nucleotides) %
nucleic acid sequence identity = (the number of identically
matching nucleotides between the two nucleic acid sequences as
determined by ALIGN-2) divided by (the total number of nucleotides
of the PRO-DNA nucleic acid sequence) = 4 divided by 12 = 33.3%
II. Compositions and Methods of the Invention
[0140] A. Full-Length PRO842 Polypeptides
[0141] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO842 polypeptides. In particular, cDNAs
encoding various PRO842 polypeptides have been identified and
isolated, as disclosed in further detail in the Examples below. It
is noted that proteins produced in separate expression rounds may
be given different PRO numbers but the UNQ number is unique for any
given DNA and the encoded protein, and will not be changed.
However, for sake of simplicity, in the present specification the
protein encoded by the full length native nucleic acid molecules
disclosed herein as well as all further native homologues and
variants included in the foregoing definition of PRO, will be
referred to as "PRO/number", regardless of their origin or mode of
preparation.
[0142] As disclosed in the Examples below, cDNA clones have been
deposited with the ATCC. The actual nucleotide sequences of those
clones can readily be determined by the skilled artisan by
sequencing of the deposited clone using routine methods in the art.
The predicted amino acid sequence can be determined from the
nucleotide sequence using routine skill. For the PRO842
polypeptides and encoding nucleic acids described herein,
Applicants have identified what is believed to be the reading frame
best identifiable with the sequence information available at the
time.
[0143] B. PRO842 Polypeptide Variants
[0144] In addition to the full-length native sequence PRO842
polypeptides described herein, it is contemplated that PRO842
variants can be prepared. PRO842 variants can be prepared by
introducing appropriate nucleotide changes into the PRO842 DNA,
and/or by synthesis of the desired PRO842 polypeptide. Those
skilled in the art will appreciate that amino acid changes may
alter post-translational processes of the PRO842, such as changing
the number or position of glycosylation sites or altering the
membrane anchoring characteristics.
[0145] Variations in the native full-length sequence PRO842 or in
various domains of the PRO842 described herein, can be made, for
example, using any of the techniques and guidelines for
conservative and non-conservative mutations set forth, for
instance, in U.S. Pat. No. 5,364,934. Variations may be a
substitution, deletion or insertion of one or more codons encoding
the PRO842 that results in a change in the amino acid sequence of
the PRO842 as compared with the native sequence PRO842. Optionally
the variation is by substitution of at least one amino acid with
any other amino acid in one or more of the domains of the PRO842.
Guidance in determining which amino acid residue may be inserted,
substituted or deleted without adversely affecting the desired
activity may be found by comparing the sequence of the PRO842 with
that of homologous known protein molecules and minimizing the
number of amino acid sequence changes made in regions of high
homology. Amino acid substitutions can be the result of replacing
one amino acid with another amino acid having similar structural
and/or chemical properties, such as the replacement of a leucine
with a serine, i.e., conservative amino acid replacements.
Insertions or deletions may optionally be in the range of about 1
to 5 amino acids. The variation allowed may be determined by
systematically making insertions, deletions or substitutions of
amino acids in the sequence and testing the resulting variants for
activity exhibited by the full-length or mature native
sequence.
[0146] PRO842 polypeptide fragments are provided herein. Such
fragments may be truncated at the N-terminus or C-terminus, or may
lack internal residues, for example, when compared with a full
length native protein. Certain fragments lack amino acid residues
that are not essential for a desired biological activity of the
PRO842 polypeptide.
[0147] PRO842 fragments may be prepared by any of a number of
conventional techniques. Desired peptide fragments may be
chemically synthesized. An alternative approach involves generating
PRO842 fragments by enzymatic digestion, e.g., by treating the
protein with an enzyme known to cleave proteins at sites defined by
particular amino acid residues, or by digesting the DNA with
suitable restriction enzymes and isolating the desired fragment.
Yet another suitable technique involves isolating and amplifying a
DNA fragment encoding a desired polypeptide fragment, by polymerase
chain reaction (PCR). Oligonucleotides that define the desired
termini of the DNA fragment are employed at the 5' and 3' primers
in the PCR. Preferably, PRO842 polypeptide fragments share at least
one biological and/or immunological activity with the native PRO842
polypeptide disclosed herein.
[0148] In particular embodiments, conservative substitutions of
interest are shown in Table 6 under the heading of preferred
substitutions. If such substitutions result in a change in
biological activity, then more substantial changes, denominated
exemplary substitutions in Table 6, or as further described below
in reference to amino acid classes, are introduced and the products
screened. TABLE-US-00005 TABLE 6 Original Exemplary Preferred
Residue Substitutions Substitutions Ala (A) val; leu; ile val Arg
(R) lys; gln; asn lys Asn (N) gln; his; lys; arg gln Asp (D) glu
glu Cys (C) ser ser Gln (Q) asn asn Glu (E) asp asp Gly (G) pro;
ala ala His (H) asn; gln; lys; arg arg Ile (I) leu; val; met; ala;
phe; leu norleucine Leu (L) norleucine; ile; val; ile met; ala; phe
Lys (K) arg; gln; asn arg Met (M) leu; phe; ile leu Phe (F) leu;
val; ile; ala; tyr leu Pro (P) ala ala Ser (S) thr thr Thr (T) ser
ser Trp (W) tyr; phe tyr Tyr (Y) trp; phe; thr; ser phe Val (V)
ile; leu; met; phe; leu ala; norleucine
[0149] Substantial modifications in function or immunological
identity of the PRO842 polypeptide are accomplished by selecting
substitutions that differ significantly in their effect on
maintaining (a) the structure of the polypeptide backbone in the
area of the substitution, for example, as a sheet or helical
conformation, (b) the charge or hydrophobicity of the molecule at
the target site, or (c) the bulk of the side chain. Naturally
occurring residues are divided into groups based on common
side-chain properties: [0150] (1) hydrophobic: norleucine, met,
ala, val, leu, ile; [0151] (2) neutral hydrophilic: cys, ser, thr;
[0152] (3) acidic: asp, glu; [0153] (4) basic: asn, gin, his, lys,
arg; [0154] (5) residues that influence chain orientation: gly,
pro; and [0155] (6) aromatic: trp, tyr, phe.
[0156] Non-conservative substitutions will entail exchanging a
member of one of these classes for another class. Such substituted
residues also may be introduced into the conservative substitution
sites or, more preferably, into the remaining (non-conserved)
sites.
[0157] The variations can be made using methods known in the art
such as oligonucleotide-mediated (site-directed) mutagenesis,
alanine scanning, and PCR mutagenesis. Site-directed mutagenesis
[Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al.,
Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis (Wells et
al. Gene, 34:315 [1985]), restriction selection mutagenesis (Wells
et al., Philos. Trans. R. Soc. London SerA. 317:415 (1986]) or
other known techniques can be performed on the cloned DNA to
produce the PRO842 variant DNA.
[0158] Scanning amino acid analysis can also be employed to
identify one or more amino acids along a contiguous sequence. Among
the preferred scanning amino acids are relatively small, neutral
amino acids. Such amino acids include alanine, glycine, serine, and
cysteine. Alanine is typically a preferred scanning amino acid
among this group because it eliminates the side-chain beyond the
beta-carbon and is less likely to alter the main-chain conformation
of the variant (Cunningham and Wells, Science, 244: 1081-1085
[1989]). Alanine is also typically preferred because it is the most
common amino acid. Further, it is frequently found in both buried
and exposed positions (Creighton, The Proteins, (W.H. Freeman &
Co., N.Y.); Chothia, J. Mol. Biol., 150:1 [1976]). If alanine
substitution does not yield adequate amounts of variant, an
isoteric amino acid can be used.
[0159] C. Modifications of PRO842
[0160] Covalent modifications of PRO842 are included within the
scope of this invention. One type of covalent modification includes
reacting targeted amino acid residues of a PRO842 polypeptide with
an organic derivatizing agent that is capable of reacting with
selected side chains or the N- or C-terminal residues of the
PRO842. Derivatization with bifunctional agents is useful, for
instance, for crosslinking PRO842 to a water-insoluble support
matrix or surface for use in the method for purifying anti-PRO842
antibodies, and vice-versa. Commonly used crosslinking agents
include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde,
N-hydroxysuccinimide esters, for example, esters with
4-azidosalicylic acid, homobifunctional imidoesters, including
disuccinimidyl esters such as
3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides
such as bis-N-maleimido-1,8-octane and agents such as
methyl-3-[(p-azidophenyl)dithio]propioimidate.
[0161] Other modifications include deamidation of glutaminyl and
asparaginyl residues to the corresponding glutamyl and aspartyl
residues, respectively, hydroxylation of proline and lysine,
phosphorylation of hydroxyl groups of seryl or threonyl residues,
methylation of the .alpha.-amino groups of lysine, arginine, and
histidine side chains [T. E. Creighton, Proteins: Structure and
Molecular Properties, W.H. Freeman & Co., San Francisco, pp.
79-86 (1983)], acetylation of the N-terminal amine, and amidation
of any C-terminal carboxyl group.
[0162] Another type of covalent modification of the PRO842
polypeptide included within the scope of this invention comprises
altering the native glycosylation pattern of the polypeptide.
"Altering the native glycosylation pattern" is intended for
purposes herein to mean deleting one or more carbohydrate moieties
found in native sequence PRO842 (either by removing the underlying
glycosylation site or by deleting the glycosylation by chemical
and/or enzymatic means), and/or adding one or more glycosylation
sites that are not present in the native sequence PRO842. In
addition, the phrase includes qualitative changes in the
glycosylation of the native proteins, involving a change in the
nature and proportions of the various carbohydrate moieties
present. Addition of glycosylation sites to the PRO842 polypeptide
may be accomplished by altering the amino acid sequence. The
alteration may be made, for example, by the addition of, or
substitution by, one or more serine or threonine residues to the
native sequence PRO842 (for O-liriked glycosylation sites). The
PRO842 amino acid sequence may optionally be altered through
changes at the DNA level, particularly by mutating the DNA encoding
the PRO842 polypeptide at preselected bases such that codons are
generated that will translate into the desired amino acids.
[0163] Another means of increasing the number of carbohydrate
moieties on the PRO842 polypeptide is by chemical or enzymatic
coupling of glycosides to the polypeptide. Such methods are
described in the art. e.g., in WO 87/05330 published 11 Sep. 1987,
and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306
(1981).
[0164] Removal of carbohydrate moieties present on the PRO842
polypeptide may be accomplished chemically or enzymatically or by
mutational substitution of codons encoding for amino acid residues
that serve as targets for glycosylation. Chemical deglycosylation
techniques are known in the art and described, for instance, by
Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by
Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of
carbohydrate moieties on polypeptides can be achieved by the use of
a variety of endo- and exo-glycosidases as described by Thotakura
et al., Meth. Enzymol., 138:350 (1987).
[0165] Another type of covalent modification of PRO842 comprises
linking the PRO842 polypeptide to one of a variety of
nonproteinaceous polymers, e.g., polyethylene glycol (PEG),
polypropylene glycol, or polyoxyalkylenes, in the manner set forth
in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417;
4,791,192 or 4,179,337.
[0166] The PRO842 of the present invention may also be modified in
a way to form a chimeric molecule comprising PRO842 fused to
another, heterologous polypeptide or amino acid sequence.
[0167] In one embodiment, such a chimeric molecule comprises a
fusion of the PRO842 with a tag polypeptide which provides an
epitope to which an anti-tag antibody can selectively bind. The
epitope tag is generally placed at the amino- or carboxyl-terminus
of the PRO842. The presence of such epitope-tagged forms of the
PRO842 can be detected using an antibody against the tag
polypeptide. Also, provision of the epitope tag enables the PRO842
to be readily purified by affinity purification using an anti-tag
antibody or another type of affinity matrix that binds to the
epitope tag. Various tag polypeptides and their respective
antibodies are well known in the art. Examples include
poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly)
tags; the flu HA tag polypeptide and its antibody 12CA5 (Field et
al., Mol. Cell. Biol., 8:2159-2165 (1988)1; the c-myc tag and the
8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al.,
Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes
Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et
al., Protein Engineering, 3(6):547-553 (1990)]. Other tag
polypeptides include the Flag-peptide [Hopp et al., BioTechnology,
6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al.,
Science, 255:192-194 (1992)]; an .alpha.-tubulin epitope peptide
[Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the
T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl.
Acad. Sci. USA, 87:6393-6397 (1990)].
[0168] In an alternative embodiment, the chimeric molecule may
comprise a fusion of the PRO842 with an immunoglobulin or a
particular region of an immunoglobulin. For a bivalent form of the
chimeric molecule (also referred to as an "immunoadhesin"), such a
fusion could be to the Fc region of an IgG molecule. The Ig fusions
preferably include the substitution of a soluble (transmembrane
domain deleted or inactivated) form of a PRO842 polypeptide in
place of at least one variable region within an Ig molecule. In a
particularly preferred embodiment, the immunoglobulin fusion
includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3
regions of an IgG1 molecule. For the production of immunoglobulin
fusions see also U.S. Pat. No. 5,428,130 issued Jun. 27, 1995.
[0169] In yet a further embodiment, the PRO842 polypeptides of the
present invention may also be modified in a way to form a chimeric
molecule comprising a PRO842 polypeptide fused to a leucine zipper.
Various leucine zipper polypeptides have been described in the art.
See, e.g., Landschulz et al., Science, 240:1759 (1988); WO
94/10308; Hoppe et al., FEBS Letters. 344:1991(1994); Maniatis et
al., Nature, 341:24 (1989). It is believed that use of a leucine
zipper fused to a PRO842 polypeptide may be desirable to assist in
dimerizing or trimerizing soluble PRO842 polypeptide in solution.
Those skilled in the art will appreciate that the leucine zipper
may be fused at either the- or C-terminal end of the PRO842
molecule.
[0170] D. Preparation of PRO842
[0171] The description below relates primarily to production of
PRO842 by culturing cells transformed or transfected with a vector
containing PRO842 nucleic acid. It is, of course, contemplated that
alternative methods, which are well known in the art, may be
employed to prepare PRO842. For instance, the PRO842 sequence, or
portions thereof, may be produced by direct peptide synthesis using
solid-phase techniques [see, e.g., Stewart et al., Solid-Phase
Peptide Synthesis, W.H. Freeman Co., San Francisco, Calif. (1969);
Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. In vitro
protein synthesis may be performed using manual techniques or by
automation. Automated synthesis may be accomplished, for instance,
using an Applied Biosystems Peptide Synthesizer (Foster City,
Calif.) using manufacturer's instructions. Various portions of the
PRO842 may be chemically synthesized separately and combined using
chemical or enzymatic methods to produce the full-length
PRO842.
[0172] 1. Isolation of DNA Encoding PRO842
[0173] DNA encoding PRO842 may be obtained from a cDNA library
prepared from tissue believed to possess the PRO842 mRNA and to
express it at a detectable level. Accordingly, human PRO842 DNA can
be conveniently obtained from a cDNA library prepared from human
tissue, such as described in the Examples. The PRO842-encoding gene
may also be obtained from a genomic library or by known synthetic
procedures (e.g., automated nucleic acid synthesis).
[0174] Libraries can be screened with probes (such as antibodies to
the PRO842 or oligonucleotides of at least about 20-80 bases)
designed to identify the gene of interest or the protein encoded by
it. Screening the cDNA or genomic library with the selected probe
may be conducted using standard procedures, such as described in
Sambrook et al., Molecular Cloning: A Laboratory Manual (New York:
Cold Spring Harbor Laboratory Press, 1989). An alternative means to
isolate the gene encoding PRO842 is to use PCR methodology
[Sambrook et al., supra; Dieffenbach et al., PCR Primer: A
Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].
[0175] The Examples below describe techniques for screening a cDNA
library. The oligonucleotide sequences selected as probes should be
of sufficient length and sufficiently unambiguous that false
positives are minimized. The oligonucleotide is preferably labeled
such that it can be detected upon hybridization to DNA in the
library being screened. Methods of labeling are well known in the
art, and include the use of radiolabels like .sup.2P-labeled ATP,
biotinylation or enzyme labeling. Hybridization conditions,
including moderate stringency and high stringency, are provided in
Sambrook et al., supra.
[0176] Sequences identified in such library screening methods can
be compared and aligned to other known sequences deposited and
available in public databases such as GenBank or other private
sequence databases. Sequence identity (at either the amino acid or
nucleotide level) within defined regions of the molecule or across
the full-length sequence can be determined using methods known in
the art and as described herein.
[0177] Nucleic acid having protein coding sequence may be obtained
by screening selected cDNA or genomic libraries using the deduced
amino acid sequence disclosed herein for the first time, and, if
necessary, using conventional primer extension procedures as
described in Sambrook et al., supra, to detect precursors and
processing intermediates of mRNA that may not have been
reverse-transcribed into cDNA.
[0178] 2. Selection and Transformation of Host Cells
[0179] Host cells are transfected or transformed with expression or
cloning vectors described herein for PRO842 production and cultured
in conventional nutrient media modified as appropriate for inducing
promoters, selecting transformants, or amplifying the genes
encoding the desired sequences. The culture conditions, such as
media, temperature, pH and the like, can be selected by the skilled
artisan without undue experimentation. In general, principles,
protocols, and practical techniques for maximizing the productivity
of cell cultures can be found in Mammalian Cell Biotechnology: a
Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook
et al., supra.
[0180] Methods of eukaryotic cell transfection and prokaryotic cell
transformation are known to the ordinarily skilled artisan, for
example, CaCl.sub.2, CaPO.sub.4, liposome-mediated and
electroporation. Depending on the host cell used, transformation is
performed using standard techniques appropriate to such cells. The
calcium treatment employing calcium chloride, as described in
Sambrook et al., supra, or electroporation is generally used for
prokaryotes. Infection with Agrobacterium tumefaciens is used for
transformation of certain plant cells, as described by Shaw et al.,
Gene, 23:315 (1983) and WO 89/05859 published 29 Jun. 1989. For
mammalian cells without such cell walls, the calcium phosphate
precipitation method of Graham and van der Eb, Virology, 52:456-457
(1978) can be employed. General aspects of mammalian cell host
system transfections have been described in U.S. Pat. No.
4,399,216. Transformaitions into yeast are typically carried out
according to the method of Van Solingen et al., J. Bact., 130:946
(1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829
(1979). However, other methods for introducing DNA into cells, such
as by nuclear microinjection, electroporation, bacterial protoplast
fusion with intact cells, or polycations, e.g., polybrene,
polyornithine, may also be used. For various techniques for
transforming mammalian cells, see Keown et al., Methods in
Enzymology, 185:527-537 (1990) and Mansour et al., Nature,
336:348-352 (1988).
[0181] Suitable host cells for cloning or expressing the DNA in the
vectors herein include prokaryote, yeast, or higher eukaryote
cells. Suitable prokaryotes include but are not limited to
eubacteria, such as Gram-negative or Gram-positive organisms, for
example, Enterobacteriaceae such as E. coli. Various E. coli
strains are publicly available, such as E. coli K12 strain MM294
(ATCC 31,446); E. coli X1776 (ATCC 31,537); E. coli strain W3110
(ATCC 27,325) and K5772 (ATCC 53,635). Other suitable prokaryotic
host cells include Enterobacteriaceae such as Escherichia, e.g., E.
coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g.,
Salmonella typhimurium, Serratia, e.g., Serratia narcescans, and
Shigella, as well as Bacilli such as B. subtilis and B.
licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710
published 12 Apr. 1989), Pseudomonas such as P. aeruginosa, and
Streptomyces. These examples are illustrative rather than limiting.
Strain W3110 is one particularly preferred host or parent host
because it is a common host strain for recombinant DNA product
fermentations. Preferably, the host cell secretes minimal amounts
of proteolytic enzymes. For example, strain W3110 may be modified
to effect a genetic mutation in the genes encoding proteins
endogenous to the host, with examples of such hosts including E.
coli W3110 strain IA2, which has the complete genotype tonA; E.
coli W3110 strain 9E4, which has the complete genotype tonA ptr3;
E. coli W3110 strain 27C7 (ATCC 55,244), which has the complete
genotype tonA ptr3 phoA E15 (argF-lac)169 degp ompT kan.sup.r; E.
coli W3110 strain 37D6, which has the complete genotype tonA
ptr3phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan.sup.r; E. coli
W3110 strain 40B4, which is strain 37D6 with a non-kanamycin
resistant degP deletion mutation; and an E. coli strain having
mutant periplasmic protease disclosed in U.S. Pat. No. 4,946,783
issued 7 Aug. 1990. Alternatively, in vitro methods of cloning,
e.g., PCR or other nucleic acid polymerase reactions, are
suitable.
[0182] In addition to prokaryotes, eukaryotic microbes such as
filamentous fungi or yeast are suitable cloning or expression hosts
for PRO842-encoding vectors. Saccharomyces cerevisiae is a commonly
used lower eukaryotic host microorganism. Others include
Schizosaccharomyces pombe [Beach and Nurse, Nature, 290: 140
(1981); EP 139,383 published 2 May 1985]; Kluyveromyces hosts (U.S.
Pat. No. 4,943,529; Fleer et al., Bio/Technology, 2:968-975 [1991])
such as, e.g., K. lactis (MW98-8C, CBS683, CBS4574; Louvencourt et
al., J. Bacteriol., 154(2):737-742 [1983]), K. fragilis (ATCC
12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178),
K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906; Van den
Berg et al., Bio/Technology, 8:135 [1990]), K. thermotolerans, and
K. narxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070;
Sreekrishna et al., J. Basic Microbiol., 28:265-278 [1988]);
Candida, Trichoderma reesia (EP 244,234); Neurospora crassa (Case
et al., Proc. Natl. Acad. Sci. USA, 76:5259-5263 [1979]);
Schwanniomyces such as Schwanniomyces occidentalis (EP 394,538
published 31 Oct. 1990); and filamentous fungi such as, e.g.,
Neurospora, Penicillium, Tolypocladium (WO 91/00357 published 10
Jan. 1991), and Aspergillus hosts such as A. nidulans (Ballance et
al., Biochem. Biophys. Res. Commun., 112:284-289 [1983]; Tilburn et
al., Gene, 26:205-221 [1983]; Yeltonetal., Proc. Natl. Acad. Sci.
USA, 81:1470-1474 [1984]) and A. niger (Kelly and Hynes, EMBO J.,
4:475-479 [1985]). Methylotropic yeasts are suitable herein and
include, but are not limited to, yeast capable of growth on
methanol selected from the genera consisting of Hansenula, Candida,
Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula. A
list of specific species that are exemplary of this class of yeasts
may be found in C. Anthony, The Biochemistry of Methylotrophs, 269
(1982).
[0183] Suitable host cells for the expression of glycosylated
PRO842 are derived from multicellular organisms. Examples of
invertebrate cells include insect cells such as Drosophila S2 and
Spodoptera Sf9 or Spodoptera High 5 cells, as well as plant cells.
Examples of useful mammalian host cell lines include Chinese
hamster ovary (CHO) and COS cells. More specific examples include
monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651);
human embryonic kidney line (293 or 293 cells subcloned for growth
in suspension culture, Graham et al., J. Gen Virol., 36:59 (1977));
Chinese hamster ovary cells/-DHFR(CHO, Urlaub and Chasin. Proc.
Natl. Acad. Sci. USA, 77:4216 [1980]); mouse sertoli cells (TM4,
Mather. Biol. Reprod. 23:243-251 [1980]); human lung cells (W138,
ATCC CCL 75); human liver cells (Hep G2, HB 8065): and mouse
mammary tumor (MMT 060562, ATCC CCL51). The selection of the
appropriate host cell is deemed to be within the skill in the
art.
[0184] 3. Selection and Use of a Replicable Vector
[0185] The nucleic acid (e.g., cDNA or genomic DNA) encoding PRO842
may be inserted into a replicable vector for cloning (amplification
of the DNA) or for expression. Various vectors are publicly
available. The vector may, for example, be in the form of a
plasmid, cosmid, viral particle, or phage. The appropriate nucleic
acid sequence may be inserted into the vector by a variety of
procedures. In general, DNA is inserted into an appropriate
restriction endonuclease site(s) using techniques known in the art.
Vector components generally include, but are not limited to, one or
more of a signal sequence, an origin of replication, one or more
marker genes, an enhancer element, a promoter, and a transcription
termination sequence. Construction of suitable vectors containing
one or more of these components employs standard ligation
techniques which are known to the skilled artisan.
[0186] The PRO842 may be produced recombinantly not only directly,
but also as a fusion polypeptide with a heterologous polypeptide,
which may be a signal sequence or other polypeptide having a
specific cleavage site at the N-terminus of the mature protein or
polypeptide. In general, the signal sequence may be a component of
the vector, or it may be a part of the PRO842-encoding DNA that is
inserted into the vector. The signal sequence may be a prokaryotic
signal sequence selected, for example, from the group of the
alkaline phosphatase, penicillinase, lpp, or heat-stable
enterotoxin II leaders. For yeast secretion the signal sequence may
be, e.g., the yeast invertase leader, alpha factor leader
(including Saccharomyces and Kluyveromyces .alpha.-factor leaders,
the latter described in U.S. Pat. No. 5,010,182), or acid
phosphatase leader, the C. albicans glucoamylase leader (EP 362,179
published 4 Apr. 1990), or the signal described in WO 90/13646
published 15 Nov. 1990. In mammalian cell expression, mammalian
signal sequences may be used to direct secretion of the protein,
such as signal sequences from secreted polypeptides of the same or
related species, as well as viral secretory leaders.
[0187] Both expression and cloning vectors contain a nucleic acid
sequence that enables the vector to replicate in one or more
selected host cells. Such sequences are well known for a variety of
bacteria, yeast, and viruses. The origin of replication from the
plasmid pBR322 is suitable for most Gram-negative bacteria, the
2.mu. plasmid origin is suitable for yeast, and various viral
origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for
cloning vectors in mammalian cells.
[0188] Expression and cloning vectors will typically contain a
selection gene, also termed a selectable marker. Typical selection
genes encode proteins that (a) confer resistance to antibiotics or
other toxins, e.g., ampicillin, neomycin, methotrexate, or
tetracycline, (b) complement auxotrophic deficiencies, or (c)
supply critical nutrients not available from complex media, e.g.,
the gene encoding D-alanine racemase for Bacilli.
[0189] An example of suitable selectable markers for mammalian
cells are those that enable the identification of cells competent
to take up the PRO842-encoding nucleic acid, such as DHFR or
thymidine kinase. An appropriate host cell when wild-type DHFR is
employed is the CHO cell line deficient in DHFR activity, prepared
and propagated as described by Urlaub et al., Proc. Natl. Acad.
Sci. USA, 77:4216 (1980). A suitable selection gene for use in
yeast is the Irpl gene present in the yeast plasmid YRp7
[Stinchcomb et al. Nature, 282:39 (1979); Kingsman et al., Gene,
7:141 (1979); Tschemper et al., Gene, 10: 157 (1980)]. The trpi
gene provides a selection marker for a mutant strain of yeast
lacking the ability to grow in tryptophan, for example, ATCC No.
44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].
[0190] Expression and cloning vectors usually contain a promoter
operably linked to the PRO842-encoding nucleic acid sequence to
direct mRNA synthesis. Promoters recognized by a variety of
potential host cells are well known. Promoters suitable for use
with prokaryotic hosts include the P-lactamase and lactose promoter
systems [Chang et al., Nature, 275:615 (1978); Goeddel et al.,
Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (trp)
promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP
36,776], and hybrid promoters such as the tac promoter [deBoer et
al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for
use in bacterial systems also will contain a Shine-Dalgarno (S.D.)
sequence operably linked to the DNA encoding PRO842.
[0191] Examples of suitable promoting sequences for use with yeast
hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman
et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic
enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland,
Biochemistry, 17:4900 (1978)], such as enolase,
glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate
decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase,
3-phosphoglycerate mutase, pyruvate kinase, triosephosphate
isomerase, phosphoglucose isomerase, and glucokinase.
[0192] Other yeast promoters, which are inducible promoters having
the additional advantage of transcription controlled by growth
conditions, are the promoter regions for alcohol dehydrogenase 2,
isocytochrome C, acid phosphatase, degradative enzymes associated
with nitrogen metabolism, metallothionein,
glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible
for maltose and galactose utilization. Suitable vectors and
promoters for use in yeast expression are further described in EP
73,657.
[0193] PRO842 transcription from vectors in mammalian host cells is
controlled, for example, by promoters obtained from the genomes of
viruses such as polyoma virus, fowipox virus (UK 2,211,504
published 5 Jul. 1989), adenovirus (such as Adenovirus 2), bovine
papilloma virus, avian sarcoma virus, cytomegalovirus, a
retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from
heterologous mammalian promoters, e.g., the actin promoter or an
immunoglobulin promoter, and from heat-shock promoters, provided
such promoters are compatible with the host cell systems.
[0194] Transcription of a DNA encoding the PRO842 by higher
eukaryotes may be increased by inserting an enhancer sequence into
the vector. Enhancers are cis-acting elements of DNA, usually about
from 10 to 300 bp, that act on a promoter to increase its
transcription. Many enhancer sequences are now known from mammalian
genes (globin, elastase, albumin, .alpha.-fetoprotein, and
insulin). Typically, however, one will use an enhancer from a
eukaryotic cell virus. Examples include the SV40 enhancer on the
late side of the replication origin (bp 100-270), the
cytomegalovirus early promoter enhancer, the polyoma enhancer on
the late side of the replication origin, and adenovirus enhancers.
The enhancer may be spliced into the vector at a position 5' or 3'
to the PRO842 coding sequence, but is preferably located at a site
5' from the promoter.
[0195] Expression vectors used in eukaryotic host cells (yeast,
fungi, insect, plant, animal, human, or nucleated cells from other
multicellular organisms) will also contain sequences necessary for
the termination of transcription and for stabilizing the mRNA. Such
sequences are commonly available from the 5' and, occasionally 3',
untranslated regions of eukaryotic or viral DNAs or cDNAs. These
regions contain nucleotide segments transcribed as polyadenylated
fragments in the untranslated portion of the mRNA encoding
PRO842.
[0196] Still other methods, vectors, and host cells suitable for
adaptation to the synthesis of PRO842 in recombinant vertebrate
cell culture are described in Gething et al., Nature, 293:620-625
(1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP
117,058.
[0197] 4. Detecting Gene Amplification/Expression
[0198] Gene amplification and/or expression may be measured in a
sample directly, for example, by conventional Southern blotting,
Northern blotting to quantitate the transcription of mRNA (Thomas,
Proc. Natl. Acad. Sci. USA, 77:5201-5205 [1980]), dot blotting (DNA
analysis), or in situ hybridization, using an appropriately labeled
probe, based on the sequences provided herein. Alternatively,
antibodies may be employed that can recognize specific duplexes,
including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes
or DNA-protein duplexes. The antibodies in turn may be labeled and
the assay may be carried out where the duplex is bound to a
surface, so that upon the formation of duplex on the surface, the
presence of antibody bound to the duplex can be detected.
[0199] Gene expression, alternatively, may be measured by
immunological methods, such as immunohistochemical staining of
cells or tissue sections and assay of cell culture or body fluids,
to quantitate directly the expression of gene product. Antibodies
useful for immunohistochemical staining and/or assay of sample
fluids may be either monoclonal or polyclonal, and may be prepared
in any mammal. Conveniently, the antibodies may be prepared against
a native sequence PRO842 polypeptide or against a synthetic peptide
based on the DNA sequences provided herein or against exogenous
sequence fused to PRO842 DNA and encoding a specific antibody
epitope.
[0200] 5. Purification of Polypeptide
[0201] Forms of PRO842 may be recovered from culture medium or from
host cell lysates. If membrane-bound, it can be released from the
membrane using a suitable detergent solution (e.g., Triton-X 100)
or by enzymatic cleavage. Cells employed in expression of PRO842
can be disrupted by various physical or chemical means, such as
freeze-thaw cycling, sonication, mechanical disruption, or cell
lysing agents.
[0202] It may be desired to purify PRO842 from recombinant cell
proteins or polypeptides. The following procedures are exemplary of
suitable purification procedures: by fractionation on an
ion-exchange column; ethanol precipitation; reverse phase HPLC;
chromatography on silica or on a cation-exchange resin such as
DEAE: chromatofocusing; SDS-PAGE; ammonium sulfate precipitation;
gel filtration using, for example, Sephadex G-75; Protein A
Sepharose columns to remove contaminants such as [gG; and metal
chelating columns to bind epitope-tagged forms of the PRO842.
Various methods of protein purification may be employed and such
methods are known in the art and described for example in
Deutscher, Methods in Enzymology, 182 (1990): Scopes. Protein
Purification: Principles and Practice, Springer-Verlag. New York
(1982). The purification step(s) selected will depend, for example,
on the nature of the production process used and the particular
PRO842 produced.
[0203] E. Uses for PRO842
[0204] Nucleotide sequences (or their complement) encoding PRO842
have various applications in the art of molecular biology,
including uses as hybridization probes, in chromosome and gene
mapping and in the generation of anti-sense RNA and DNA. PRO842
nucleic acid will also be useful for the preparation of PRO842
polypeptides by the recombinant techniques described herein.
[0205] The full-length native sequence PRO842 gene, or portions
thereof, may be used as hybridization probes for a cDNA library to
isolate the full-length PRO842 cDNA or to isolate still other cDNAs
(for instance, those encoding naturally-occurring variants of
PRO842 or PRO842 from other species) which have a desired sequence
identity to the native PRO842 sequence disclosed herein.
Optionally, the length of the probes will be about 20 to about 50
bases. The hybridization probes may be derived from at least
partially novel regions of the full length native nucleotide
sequence wherein those regions may be determined without undue
experimentation or from genomic sequences including promoters,
enhancer elements and introns of native sequence PRO842. By way of
example, a screening method will comprise isolating the coding
region of the PRO842 gene using the known DNA sequence to
synthesize a selected probe of about 40 bases. Hybridization probes
may be labeled by a variety of labels, including radionucleotides
such as .sup.32P or .sup.35S, or enzymatic labels such as alkaline
phosphatase coupled to the probe via avidin/biotin coupling
systems. Labeled probes having a sequence complementary to that of
the PRO842 gene of the present invention can be used to screen
libraries of human cDNA, genomic DNA or mRNA to determine which
members of such libraries the probe hybridizes to. Hybridization
techniques are described in further detail in the Examples
below.
[0206] Any EST sequences disclosed in the present application may
similarly be employed as probes, using the methods disclosed
herein.
[0207] Other useful fragments of the PRO842 nucleic acids include
antisense or sense oligonucleotides comprising a singe-stranded
nucleic acid sequence (either RNA or DNA) capable of binding to
target PRO842 mRNA (sense) or PRO842 DNA (antisense) sequences.
Antisense or sense oligonucleotides, according to the present
invention, comprise a fragment of the coding region of PRO842 DNA.
Such a fragment generally comprises at least about 14 nucleotides,
preferably from about 14 to 30 nucleotides. The ability to derive
an antisense or a sense oligonucleotide, based upon a cDNA sequence
encoding a given protein is described in, for example, Stein and
Cohen (Cancer Res. 48:2659, [1988]) and van der Krol et al.
(BioTechnigues. 6:958. [1988]).
[0208] Binding of antisense or sense oligonucleotides to target
nucleic acid sequences results in the formation of duplexes that
block transcription or translation of the target sequence by one of
several means, including enhanced degradation of the duplexes,
premature termination of transcription or translation, or by other
means. The antisense oligonucleotides thus may be used to block
expression of PRO842 proteins. Antisense or sense oligonucleotides
further comprise oligonucleotides having modified
sugar-phosphodiester backbones (or other sugar linkages, such as
those described in WO 91/06629) and wherein such sugar linkages are
resistant to endogenous nucleases. Such oligonucleotides with
resistant sugar linkages are stable in vivo (i.e. capable of
resisting enzymatic degradation) but retain sequence specificity to
be able to bind to target nucleotide sequences.
[0209] Other examples of sense or antisense oligonucleotides
include those oligonucleotides which are covalently linked to
organic moieties, such as those described in WO 90/10048, and other
moieties that increases affinity of the oligonucleotide for a
target nucleic acid sequence, such as poly-(L-lysine). Further
still, intercalating agents, such as ellipticine, and alkylating
agents or metal complexes may be attached to sense or antisense
oligonucleotides to modify binding specificities of the antisense
or sense oligonucleotide for the target nucleotide sequence.
[0210] Antisense or sense oligonucleotides may be introduced into a
cell containing the target nucleic acid sequence by any gene
transfer method, including, for example, CaPO.sub.4-mediated DNA
transfection, electroporation, or by using gene transfer vectors
such as Epstein-Barr virus. In a preferred procedure, an antisense
or sense oligonucleotide is inserted into a suitable retroviral
vector. A cell containing the target nucleic acid sequence is
contacted with the recombinant retroviral vector, either in vivo or
ex vivo. Suitable retroviral vectors include, but are not limited
to, those derived from the murine retrovirus M-MuLV, N2 (a
retrovirus derived from M-MuLV), or the double copy vectors
designated DCT5A, DCT5B and DCT5C (see WO 90/13641).
[0211] Sense or antisense oligonucleotides also may be introduced
into a cell containing the target nucleotide sequence by formation
of a conjugate with a ligand binding molecule, as described in WO
91/04753. Suitable ligand binding molecules include, but are not
limited to, cell surface receptors, growth factors, other
cytokines, or other ligands that bind to cell surface receptors.
Preferably, conjugation of the ligand binding molecule does not
substantially interfere with the ability of the ligand binding
molecule to bind to its corresponding molecule or receptor, or
block entry of the sense or antisense oligonucleotide or its
conjugated version into the cell.
[0212] Alternatively, a sense or an antisense oligonucleotide may
be introduced into a cell containing the target nucleic acid
sequence by formation of an oligonucleotide-lipid complex, as
described in WO 90/10448. The sense or antisense
oligonucleotide-lipid complex is preferably dissociated within the
cell by an endogenous lipase.
[0213] Antisense or sense RNA or DNA molecules are generally at
least about 5 bases in length, about 10 bases in length, about 15
bases in length, about 20 bases in length, about 25 bases in
length, about 30 bases in length, about 35 bases in length, about
40 bases in length, about 45 bases in length, about 50 bases in
length, about 55 bases in length, about 60 bases in length, about
65 bases in length, about 70 bases in length, about 75 bases in
length, about 80 bases in length, about 85 bases in length, about
90 bases in length, about 95 bases in length, about 100 bases in
length, or more.
[0214] The probes may also be employed in PCR techniques to
generate a pool of sequences for identification of closely related
PRO842 coding sequences.
[0215] Nucleotide sequences encoding a PRO842 can also be used to
construct hybridization probes for mapping the gene which encodes
that PRO842 and for the genetic analysis of individuals with
genetic disorders. The nucleotide sequences provided herein may be
mapped to a chromosome and specific regions of a chromosome using
known techniques, such as in situ hybridization, linkage analysis
against known chromosomal markers, and hybridization screening with
libraries.
[0216] When the coding sequences for PRO842 encode a protein which
binds to another protein (example, where the PRO842 is a receptor),
the PRO842 can be used in assays to identify the other proteins or
molecules involved in the binding interaction. By such methods,
inhibitors of the receptor/ligand binding interaction can be
identified, proteins involved in such binding interactions can also
be used to screen for peptide or small molecule inhibitors or
agonists of the binding interaction. Also, the receptor PRO842 can
be used to isolate correlative ligand(s). Screening assays can be
designed to find lead compounds that mimic the biological activity
of a native PRO842 or a receptor for PRO842. Such screening assays
will include assays amenable to high-throughput screening of
chemical libraries, making them particularly suitable for
identifying small molecule drug candidates. Small molecules
contemplated include synthetic organic or inorganic compounds. The
assays can be performed in a variety of formats, including
protein-protein binding assays, biochemical screening assays,
immunoassays and cell based assays, which are well characterized in
the art.
[0217] Nucleic acids which encode PRO842 or its modified forms can
also be used to generate either transgenic animals or "knock out"
animals which, in turn, are useful in the development and screening
of therapeutically useful reagents. A transgenic animal (e.g., a
mouse or rat) is an animal having cells that contain a transgene,
which transgene was introduced into the animal or an ancestor of
the animal at a prenatal, e.g., an embryonic stage. A transgene is
a DNA which is integrated into the genome of a cell from which a
transgenic animal develops. In one embodiment, cDNA encoding PRO842
can be used to clone genomic DNA encoding PRO842 in accordance with
established techniques and the genomic sequences used to generate
transgenic animals that contain cells which express DNA encoding
PRO842. Methods for generating transgenic animals, particularly
animals such as mice or rats, have become conventional in the art
and are described, for example, in U.S. Pat. Nos. 4,736,866 and
4,870,009. Typically, particular cells would be targeted for PRO842
transgene incorporation with tissue-specific enhancers. Transgenic
animals that include a copy of a transgene encoding PRO842
introduced into the germ line of the animal at an embryonic stage
can be used to examine the effect of increased expression of DNA
encoding PRO842. Such animals can be used as tester animals for
reagents thought to confer protection from, for example,
pathological conditions associated with its overexpression. In
accordance with this facet of the invention, an animal is treated
with the reagent and a reduced incidence of the pathological
condition, compared to untreated animals bearing the transgene,
would indicate a potential therapeutic intervention for the
pathological condition.
[0218] Alternatively, non-human homologues of PRO842 can be used to
construct a PRO842 "knock out" animal which has a defective or
altered gene encoding PRO842 as a result of homologous
recombination between the endogenous gene encoding PRO842 and
altered genomic DNA encoding PRO842 introduced into an embryonic
stem cell of the animal. For example, cDNA encoding PRO842 can be
used to clone genomic DNA encoding PRO842 in accordance with
established techniques. A portion of the genomic DNA encoding
PRO842 can be deleted or replaced with another gene, such as a gene
encoding a selectable marker which can be used to monitor
integration. Typically, several kilobases of unaltered flanking DNA
(both at the 5' and 3' ends) are included in the vector [see e.g.,
Thomas and Capecchi, Cell, 51:503 (1987) for a description of
homologous recombination vectors]. The vector is introduced into an
embryonic stem cell line (e.g., by electroporation) and cells in
which the introduced DNA has homologously recombined with the
endogenous DNA are selected (see, e.g. L1 et al., Cell, 69:915
(1992)]. The selected cells are then injected into a blastocyst of
an animal (e.g., a mouse or rat) to form aggregation chimeras [see,
e.g. Bradley, in Teratocarcinomas and Embryonic Stem Cells: A
Practical Approach, E. J. Robertson, ed. (IRL. Oxford, 1987), pp.
113-152). A chimeric embryo can then be implanted into a suitable
pseudopregnant female foster animal and the embryo brought to term
to create a "knock out" animal. Progeny harboring the homologously
recombined DNA in their germ cells can be identified by standard
techniques and used to breed animals in which all cells of the
animal contain the homologously recombined DNA. Knockout animals
can be characterized for instance, for their ability to defend
against certain pathological conditions and for their development
of pathological conditions due to absence of the PRO842
polypeptide.
[0219] Nucleic acid encoding the PRO842 polypeptides may also be
used in gene therapy. In gene therapy applications, genes are
introduced into cells in order to achieve in vivo synthesis of a
therapeutically effective genetic product, for example for
replacement of a defective gene. "Gene therapy" includes both
conventional gene therapy where a lasting effect is achieved by a
single treatment, and the administration of gene therapeutic
agents, which involves the one time or repeated administration of a
therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can
be used as therapeutic agents for blocking the expression of
certain genes in vivo. It has already been shown that short
antisense oligonucleotides can be imported into cells where they
act as inhibitors, despite their low intracellular concentrations
caused by their restricted uptake by the cell membrane. (Zamecnik
et al., Proc. Natl. Acad. Sci. USA, 83:4143-4146 [1986]). The
oligonucleotides can be modified to enhance their uptake, e.g., by
substituting their negatively charged phosphodiester groups by
uncharged groups.
[0220] There are a variety of techniques available for introducing
nucleic acids into viable cells. The techniques vary depending upon
whether the nucleic acid is transferred into cultured cells in
vitro, or in vivo in the cells of the intended host. Techniques
suitable for the transfer of nucleic acid into mammalian cells in
vitro include the use of liposomes, electroporation,
microinjection, cell fusion, DEAE-dextran, the calcium phosphate
precipitation method, etc. The currently preferred in vivo gene
transfer techniques include transfection with viral (typically
retroviral) vectors and viral coat protein-liposome mediated
transfection (Dzau et al., Trends in Biotechnology, 11: 205-210
[1993]). In some situations it is desirable to provide the nucleic
acid source with an agent that targets the target cells, such as an
antibody specific for a cell surface membrane protein or the target
cell, a ligand for a receptor on the target cell, etc. Where
liposomes are employed, proteins which bind to a cell surface
membrane protein associated with endocytosis may be used for
targeting and/or to facilitate uptake, e.g., capsid proteins or
fragments thereof tropic for a particular cell type, antibodies for
proteins which undergo internalization in cycling, proteins that
target intracellular localization and enhance intracellular
half-life. The technique of receptor-mediated endocytosis is
described, for example, by Wu et al., J. Biol. Chem., 262:
4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA,
87: 3410-3414 (1990). For review of gene marking and gene therapy
protocols see Anderson et al., Science, 256: 808-813 (1992).
[0221] The PRO842 polypeptides described herein may also be
employed as molecular weight markers for protein electrophoresis
purposes and the isolated nucleic acid sequences may be used for
recombinantly expressing those markers.
[0222] The nucleic acid molecules encoding the PRO842 polypeptides
or fragments thereof described herein are useful for chromosome
identification. In this regard, there exists an ongoing need to
identify new chromosome markers, since relatively few chromosome
marking reagents, based upon actual sequence data are presently
available. Each PRO842 nucleic acid molecule of the present
invention can be used as a chromosome marker.
[0223] The PRO842 polypeptides and nucleic acid molecules of the
present invention may also be used diagnostically for tissue
typing, wherein the PRO842 polypeptides of the present invention
may be differentially expressed in one tissue as compared to
another, preferably in a diseased tissue as compared to a normal
tissue of the same tissue type. PRO842 nucleic acid molecules will
find use for generating probes for PCR, Northern analysis, Southern
analysis and Western analysis.
[0224] The PRO842 polypeptides described herein may also be
employed as therapeutic agents. The PRO842 polypeptides of the
present invention can be formulated according to known methods to
prepare pharmaceutically useful compositions, whereby the PRO842
product hereof is combined in admixture with a pharmaceutically
acceptable carrier vehicle. Therapeutic formulations are prepared
for storage by mixing the active ingredient having the desired
degree of purity with optional physiologically acceptable carriers,
excipients or stabilizers (Remington's Pharmaceutical Sciences 16th
edition, Osol, A. Ed. (1980)), in the form of lyophilized
formulations or aqueous solutions. Acceptable carriers, excipients
or stabilizers are nontoxic to recipients at the dosages and
concentrations employed, and include buffers such as phosphate,
citrate and other organic acids; antioxidants including ascorbic
acid; low molecular weight (less than about 10 residues)
polypeptides; proteins, such as serum albumin, gelatin or
immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone,
amino acids such as glycine, glutamine, asparagine, arginine or
lysine; monosaccharides, disaccharides and other carbohydrates
including glucose, mannose, or dextrins; chelating agents such as
EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming
counterions such as sodium; and/or nonionic surfactants such as
TWEEN.TM., PLURONICS.TM. or PEG.
[0225] The formulations to be used for in vivo administration must
be sterile. This is readily accomplished by filtration through
sterile filtration membranes, prior to or following lyophilization
and reconstitution.
[0226] Therapeutic compositions herein generally are placed into a
container having a sterile access port, for example, an intravenous
solution bag or vial having a stopper pierceable by a hypodermic
injection needle.
[0227] The route of administration is in accord with known methods,
e.g., injection or infusion by intravenous, intraperitoneal,
intracerebral, intramuscular, intraocular, intraarterial or
intralesional routes, topical administration, or by sustained
release systems.
[0228] Dosages and desired drug concentrations of pharmaceutical
compositions of the present invention may vary depending on the
particular use envisioned. The determination of the appropriate
dosage or route of administration is well within the skill of an
ordinary physician. Animal experiments provide reliable guidance
for the determination of effective doses for human therapy.
Interspecies scaling of effective doses can be performed following
the principles laid down by Mordenti, J. and Chappell, W. "The use
of interspecies scaling in toxicokinetics" In Toxicokinetics and
New Drug Development, Yacobi et al., Eds., Pergamon Press. New York
1989, pp. 42-96.
[0229] When in vivo administration of a PRO842 polypeptide or
agonist or antagonist thereof is employed, normal dosage amounts
may vary from about 10 ng/kg to up to 100 mg/kg of mammal body
weight or more per day, preferably about 1 .mu.g/kg/day to 10
mg/kg/day, depending upon the route of administration. Guidance as
to particular dosages and methods of delivery is provided in the
literature; see, for example. U.S. Pat. Nos. 4,657,760; 5,206,344:
or 5,225.212. It is anticipated that different formulations will be
effective for different treatment compounds and different
disorders, that administration targeting one organ or tissue, for
example, may necessitate delivery in a manner different from that
to another organ or tissue.
[0230] Where sustained-release administration of a PRO842
polypeptide is desired in a formulation with release
characteristics suitable for the treatment of any disease or
disorder requiring administration of the PRO842 polypeptide,
microencapsulation of the PRO842 polypeptide is contemplated.
Microencapsulation of recombinant proteins for sustained release
has been successfully performed with human growth hormone (rhGH),
interferon-(rhlFN--), interleukin-2, and MN rgp120. Johnson et al.,
Nat. Med., 2:795-799 (1996); Yasuda, Biomed. Ther., 27:1221-1223
(1993); Hora et al., Bio/Technology. 8:755-758 (1990); Cleland,
"Design and Production of Single Immunization Vaccines Using
Polylactide Polyglycolide Microsphere Systems," in Vaccine Design:
The Subunit and Adjuvant Approach, Powell and Newman, eds, (Plenum
Press: New York, 1995), pp. 439-462; WO 97/03692, WO 96/40072, WO
96/07399; and U.S. Pat. No. 5,654,010.
[0231] The sustained-release formulations of these proteins were
developed using poly-lactic-coglycolic acid (PLGA) polymer due to
its biocompatibility and wide range of biodegradable properties.
The degradation products of PLGA, lactic and glycolic acids, can be
cleared quickly within the human body. Moreover, the degradability
of this polymer can be adjusted from months to years depending on
its molecular weight and composition. Lewis, "Controlled release of
bioactive agents from lactide/glycolide polymer," in: M. Chasin and
R. Langer (Eds.), Biodegradable Polymers as Drug Delivery Systems
(Marcel Dekker: New York, 1990), pp. 1-41.
[0232] This invention encompasses methods of screening compounds to
identify those that mimic the PRO842 polypeptide (agonists) or
prevent the effect of the PRO842 polypeptide (antagonists).
Screening assays for antagonist drug candidates are designed to
identify compounds that bind or complex with the PRO842
polypeptides encoded by the genes identified herein, or otherwise
interfere with the interaction of the encoded polypeptides with
other cellular proteins. Such screening assays will include assays
amenable to high-throughput screening of chemical libraries, making
them particularly suitable for identifying small molecule drug
candidates.
[0233] The assays can be performed in a variety of formats,
including protein-protein binding assays, biochemical screening
assays, immunoassays, and cell-based assays, which are well
characterized in the art.
[0234] All assays for antagonists are common in that they call for
contacting the drug candidate with a PRO842 polypeptide encoded by
a nucleic acid identified herein under conditions and for a time
sufficient to allow these two components to interact.
[0235] In binding assays, the interaction is binding and the
complex formed can be isolated or detected in the reaction mixture.
In a particular embodiment, the PRO842 polypeptide encoded by the
gene identified herein or the drug candidate is immobilized on a
solid phase, e.g., on a microtiter plate, by covalent or
non-covalent attachments. Non-covalent attachment generally is
accomplished by coating the solid surface with a solution of the
PRO842 polypeptide and drying. Alternatively, an immobilized
antibody, e.g., a monoclonal antibody, specific for the PRO842
polypeptide to be immobilized can be used to anchor it to a solid
surface. The assay is performed by adding the non-immobilized
component, which may be labeled by a detectable label, to the
immobilized component, e.g., the coated surface containing the
anchored component. When the reaction is complete, the non-reacted
components are removed, e.g. by washing, and complexes anchored on
the solid surface are detected. When the originally non-immobilized
component carries a detectable label, the detection of label
immobilized on the surface indicates that complexing occurred.
Where the originally non-immobilized component does not carry a
label, complexing can be detected, for example, by using a labeled
antibody specifically binding the immobilized complex.
[0236] If the candidate compound interacts with but does not bind
to a particular PRO842 polypeptide encoded by a gene identified
herein, its interaction with that polypeptide can be assayed by
methods well known for detecting protein-protein interactions. Such
assays include traditional approaches, such as, e.g.,
cross-linking, co-immunoprecipitation, and co-purification through
gradients or chromatographic columns. In addition, protein-protein
interactions can be monitored by using a yeast-based genetic system
described by Fields and co-workers (Fields and Song, Nature
(London), 340:245-246 [1989]); Chien et al., Proc. Natl. Acad. Sci.
USA, 88:9578-9582 [1991]) as disclosed by Chevray and Nathans,
Proc. Natl. Acad. Sci. USA, 89:5789-5793 (1991). Many
transcriptional activators, such as yeast GAL4, consist of two
physically discrete modular domains, one acting as the DNA-binding
domain, the other one functioning as the transcription-activation
domain. The yeast expression system described in the foregoing
publications (generally referred to as the "two-hybrid system")
takes advantage of this property, and employs two hybrid proteins,
one in which the target protein is fused to the DNA-binding domain
of GAL4, and another, in which candidate activating proteins are
fused to the activation domain. The expression of a GAL1-lacZ
reporter gene under control of a GAL4-activated promoter depends on
reconstitution of GAL4 activity via protein-protein interaction.
Colonies containing interacting polypeptides are detected with a
chromogenic substrate for .beta.-galactosidase. A complete kit
(MATCHMAKER.TM.) for identifying protein-protein interactions
between two specific proteins using the two-hybrid technique is
commercially available from Clontech. This system can also be
extended to map protein domains involved in specific protein
interactions as well as to pinpoint amino acid residues that are
crucial for these interactions.
[0237] Compounds that interfere with the interaction of a gene
encoding a PRO842 polypeptide identified herein and other intra- or
extracellular components can be tested as follows: usually a
reaction mixture is prepared containing the product of the gene and
the intra- or extracellular component under conditions and for a
time allowing for the interaction and binding of the two products.
To test the ability of a candidate compound to inhibit binding, the
reaction is run in the absence and in the presence of the test
compound. In addition, a placebo may be added to a third reaction
mixture, to serve as positive control. The binding (complex
formation) between the test compound and the intra- or
extracellular component present in the mixture is monitored as
described hereinabove. The formation of a complex in the control
reaction(s) but not in the reaction mixture containing the test
compound indicates that the test compound interferes with the
interaction of the test compound and its reaction partner.
[0238] To assay for antagonists, the PRO842 polypeptide may be
added to a cell along with the compound to be screened for a
particular activity and the ability of the compound to inhibit the
activity of interest in the presence of the PRO842 polypeptide
indicates that the compound is an antagonist to the PRO842
polypeptide. Alternatively, antagonists may be detected by
combining the PRO842 polypeptide and a potential antagonist with
membrane-bound PRO842 polypeptide receptors or recombinant
receptors under appropriate conditions for a competitive inhibition
assay. The PRO842 polypeptide can be labeled, such as by
radioactivity, such that the number of PRO842 polypeptide molecules
bound to the receptor can be used to determine the effectiveness of
the potential antagonist. The gene encoding the receptor can be
identified by numerous methods known to those of skill in the art,
for example, ligand panning and FACS sorting. Coligan et al.,
Current Protocols in Immun., 1(2): Chapter 5 (1991). Preferably,
expression cloning is employed wherein polyadenylated RNA is
prepared from a cell responsive to the PRO842 polypeptide and a
cDNA library created from this RNA is divided into pools and used
to transfect COS cells or other cells that are not responsive to
the PRO842 polypeptide. Transfected cells that are grown on glass
slides are exposed to labeled PRO842 polypeptide. The PRO842
polypeptide can be labeled by a variety of means including
iodination or inclusion of a recognition site for a site-specific
protein kinase. Following fixation and incubation, the slides are
subjected to autoradiographic analysis. Positive pools are
identified and sub-pools are prepared and re-transfected using an
interactive sub-pooling and re-screening process, eventually
yielding a single clone that encodes the putative receptor.
[0239] As an alternative approach for receptor identification,
labeled PRO842 polypeptide can be photoaffinity-linked with cell
membrane or extract preparations that express the receptor
molecule. Cross-linked material is resolved by PAGE and exposed to
X-ray film. The labeled complex containing the receptor can be
excised, resolved into peptide fragments, and subjected to protein
micro-sequencing. The amino acid sequence obtained from
micro-sequencing would be used to design a set of degenerate
oligonucleotide probes to screen a cDNA library to identify the
gene encoding the putative receptor.
[0240] In another assay for antagonists, mammalian cells or a
membrane preparation expressing the receptor would be incubated
with labeled PRO842 polypeptide in the presence of the candidate
compound. The ability of the compound to enhance or block this
interaction could then be measured.
[0241] More specific examples of potential antagonists include an
oligonucleotide that binds to the fusions of immunoglobulin with
PRO842 polypeptide, and, in particular, antibodies including,
without limitation, poly- and monoclonal antibodies and antibody
fragments, single-chain antibodies, anti-idiotypic antibodies, and
chimeric or humanized versions of such antibodies or fragments, as
well as human antibodies and antibody fragments. Alternatively, a
potential antagonist may be a closely related protein, for example,
a mutated form of the PRO842 polypeptide that recognizes the
receptor but imparts no effect, thereby competitively inhibiting
the action of the PRO842 polypeptide.
[0242] Another potential PRO842 polypeptide antagonist is an
antisense RNA or DNA construct prepared using antisense technology,
where, e.g., an antisense RNA or DNA molecule acts to block
directly the translation of mRNA by hybridizing to targeted mRNA
and preventing protein translation. Antisense technology can be
used to control gene expression through triple-helix formation or
antisense DNA or RNA, both of which methods are based on binding of
a polynucleotide to DNA or RNA. For example, the 5' coding portion
of the polynucleotide sequence, which encodes the mature PRO842
polypeptides herein, is used to design an antisense RNA
oligonucleotide of from about 10 to 40 base pairs in length. A DNA
oligonucleotide is designed to be complementary to a region of the
gene involved in transcription (triple helix--see Lee et al., Nucl.
Acids Res., 6:3073 (1979); Cooney et al., Science, 241:456 (1988);
Dervan et al., Science, 251:1360 (1991)), thereby preventing
transcription and the production of the PRO842 polypeptide. The
antisense RNA oligonucleotide hybridizes to the mRNA in vivo and
blocks translation of the mRNA molecule into the PRO842 polypeptide
(antisense--Okano. Neurochem., 56:560 (1991); Oligodeoxynucleotides
as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton,
Fla., 1988). The oligonucleotides described above can also be
delivered to cells such that the antisense RNA or DNA may be
expressed in vivo to inhibit production of the PRO842 polypeptide.
When antisense DNA is used, oligodeoxyribonucleotides derived from
the translation-initiation site, e.g., between about -10 and +10
positions of the target gene nucleotide sequence, are
preferred.
[0243] Potential antagonists include small molecules that bind to
the active site, the receptor binding site, or growth factor or
other relevant binding site of the PRO842 polypeptide, thereby
blocking the normal biological activity of the PRO842 polypeptide.
Examples of small molecules include, but are not limited to, small
peptides or peptide-like molecules, preferably soluble peptides,
and synthetic non-peptidyl organic or inorganic compounds.
[0244] Ribozymes are enzymatic RNA molecules capable of catalyzing
the specific cleavage of RNA. Ribozymes act by sequence-specific
hybridization to the complementary target RNA, followed by
endonucleolytic cleavage. Specific ribozyme cleavage sites within a
potential RNA target can be identified by known techniques. For
further details see, e.g., Rossi, Current Biology, 4:469-471
(1994), and PCT publication No. WO 97/33551 (published Sep. 18,
1997).
[0245] Nucleic acid molecules in triple-helix formation used to
inhibit transcription should be single-stranded and composed of
deoxynucleotides. The base composition of these oligonucleotides is
designed such that it promotes triple-helix formation via Hoogsteen
base-pairing rules, which generally require sizeable stretches of
purines or pyrimidines on one strand of a duplex. For further
details see, e.g., PCT publication No. WO 97/33551, supra.
[0246] These small molecules can be identified by any one or more
of the screening assays discussed hereinabove and/or by any other
screening techniques well known for those skilled in the art.
[0247] Diagnostic and therapeutic uses of the herein disclosed
molecules may also be based upon the positive functional assay hits
disclosed and described below
[0248] F. Tissue Distribution
[0249] The location of tissues expressing the PRO842 can be
identified by determining mRNA expression in various human tissues.
The location of such genes provides information about which tissues
are most likely to be affected by the stimulating and inhibiting
activities of the PRO842 polypeptides. The location of a gene in a
specific tissue also provides sample tissue for the activity
blocking assays discussed below.
[0250] As noted before, gene expression in various tissues may be
measured by conventional Southern blotting, Northern blotting to
quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad.
Sci. USA, 77:5201-5205 [1980]), dot blotting (DNA analysis), or in
situ hybridization, using an appropriately labeled probe, based on
the sequences provided herein. Alternatively, antibodies may be
employed that can recognize specific duplexes, including DNA
duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein
duplexes.
[0251] Gene expression in various tissues, alternatively, may be
measured by immunological methods, such as immunohistochemical
staining of tissue sections and assay of cell culture or body
fluids, to quantitate directly the expression of gene product.
Antibodies useful for immunohistochemical staining and/or assay of
sample fluids may be either monoclonal or polyclonal, and may be
prepared in any mammal. Conveniently, the antibodies may be
prepared against a native sequence of a PRO842 polypeptide or
against a synthetic peptide based on the DNA sequences encoding the
PRO842 polypeptide or against an exogenous sequence fused to a DNA
encoding a PRO842 polypeptide and encoding a specific antibody
epitope. General techniques for generating antibodies, and special
protocols for Northern blotting and in situ hybridization are
provided below.
[0252] G. Antibody Binding Studies
[0253] The activity of the PRO842 polypeptides can be further
verified by antibody binding studies, in which the ability of
anti-PRO842 antibodies to inhibit the effect of the PRO842
polypeptides, respectively, on tissue cells is tested. Exemplary
antibodies include polyclonal, monoclonal, humanized, bispecific,
and heteroconjugate antibodies, the preparation of which will be
described hereinbelow.
[0254] Antibody binding studies may be carried out in any known
assay method, such as competitive binding assays, direct and
indirect sandwich assays, and immunoprecipitation assays. Zola,
Monoclonal Antibodies: A Manual of Techniques, pp. 147-158 (CRC
Press, Inc., 1987).
[0255] Competitive binding assays rely on the ability of a labeled
standard to compete with the test sample analyte for binding with a
limited amount of antibody. The amount of target protein in the
test sample is inversely proportional to the amount of standard
that becomes bound to the antibodies. To facilitate determining the
amount of standard that becomes bound, the antibodies preferably
are insolubilized before or after the competition, so that the
standard and analyte that are bound to the antibodies may
conveniently be separated from the standard and analyte which
remain unbound.
[0256] Sandwich assays involve the use of two antibodies, each
capable of binding to a different immunogenic portion, or epitope,
of the protein to be detected. In a sandwich assay, the test sample
analyte is bound by a first antibody which is immobilized on a
solid support, and thereafter a second antibody binds to the
analyte, thus forming an insoluble three-part complex. See, e.g.,
U.S. Pat. No. 4,376,110. The second antibody may itself be labeled
with a detectable moiety (direct sandwich assays) or may be
measured using an anti-immunoglobulin antibody that is labeled with
a detectable moiety (indirect sandwich assay). For example, one
type of sandwich assay is an ELISA assay, in which case the
detectable moiety is an enzyme. For immunohistochemistry, the
tissue sample may be fresh or frozen or may be embedded in paraffin
and fixed with a preservative such as formalin, for example.
[0257] H. Cell-Based Assays
[0258] Cell-based assays and animal models for immune related
diseases can be used to further understand the relationship between
the genes and polypeptides identified herein and the development
and pathogenesis of immune related disease.
[0259] In a different approach, cells of a cell type known to be
involved in a particular immune related disease are transfected
with the cDNAs described herein, and the ability of these cDNAs to
stimulate or inhibit immune function is analyzed. Suitable cells
can be transfected with the desired gene, and monitored for immune
function activity. Such transfected cell lines can then be used to
test the ability of poly- or monoclonal antibodies or antibody
compositions to inhibit or stimulate immune function, for example
to modulate T-cell proliferation or inflammatory cell infiltration.
Cells transfected with the coding sequences of the genes identified
herein can further be used to identify drug candidates for the
treatment of immune related diseases.
[0260] In addition, primary cultures derived from transgenic
animals (as described below) can be used in the cell-based assays
herein, although stable cell lines are preferred. Techniques to
derive continuous cell lines from transgenic animals are well known
in the art (see, e.g., Small et al., Mol. Cell. Biol. 5: 642-648
[19851).
[0261] One suitable cell based assay is the mixed lymphocyte
reaction (MLR). Current Protocols in Immunology, unit 3.12; edited
by J E Coligan, A M Kruisbeek, D H Marglies, E M Shevach, W
Strober, National Institutes of Health, Published by John Wiley
& Sons, Inc. In this assay, the ability of a test compound to
stimulate or inhibit the proliferation of activated T cells is
assayed. A suspension of responder T cells is cultured with
allogeneic stimulator cells and the proliferation of T cells is
measured by uptake of tritiated thymidine. This assay is a general
measure of T cell reactivity. Since the majority of T cells respond
to and produce IL-2 upon activation, differences in responsiveness
in this assay in part reflect differences in IL-2 production by the
responding cells. The MLR results can be verified by a standard
lymphokine (IL-2) detection assay. Current Protocols in Immunology,
above, 3.15, 6.3.
[0262] A proliferative T cell response in an MLR assay may be due
to direct mitogenic properties of an assayed molecule or to
external antigen induced activation. Additional verification of the
T cell stimulatory activity of the PRO842 polypeptides can be
obtained by a costimulation assay. T cell activation requires an
antigen specific signal mediated through the T-cell receptor (TCR)
and a costimulatory signal mediated through a second ligand binding
interaction, for example, the B7 (CD80, CD86)/CD28 binding
interaction. CD28 crosslinking increases lymphokine secretion by
activated T cells. T cell activation has both negative and positive
controls through the binding of ligands which have a negative or
positive effect. CD28 and CTLA-4 are related glycoproteins in the
Ig superfamily which bind to B7. CD28 binding to B7 has a positive
costimulation effect of T cell activation; conversely, CTLA-4
binding to B7 has a negative T cell deactivating effect. Chambers,
C. A. and Allison, J. P. Curr. Opin. Immunol. (1997) 9:396.
Schwartz, R. H., Cell (1992) 71:1065; Linsley, P. S. and Ledbetter,
J. A., Annu. Rev. Immunol. (1993) 11:191; June, C. H. et al.,
Immunol. Today (1994) 15:321; Jenkins, M. K., Immunity (1994)
1:405. In a costimulation assay, the PRO842 polypeptides are
assayed for T cell costimulatory or inhibitory activity.
[0263] PRO842 polypeptides, as well as other compounds of the
invention, which are stimulators (costimulators) of T cell
proliferation and agonists, e.g., agonist antibodies, thereto as
determined by MLR and costimulation assays, for example, are useful
in treating immune related diseases characterized by poor,
suboptimal or inadequate immune function. These diseases are
treated by stimulating the proliferation and activation of T cells
(and T cell mediated immunity) and enhancing the immune response in
a marnmal through administration of a stimulatory compound, such as
the stimulating PRO842 polypeptides. The stimulating polypeptide
may, for example, be a PRO842 polypeptide or an agonist antibody
thereof.
[0264] Direct use of a stimulating compound as in the invention has
been validated in experiments with 4-1BB glycoprotein, a member of
the tumor necrosis factor receptor family, which binds to a ligand
(4-1BBL) expressed on primed T cells and signals T cell activation
and growth. Alderson, M. E. et al., J. Immunol., 24:2219
(1994).
[0265] The use of an agonist stimulating compound has also been
validated experimentally. Activation of 4-1BB by treatment with an
agonist anti-4-1BB antibody enhances eradication of tumors.
Hellstrom. 1, and Helistrom, K. E., Crit. Rev. Immunol. 18:1
(1998). Immunoadjuvant therapy for treatment of tumors, described
in more detail below, is another example of the use of the
stimulating compounds of the invention. An immune stimulating or
enhancing effect can also be achieved by antagonizing or blocking
the activity of a PRO842 which has been found to be inhibiting in
the MLR assay. Negating the inhibitory activity of the compound
produces a net stimulatory effect. Suitable antagonists/blocking
compounds are antibodies or fragments thereof which recognize and
bind to the inhibitory protein, thereby blocking the effective
interaction of the protein with its receptor and inhibiting
signaling through the receptor. This effect has been validated in
experiments using anti-CTLA-4 antibodies which enhance T cell
proliferation, presumably by removal of the inhibitory signal
caused by CTLA-4 binding. Walunas, T. L. et al., Immunity. 1:405
(1994).
[0266] Alternatively, an immune stimulating or enhancing effect can
also be achieved by administration of a PRO842 polypeptide which
has vascular permeability enhancing properties. Enhanced vacuolar
permeability would be beneficial to disorders which can be
attenuated by local infiltration of immune cells (e.g., monocytes,
eosinophils, PMNs) and inflammation.
[0267] On the other hand, PRO842 polypeptides, as well as other
compounds of the invention, which are direct inhibitors of T cell
proliferation/activation, lymphokine secretion, and/or vascular
permeability can be directly used to suppress the immune response.
These compounds are useful to reduce the degree of the immune
response and to treat immune related diseases characterized by a
hyperactive, superoptimal, or autoimmune response. This use of the
compounds of the invention has been validated by the experiments
described above in which CTLA4 binding to receptor B7 deactivates T
cells. The direct inhibitory compounds of the invention function in
an analogous manner. The use of compound which suppress vascular
permeability would be expected to reduce inflammation. Such uses
would be beneficial in treating conditions associated with
excessive inflammation.
[0268] Alternatively, compounds, e.g., antibodies, which bind to
stimulating PRO842 polypeptides and block the stimulating effect of
these molecules produce a net inhibitory effect and can be used to
suppress the T cell mediated immune response by inhibiting T cell
proliferation/activation and/or lymphokine secretion. Blocking the
stimulating effect of the polypeptides suppresses the immune
response of the mammal. This use has been validated in experiments
using an anti-IL2 antibody. In these experiments, the antibody
binds to IL2 and blocks binding of IL2 to its receptor thereby
achieving a T cell inhibitory effect.
[0269] 1. Animal Models
[0270] The results of the cell based in vitro assays can be further
verified using in vivo animal models and assays for T-cell
function. A variety of well known animal models can be used to
further understand the role of the genes identified herein in the
development and pathogenesis of immune related disease, and to test
the efficacy of candidate therapeutic agents, including antibodies,
and other antagonists of the native polypeptides, including small
molecule antagonists. The in vivo nature of such models makes them
predictive of responses in human patients. Animal models of immune
related diseases include both non-recombinant and recombinant
(transgenic) animals. Non-recombinant animal models include, for
example, rodent. e.g., murine models. Such models can be generated
by introducing cells into syngeneic mice using standard techniques,
e.g., subcutaneous injection, tail vein injection, spleen
implantation, intraperitoneal implantation, implantation under the
renal capsule, etc.
[0271] Graft-versus-host disease occurs when immunocompetent cells
are transplanted into immunosuppressed or tolerant patients. The
donor cells recognize and respond to host antigens. The response
can vary from life threatening severe inflammation to mild cases of
diarrhea and weight loss. Graft-versus-host disease models provide
a means of assessing T cell reactivity against MHC antigens and
minor transplant antigens. A suitable procedure is described in
detail in Current Protocols in Immunology, above, unit 4.3.
[0272] An animal model for skin allograft rejection is a means of
testing the ability of T cells to mediate in vivo tissue
destruction and a measure of their role in transplant rejection.
The most common and accepted models use murine tail-skin grafts.
Repeated experiments have shown that skin allograft rejection is
mediated by T cells, helper T cells and killer-effector T cells,
and not antibodies. Auchincloss, H. Jr. and Sachs, D. H.,
Fundamental Immunology, 2nd ed., W. E. Paul ed., Raven Press, NY,
889-992 (1989). A suitable procedure is described in detail in
Current Protocols in Immunology, above, unit 4.4. Other transplant
rejection models which can be used to test the compounds of the
invention are the allogeneic heart transplant models described by
Tanabe, M. et al., Transplantation. 58:23 (1994) and Tinubu, S. A.
et al., J. Immunol., 4330-4338 (1994).
[0273] Animal models for delayed type hypersensitivity provides an
assay of cell mediated immune function as well. Delayed type
hypersensitivity reactions are a T cell mediated in vivo immune
response characterized by inflammation which does not reach a peak
until after a period of time has elapsed after challenge with an
antigen. These reactions also occur in tissue specific autoimmune
diseases such as multiple sclerosis (MS) and experimental
autoimmune encephalomyelitis (EAE, a model for MS). A suitable
procedure is described in detail in Current Protocols in
Immunology, above, unit 4.5.
[0274] EAE is a T cell mediated autoimmune disease characterized by
T cell and mononuclear cell inflammation and subsequent
demyelination of axons in the central nervous system. EAE is
generally considered to be a relevant animal model for MS in
humans. Bolton, C., Multiple Sclerosis, 1:143 (1995). Both acute
and relapsing-remitting models have been developed. The compounds
of the invention can be tested for T cell stimulatory or inhibitory
activity against immune mediated demyelinating disease using the
protocol described in Current Protocols in Immunology, above, units
15.1 and 15.2. See also the models for myelin disease in which
oligodendrocytes or Schwann cells are grafted into the central
nervous system as described in Duncan, I. D. et al., Molec. Med.
Today, 554-561 (1997).
[0275] Contact hypersensitivity is a simple delayed type
hypersensitivity in vivo assay of cell mediated immune function. In
this procedure, cutaneous exposure to exogenous haptens which gives
rise to a delayed type hypersensitivity reaction which is measured
and quantitated. Contact sensitivity involves an initial
sensitizing phase followed by an elicitation phase. The elicitation
phase occurs when the T lymphocytes encounter an antigen to which
they have had previous contact. Swelling and inflammation occur,
making this an excellent model of human allergic contact
dermatitis. A suitable procedure is described in detail in Current
Protocols in Immunology, Eds. J. E. Cologan, A. M. Kruisbeek, D. H.
Margulies, E. M. Shevach and W. Strober, John Wiley & Sons,
Inc., unit 4.2 (1994). 1 also Grabbe, S. and Schwarz, T, Immun.
Today. 19 (1): 37-44 (1998).
[0276] An animal model for arthritis is collagen-induced arthritis.
This model shares clinical, histological and immunological
characteristics of human autoimmune rheumatoid arthritis and is an
acceptable model for human autoimmune arthritis. Mouse and rat
models are characterized by synovitis, erosion of cartilage and
subchondral bone. The compounds of the invention can be tested for
activity against autoimmune arthritis using the protocols described
in Current Protocols in Immunology, above, units 15.5. See also the
model using a monoclonal antibody to CD18 and VLA-4 integrins
described in lssekutz, A. C. et al., Immunology, 88:569 (1996).
[0277] A model of asthma has been described in which
antigen-induced airway hyper-reactivity, pulmonary eosinophilia and
inflammation are induced by sensitizing an animal with ovalbumin
and then challenging the animal with the same protein delivered by
aerosol. Several animal models (guinea pig, rat, non-human primate)
show symptoms similar to atopic asthma in humans upon challenge
with aerosol antigens. Murine models have many of the features of
human asthma. Suitable procedures to test the compounds of the
invention for activity and effectiveness in the treatment of asthma
are described by Wolyniec, W. W. et al., Am. J. Respir. Cell Mol.
Biol., 18:777 (1998) and the references cited therein.
[0278] Additionally, the compounds of the invention can be tested
on animal models for psoriasis like diseases. Evidence suggests a T
cell pathogenesis for psoriasis. The compounds of the invention can
be tested in the scid/scid mouse model described by Schon, M. P. et
al., Nat. Med., 3:183 (1997), in which the mice demonstrate
histopathologic skin lesions resembling psoriasis. Another suitable
model is the human skin/scid mouse chimera prepared as described by
Nickoloff, B. J. et al., Am. J. Path., 146:580 (1995).
[0279] Recombinant (transgenic) animal models can be engineered by
introducing the coding portion of the genes identified herein into
the genome of animals of interest, using standard techniques for
producing transgenic animals. Animals that can serve as a target
for transgenic manipulation include, without limitation, mice,
rats, rabbits, guinea pigs, sheep, goats, pigs, and non-human
primates, e.g., baboons, chimpanzees and monkeys. Techniques known
in the art to introduce a transgene into such animals include
pronucleic microinjection (Hoppe and Wanger, U.S. Pat. No.
4,873,191); retrovirus-mediated gene transfer into germ lines
(e.g., Van der Putten et al., Proc. Natl. Acad. Sci. USA., 82,
6148-615 [1985]); gene targeting in embryonic stem cells (Thompson
et al., Cell, 56, 313-321 [1989]); electroporation of embryos (Lo,
Mol. Cel. Biol., 3, 1803-1814 [1983]); sperm-mediated gene transfer
(Lavitrano et al., Cell. 57, 717-73 [1989]). For review, see, for
example, U.S. Pat. No. 4,736,866.
[0280] For the purpose of the present invention, transgenic animals
include those that carry the transgene only in part of their cells
("mosaic animals"). The transgene can be integrated either as a
single transgene, or in concatamers, e.g., head-to-head or
head-to-tail tandems. Selective introduction of a transgene into a
particular cell type is also possible by following, for example,
the technique of Lasko et al., Proc. Natl. Acad. Sci. USA. 89,
6232-636 (1992).
[0281] The expression of the transgene in transgenic animals can be
monitored by standard techniques. For example, Southern blot
analysis or PCR amplification can be used to verify the integration
of the transgene. The level of mRNA expression can then be analyzed
using techniques such as in situ hybridization, Northern blot
analysis, PCR, or immunocytochemistry.
[0282] The animals may be further examined for signs of immune
disease pathology, for example by histological examination to
determine infiltration of immune cells into specific tissues.
Blocking experiments can also be performed in which the transgenic
animals are treated with the compounds of the invention to
determine the extent of the T cell proliferation stimulation or
inhibition of the compounds. In these experiments, blocking
antibodies which bind to the PRO842 polypeptide, prepared as
described above, are administered to the animal and the effect on
immune function is determined.
[0283] Alternatively, "knock out" animals can be constructed which
have a defective or altered gene encoding a polypeptide identified
herein, as a result of homologous recombination between the
endogenous gene encoding the polypeptide and altered genomic DNA
encoding the same polypeptide introduced into an embryonic cell of
the animal. For example, cDNA encoding a particular polypeptide can
be used to clone genomic DNA encoding that polypeptide in
accordance with established techniques. A portion of the genomic
DNA encoding a particular polypeptide can be deleted or replaced
with another gene, such as a gene encoding a selectable marker
which can be used to monitor integration. Typically, several
kilobases of unaltered flanking DNA (both at the 5' and 3' ends)
are included in the vector [see e.g., Thomas and Capecchi, Cell,
51:503 (1987) for a description of homologous recombination
vectors]. The vector is introduced into an embryonic stem cell line
(e.g., by electroporation) and cells in which the introduced DNA
has homologously recombined with the endogenous DNA are selected
[see e.g., L1 et al., Cell, 69:915 (1992)]. The selected cells are
then injected into a blastocyst of an animal (e.g., a mouse or rat)
to form aggregation chimeras [see e.g., Bradley, in
Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E.
J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric
embryo can then be implanted into a suitable pseudopregnant female
foster animal and the embryo brought to term to create a "knock
out" animal. Progeny harboring the homologously recombined DNA in
their germ cells can be identified by standard techniques and used
to breed animals in which all cells of the animal contain the
homologously recombined DNA. Knockout animals can be characterized
for instance, for their ability to defend against certain
pathological conditions and for their development of pathological
conditions due to absence of the polypeptide.
[0284] J. Immuno Adjuvant Therapy
[0285] In one embodiment, the immunostimulating compounds of the
invention can be used in immunoadjuvant therapy for the treatment
of tumors (cancer). It is now well established that T cells
recognize human tumor specific antigens. One group of tumor
antigens, encoded by the MAGE, BAGE and GAGE families of genes, are
silent in all adult normal tissues, but are expressed in
significant amounts in tumors, such as melanomas, lung tumors, head
and neck tumors, and bladder carcinomas. DeSmet, C. et al., Proc.
Natl. Acad. Sci. USA, 93:7149 (1996). It has been shown that
costimulation of T cells induces tumor regression and an antitumor
response both in vitro and in vivo. Melero, I. et al., Nature
Medicine. 3:682 (1997); Kwon, E. D. et al., Proc. Natl. Acad. Sci.
USA. 94: 8099 (1997); Lynch, D. H. et al., Nature Medicine, 3:625
(1997); Finn, O. J. and Lotze, M. T., J. Immunol., 21:114 (1998).
The stimulatory compounds of the invention can be administered as
adjuvants, alone or together with a growth regulating agent,
cytotoxic agent or chemotherapeutic agent, to stimulate T cell
proliferation/activation and an antitumor response to tumor
antigens. The growth regulating, cytotoxic, or chemotherapeutic
agent may be administered in conventional amounts using known
administration regimes. Immunostimulating activity by the compounds
of the invention allows reduced amounts of the growth regulating,
cytotoxic, or chemotherapeutic agents thereby potentially lowering
the toxicity to the patient.
[0286] K. Screening Assays for Drug Candidates
[0287] Screening assays for drug candidates are designed to
identify compounds that bind to or complex with the polypeptides
encoded by the genes identified herein or a biologically active
fragment thereof, or otherwise interfere with the interaction of
the encoded polypeptides with other cellular proteins. Such
screening assays will include assays amenable to high-throughput
screening of chemical libraries, making them particularly suitable
for identifying small molecule drug candidates. Small molecules
contemplated include synthetic organic or inorganic compounds,
including peptides, preferably soluble peptides,
(poly)peptide-immunoglobulin fusions, and, in particular,
antibodies including, without limitation, poly- and monoclonal
antibodies and antibody fragments, single-chain antibodies,
anti-idiotypic antibodies, and chimeric or humanized versions of
such antibodies or fragments, as well as human antibodies and
antibody fragments. The assays can be performed in a variety of
formats, including protein-protein binding assays, biochemical
screening assays, immunoassays and cell based assays, which are
well characterized in the art. All assays are common in that they
call for contacting the drug candidate with a polypeptide encoded
by a nucleic acid identified herein under conditions and for a time
sufficient to allow these two components to interact.
[0288] In binding assays, the interaction is binding and the
complex formed can be isolated or detected in the reaction mixture.
In a particular embodiment, the polypeptide encoded by the gene
identified herein or the drug candidate is immobilized on a solid
phase, e.g., on a microtiter plate, by covalent or non-covalent
attachments. Non-covalent attachment generally is accomplished by
coating the solid surface with a solution of the polypeptide and
drying. Alternatively, an immobilized antibody, e.g., a monoclonal
antibody, specific for the polypeptide to be immobilized can be
used to anchor it to a solid surface. The assay is performed by
adding the non-immobilized component, which may be labeled by a
detectable label, to the immobilized component, e.g., the coated
surface containing the anchored component. When the reaction is
complete, the non-reacted components are removed, e.g., by washing,
and complexes anchored on the solid surface are detected. When the
originally non-immobilized component carries a detectable label,
the detection of label immobilized on the surface indicates that
complexing occurred. Where the originally non-immobilized component
does not carry a label, complexing can be detected, for example, by
using a labelled antibody specifically binding the immobilized
complex.
[0289] If the candidate compound interacts with but does not bind
to a particular protein encoded by a gene identified herein, its
interaction with that protein can be assayed by methods well known
for detecting protein-protein interactions. Such assays include
traditional approaches, such as, cross-linking,
co-immunoprecipitation, and co-purification through gradients or
chromatographic columns. In addition, protein-protein interactions
can be monitored by using a yeast-based genetic system described by
Fields and co-workers [Fields and Song, Nature (London). 340,
245-246 (1989); Chien et al., Proc. Natl. Acad. Sci. USA. 88,
9578-9582 (1991)] as disclosed by Chevray and Nathans, Proc. Natl.
Acad. Sci. USA. 89, 5789-5793 (1991). Many transcriptional
activators, such as yeast GAL4, consist of two physically discrete
modular domains, one acting as the DNA-binding domain, while the
other one functioning as the transcription activation domain. The
yeast expression system described in the foregoing publications
(generally referred to as the "two-hybrid system") takes advantage
of this property, and employs two hybrid proteins, one in which the
target protein is fused to the DNA-binding domain of GAL4, and
another, in which candidate activating proteins are fused to the
activation domain. The expression of a GAL1-lacZ reporter gene
under control of a GALA-activated promoter depends on
reconstitution of GAL4 activity via protein-protein interaction.
Colonies containing interacting polypeptides are detected with a
chromogenic substrate for .beta.-galactosidase. A complete kit
(MATCHMAKER.TM.) for identifying protein-protein interactions
between two specific proteins using the two-hybrid technique is
commercially available from Clontech. This system can also be
extended to map protein domains involved in specific protein
interactions as well as to pinpoint amino acid residues that are
crucial for these interactions.
[0290] In order to find compounds that interfere with the
interaction of a gene identified herein and other intra- or
extracellular components can be tested, a reaction mixture is
usually prepared containing the product of the gene and the intra-
or extracellular component under conditions and for a time allowing
for the interaction and binding of the two products. To test the
ability of a test compound to inhibit binding, the reaction is run
in the absence and in the presence of the test compound. In
addition, a placebo may be added to a third reaction mixture, to
serve as positive control. The binding (complex formation) between
the test compound and the intra- or extracellular component present
in the mixture is monitored as described above. The formation of a
complex in the control reaction(s) but not in the reaction mixture
containing the test compound indicates that the test compound
interferes with the interaction of the test compound and its
reaction partner.
[0291] L. Compositions and Methods for the Treatment of Immune
Related Diseases
[0292] The compositions useful in the treatment of immune related
diseases include, without limitation, proteins, antibodies, small
organic molecules, peptides, phosphopeptides, antisense and
ribozyme molecules, triple helix molecules, etc. that inhibit or
stimulate immune function, for example, T cell
proliferation/activation, lymphokine release, or immune cell
infiltration.
[0293] For example, antisense RNA and RNA molecules act to directly
block the translation of mRNA by hybridizing to targeted mRNA and
preventing protein translation. When antisense DNA is used,
oligodeoxyribonucieotides derived from the translation initiation
site, e.g., between about -10 and +10 positions of the target gene
nucleotide sequence, are preferred.
[0294] Ribozymes are enzymatic RNA molecules capable of catalyzing
the specific cleavage of RNA. Ribozymes act by sequence-specific
hybridization to the complementary target RNA, followed by
endonucleolytic cleavage. Specific ribozyme cleavage sites within a
potential RNA target can be identified by known techniques. For
further details see, e.g., Rossi, Current Biology. 4, 469-471
(1994), and PCT publication No. WO 97/33551 (published Sep. 18,
1997).
[0295] Nucleic acid molecules in triple helix formation used to
inhibit transcription should be single-stranded and composed of
deoxynucleotides. The base composition of these oligonucleotides is
designed such that it promotes triple helix formation via Hoogsteen
base pairing rules, which generally require sizeable stretches of
purines or pyrimidines on one strand of a duplex. For further
details see, e.g., PCT publication No. WO 97/33551, supra.
[0296] These molecules can be identified by any or any combination
of the screening assays discussed above and/or by any other
screening techniques well known for those skilled in the art.
[0297] M. Anti-PRO842 Antibodies
[0298] The present invention further provides anti-PRO842
antibodies. Exemplary antibodies include polyclonal, monoclonal,
humanized, bispecific, and heteroconjugate antibodies.
[0299] 1. Polyclonal Antibodies
[0300] The anti-PRO842 antibodies may comprise polyclonal
antibodies. Methods of preparing polyclonal antibodies are known to
the skilled artisan. Polyclonal antibodies can be raised in a
mammal, for example, by one or more injections of an immunizing
agent and, if desired, an adjuvant. Typically, the immunizing agent
and/or adjuvant will be injected in the mammal by multiple
subcutaneous or intraperitoneal injections. The immunizing agent
may include the PRO842 polypeptide or a fusion protein thereof. It
may be useful to conjugate the immunizing agent to a protein known
to be immunogenic in the mammal being immunized. Examples of such
immunogenic proteins include but are not limited to keyhole limpet
hemocyanin, serum albumin, bovine thyroglobulin, and soybean
trypsin inhibitor. Examples of adjuvants which may be employed
include Freund's complete adjuvant and MPL-TDM adjuvant
(monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The
immunization protocol may be selected by one skilled in the art
without undue experimentation.
[0301] 2. Monoclonal Antibodies
[0302] The anti-PRO842 antibodies may, alternatively, be monoclonal
antibodies. Monoclonal antibodies may be prepared using hybridoma
methods, such as those described by Kohler and Milstein, Nature,
256:495 (1975). In a hybridoma method, a mouse, hamster, or other
appropriate host animal, is typically immunized with an immunizing
agent to elicit lymphocytes that produce or are capable of
producing antibodies that will specifically bind to the immunizing
agent. Alternatively, the lymphocytes may be immunized in
vitro.
[0303] The immunizing agent will typically include the PRO842
polypeptide or a fusion protein thereof. Generally, either
peripheral blood lymphocytes ("PBLs") are used if cells of human
origin are desired, or spleen cells or lymph node cells are used if
non-human mammalian sources are desired. The lymphocytes are then
fused with an immortalized cell line using a suitable fusing agent,
such as polyethylene glycol, to form a hybridoma cell [Goding,
Monoclonal Antibodies: Principles and Practice, Academic Press,
(1986) pp. 59-103]. Immortalized cell lines are usually transformed
mammalian cells, particularly myeloma cells of rodent, bovine and
human origin. Usually, rat or mouse myeloma cell lines are
employed. The hybridoma cells may be cultured in a suitable culture
medium that preferably contains one or more substances that inhibit
the growth or survival of the unfused, immortalized cells. For
example, if the parental cells lack the enzyme hypoxanthine guanine
phosphoribosyl transferase (HGPRT or HPRT), the culture medium for
the hybridomas typically will include hypoxanthine, aminopterin,
and thymidine ("HAT medium"), which substances prevent the growth
of HGPRT-deficient cells.
[0304] Preferred immortalized cell lines are those that fuse
efficiently, support stable high level expression of antibody by
the selected antibody-producing cells, and are sensitive to a
medium such as HAT medium. More preferred immortalized cell lines
are murine myeloma lines, which can be obtained, for instance, from
the Salk Institute Cell Distribution Center. San Diego, Calif. and
the American Type Culture Collection. Manassas. Va. Human myeloma
and mouse-human heteromyeloma cell lines also have been described
for the production of human monoclonal antibodies [Kozbor, J.
Immunol., 133:3001 (1984): Brodeur et al., Monoclonal Antibody
Production Techniques and Applications, Marcel Dekker. Inc., New
York, (1987) pp. 51-63].
[0305] The culture medium in which the hybridoma cells are cultured
can then be assayed for the presence of monoclonal antibodies
directed against PRO842. Preferably, the binding specificity of
monoclonal antibodies produced by the hybridoma cells is determined
by immunoprecipitation or by an in vitro binding assay, such as
radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay
(ELISA). Such techniques and assays are known in the art. The
binding affinity of the monoclonal antibody can, for example, be
determined by the Scatchard analysis of Munson and Pollard, Anal.
Biochem., 107:220 (1980).
[0306] After the desired hybridoma cells are identified, the clones
may be subcloned by limiting dilution procedures and grown by
standard methods [Goding, supra]. Suitable culture media for this
purpose include, for example, Dulbecco's Modified Eagle's Medium
and RPMI-1640 medium. Alternatively, the hybridoma cells may be
grown in vivo as ascites in a mammal.
[0307] The monoclonal antibodies secreted by the subclones may be
isolated or purified from the culture medium or ascites fluid by
conventional immunoglobulin purification procedures such as, for
example, protein A-Sepharose, hydroxylapatite chromatography, gel
electrophoresis, dialysis, or affinity chromatography.
[0308] The monoclonal antibodies may also be made by recombinant
DNA methods, such as those described in U.S. Pat. No. 4,816,567.
DNA encoding the monoclonal antibodies of the invention can be
readily isolated and sequenced using conventional procedures (e.g.,
by using oligonucleotide probes that are capable of binding
specifically to genes encoding the heavy and light chains of murine
antibodies). The hybridoma cells of the invention serve as a
preferred source of such DNA. Once isolated, the DNA may be placed
into expression vectors, which are then transfected into host cells
such as simian COS cells, Chinese hamster ovary (CHO) cells, or
myeloma cells that do not otherwise produce immunoglobulin protein,
to obtain the synthesis of monoclonal antibodies in the recombinant
host cells. The DNA also may be modified, for example, by
substituting the coding sequence for human heavy and light chain
constant domains in place of the homologous murine sequences [U.S.
Pat. No. 4,816,567; Morrison et al., supra] or by covalently
joining to the immunoglobulin coding sequence all or part of the
coding sequence for a non-immunoglobulin polypeptide. Such a
non-immunoglobulin polypeptide can be substituted for the constant
domains of an antibody of the invention, or can be substituted for
the variable domains of one antigen-combining site of an antibody
of the invention to create a chimeric bivalent antibody.
[0309] The antibodies may be monovalent antibodies. Methods for
preparing monovalent antibodies are well known in the art. For
example, one method involves recombinant expression of
immunoglobulin light chain and modified heavy chain. The heavy
chain is truncated generally at any point in the Fc region so as to
prevent heavy chain crosslinking. Alternatively, the relevant
cysteine residues are substituted with another amino acid residue
or are deleted so as to prevent crosslinking.
[0310] In vitro methods are also suitable for preparing monovalent
antibodies. Digestion of antibodies to produce fragments thereof,
particularly, Fab fragments, can be accomplished using routine
techniques known in the art.
[0311] 3. Human and Humanized Antibodies
[0312] The anti-PRO842 antibodies of the invention may further
comprise humanized antibodies or human antibodies. Humanized forms
of non-human (e.g., murine) antibodies are chimeric
immunoglobulins, immunoglobulin chains or fragments thereof (such
as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding
subsequences of antibodies) which contain minimal sequence derived
from non-human immunoglobulin. Humanized antibodies include human
immunoglobulins (recipient antibody) in which residues from a
complementary determining region (CDR) of the recipient are
replaced by residues from a CDR of a non-human species (donor
antibody) such as mouse, rat or rabbit having the desired
specificity, affinity and capacity. In some instances, Fv framework
residues of the human immunoglobulin are replaced by corresponding
non-human residues. Humanized antibodies may also comprise residues
which are found neither in the recipient antibody nor in the
imported CDR or framework sequences. In general, the humanized
antibody will comprise substantially all of at least one, and
typically two, variable domains, in which all or substantially all
of the CDR regions correspond to those of a non-human
immunoglobulin and all or substantially all of the FR regions are
those of a human immunoglobulin consensus sequence. The humanized
antibody optimally also will comprise at least a portion of an
immunoglobulin constant region (Fc), typically that of a human
immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann
et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct.
Biol., 2:593-596 (1992)].
[0313] Methods for humanizing non-human antibodies are well known
in the art. Generally, a humanized antibody has one or more amino
acid residues introduced into it from a source which is non-human.
These non-human amino acid residues are often referred to as
"import" residues, which are typically taken from an "import"
variable domain. Humanization can be essentially performed
following the method of Winter and co-workers (Jones et al.,
Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327
(1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by
substituting rodent CDRs or CDR sequences for the corresponding
sequences of a human antibody. Accordingly, such "humanized"
antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567),
wherein substantially less than an intact human variable domain has
been substituted by the corresponding sequence from a non-human
species. In practice, humanized antibodies are typically human
antibodies in which some CDR residues and possibly some FR residues
are substituted by residues from analogous sites in rodent
antibodies.
[0314] Human antibodies can also be produced using various
techniques known in the art, including phage display libraries
[Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et
al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al.,
and Boerner et al., are also available for the preparation of human
monoclonal antibodies (Cole et al., Monoclonal Antibodies and
Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J.
Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be
made by introducing of human immunoglobulin loci into transgenic
animals, e.g., mice in which the endogenous immunoglobulin genes
have been partially or completely inactivated. Upon challenge,
human antibody production is observed, which closely resembles that
seen in humans in all respects, including gene rearrangement,
assembly, and antibody repertoire. This approach is described, for
example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5.569,825;
5,625,126; 5,633,425; 5.661,016, and in the following scientific
publications: Marks et al., Bio/Technology. 10, 779-783 (1992);
Lonberg et al., Nature, 368: 856-859 (1994); Morrison, Nature. 368:
812-13 (1994): Fishwild et al., Nature Biotechnology, 14: 845-51
(1996); Neuberger. Nature Biotechnology. 14: 826 (1996); Lonberg
and Huszar, Intern. Rev. Immunol., 13: 65-93 (1995).
[0315] The antibodies may also be affinity matured using known
selection and/or mutagenesis methods as described above. Preferred
affinity matured antibodies have an affinity which is five times,
more preferably 10 times, even more preferably 20 or 30 times
greater than the starting antibody (generally murine, humanized or
human) from which the matured antibody is prepared.
[0316] 4. Bispecific Antibodies
[0317] Bispecific antibodies are monoclonal, preferably human or
humanized, antibodies that have binding specificities for at least
two different antigens. In the present case, one of the binding
specificities is for the PRO842, the other one is for any other
antigen, and preferably for a cell-surface protein or receptor or
receptor subunit.
[0318] Methods for making bispecific antibodies are known in the
art. Traditionally, the recombinant production of bispecific
antibodies is based on the co-expression of two immunoglobulin
heavy-chain/light-chain pairs, where the two heavy chains have
different specificities [Milstein and Cuello, Nature, 305:537-539
(1983)]. Because of the random assortment of immunoglobulin heavy
and light chains, these hybridomas (quadromas) produce a potential
mixture of ten different antibody molecules, of which only one has
the correct bispecific structure. The purification of the correct
molecule is usually accomplished by affinity chromatography steps.
Similar procedures are disclosed in WO 93/08829, published 13 May
1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).
[0319] Antibody variable domains with the desired binding
specificities (antibody-antigen combining sites) can be fused to
immunoglobulin constant domain sequences. The fusion preferably is
with an immunoglobulin heavy-chain constant domain, comprising at
least part of the hinge, CH2, and CH3 regions. It is preferred to
have the first heavy-chain constant region (CH1) containing the
site necessary for light-chain binding present in at least one of
the fusions. DNAs encoding the immunoglobulin heavy-chain fusions
and, if desired, the immunoglobulin light chain, are inserted into
separate expression vectors, and are co-transfected into a suitable
host organism. For further details of generating bispecific
antibodies see, for example, Suresh et al., Methods in Enzymology,
121:210 (1986).
[0320] According to another approach described in WO 96/27011, the
interface between a pair of antibody molecules can be engineered to
maximize the percentage of heterodimers which are recovered from
recombinant cell culture. The preferred interface comprises at
least a part of the CH3 region of an antibody constant domain. In
this method, one or more small amino acid side chains from the
interface of the first antibody molecule are replaced with larger
side chains (e.g., tyrosine or tryptophan). Compensatory "cavities"
of identical or similar size to the large side chain(s) are created
on the interface of the second antibody molecule by replacing large
amino acid side chains with smaller ones (e.g. alanine or
threonine). This provides a mechanism for increasing the yield of
the heterodimer over other unwanted end-products such as
homodimers.
[0321] Bispecific antibodies can be prepared as full length
antibodies or antibody fragments (e.g., F(ab')2 bispecific
antibodies). Techniques for generating bispecific antibodies from
antibody fragments have been described in the literature. For
example, bispecific antibodies can be prepared can be prepared
using chemical linkage. Brennan et al. Science, 229:81 (1985)
describe a procedure wherein intact antibodies are proteolytically
cleaved to generate F(ab')2 fragments. These fragments are reduced
in the presence of the dithiol complexing agent sodium arsenite to
stabilize vicinal dithiols and prevent intermolecular disulfide
formation. The Fab' fragments generated are then converted to
thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB
derivatives is then reconverted to the Fab'-thiol by reduction with
mercaptoethylamine and is mixed with an equimolar amount of the
other Fab'-TNB derivative to form the bispecific antibody. The
bispecific antibodies produced can be used as agents for the
selective immobilization of enzymes.
[0322] Fab' fragments may be directly recovered from E. coli and
chemically coupled to form bispecific antibodies. Shalaby et al.,
J. Exp. Med. 175:217-225 (1992) describe the production of a fully
humanized bispecific antibody F(ab')2 molecule. Each Fab' fragment
was separately secreted from E. coli and subjected to directed
chemical coupling in vitro to form the bispecific antibody. The
bispecific antibody thus formed was able to bind to cells
overexpressing the ErbB2 receptor and normal human T cells, as well
as trigger the lytic activity of human cytotoxic lymphocytes
against human breast tumor targets.
[0323] Various technique for making and isolating bispecific
antibody fragments directly from recombinant cell culture have also
been described. For example, bispecific antibodies have been
produced using leucine zippers. Kostelny et al., J. Immunol.,
148(5):1547-1553 (1992). The leucine zipper peptides from the Fos
and Jun proteins were linked to the Fab' portions of two different
antibodies by gene fusion. The antibody homodimers were reduced at
the hinge region to form monomers and then re-oxidized to form the
antibody heterodimers. This method can also be utilized for the
production of antibody homodimers. The "diabody" technology
described by Hollinger et al., Proc. Natl. Acad. Sci. USA.
90:6444-6448 (1993) has provided an alternative mechanism for
making bispecific antibody fragments. The fragments comprise a
heavy-chain variable domain (V.sub.H) connected to a light-chain
variable domain (V.sub.L) by a linker which is too short to allow
pairing between the two domains on the same chain. Accordingly, the
V.sub.H and V.sub.L domains of one fragment are forced to pair with
the complementary V.sub.L and V.sub.H domains of another fragment,
thereby forming two antigen-binding sites. Another strategy for
making bispecific antibody fragments by the use of single-chain Fv
(sFv) dimers has also been reported. See, Gruber et al., J.
Immunol. 152:5368 (1994).
[0324] Antibodies with more than two valencies are contemplated.
For example, trispecific antibodies can be prepared. Tutt et al.,
J. Immunol., 147:60 (1991).
[0325] Exemplary bispecific antibodies may bind to two different
epitopes on a given PRO842 polypeptide herein. Alternatively, an
anti-PRO842 polypeptide arm may be combined with an arm which binds
to a triggering molecule on a leukocyte such as a T-cell receptor
molecule (e.g., CD2, CD3, CD28, or B7), or Fc receptors for IgG
(FcgR), such as FcgRI (CD64), FcgRII (CD32) and FcgRIII (CD16) so
as to focus cellular defense mechanisms to the cell expressing the
particular PRO842 polypeptide. Bispecific antibodies may also be
used to localize cytotoxic agents to cells which express a
particular PRO842 polypeptide. These antibodies possess a
PRO842-binding arm and an arm which binds a cytotoxic agent or a
radionuclide chelator, such as EOTUBE, DPTA. DOTA, or TETA. Another
bispecific antibody of interest binds the PRO842 polypeptide and
further binds tissue factor (TF).
[0326] 5. Heteroconjugate Antibodies
[0327] Heteroconjugate antibodies are also within the scope of the
present invention. Heteroconjugate antibodies are composed of two
covalently joined antibodies. Such antibodies have, for example,
been proposed to target immune system cells to unwanted cells [U.S.
Pat. No. 4,676,980], and for treatment of HIV infection [WO
91/00360; WO 92/200373; EP 03089]. It is contemplated that the
antibodies may be prepared in vitro using known methods in
synthetic protein chemistry, including those involving crosslinking
agents. For example, immunotoxins may be constructed using a
disulfide exchange reaction or by forming a thioether bond.
Examples of suitable reagents for this purpose include
iminothiolate and methyl-4-mercaptobutyrimidate and those
disclosed, for example, in U.S. Pat. No. 4,676,980.
[0328] 6. Effector Function Engineering
[0329] It may be desirable to modify the antibody of the invention
with respect to effector function, so as to enhance, e.g., the
effectiveness of the antibody in treating cancer. For example,
cysteine residue(s) may be introduced into the Fc region, thereby
allowing interchain disulfide bond formation in this region. The
homodimeric antibody thus generated may have improved
internalization capability and/or increased complement-mediated
cell killing and antibody-dependent cellular cytotoxicity (ADCC).
See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J.
Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with
enhanced anti-tumor activity may also be prepared using
heterobifunctional cross-linkers as described in Wolff et al.,
Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody
can be engineered that has dual Fc regions and may thereby have
enhanced complement lysis and ADCC capabilities. See Stevenson et
al., Anti-Cancer Drug Design, 3: 219-230 (1989).
[0330] 7. Immunoconjugates
[0331] The invention also pertains to immunoconjugates comprising
an antibody conjugated to a cytotoxic agent such as a
chemotherapeutic agent, toxin (e.g., an enzymatically active toxin
of bacterial, fungal, plant, or animal origin, or fragments
thereof), or a radioactive isotope (i.e., a radioconjugate).
[0332] Chemotherapeutic agents useful in the generation of such
immunoconjugates have been described above. Enzymatically active
toxins and fragments thereof that can be used include diphtheria A
chain, nonbinding active fragments of diphtheria toxin, exotoxin A
chain (from Pseudononas aeruginosa), ricin A chain, abrin A chain,
modeccin A chain, alpha-sarcin, Aleuritesfordii proteins, dianthin
proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S),
momordica charantia inhibitor, curcin, crotin, sapaonaria
officinalis inhibitor, gelonin, mitogellin, restrictocin,
phenomycin, enomycin, and the tricothecenes. A variety of
radionuclides are available for the production of radioconjugated
antibodies. Examples include .sup.212Bi, .sup.131I, .sup.131In,
.sup.90Y, and .sup.186Re.
[0333] Conjugates of the antibody and cytotoxic agent are made
using a variety of bifunctional protein-coupling agents such as
N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP),
iminothiolane (IT), bifunctional derivatives of imidoesters (such
as dimethyl adipimidate HCl), active esters (such as disuccinimidyl
suberate), aldehydes (such as glutareldehyde), bis-azido compounds
(such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium
derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine),
diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active
fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For
example, a ricin immunotoxin can be prepared as described in
Vitetta et al., Science, 23:1098 (1987). Carbon-14-labeled
1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid
(MX-DTPA) is an exemplary chelating agent for conjugation of
radionucleotide to the antibody. See WO94/11026.
[0334] In another embodiment, the antibody may be conjugated to a
"receptor" (such streptavidin) for utilization in tumor
pretargeting wherein the antibody-receptor conjugate is
administered to the patient, followed by removal of unbound
conjugate from the circulation using a clearing agent and then
administration of a "ligand" (e.g., avidin) that is conjugated to a
cytotoxic agent (e.g., a radionucleotide).
[0335] 8. Immunoliposomes
[0336] The antibodies disclosed herein may also be formulated as
immunoliposomes. Liposomes containing the antibody are prepared by
methods known in the art, such as described in Epstein et al.,
Proc. Natl. Acad. Sci. USA; 82:3688 (1985); Hwang et al., Proc.
Natl Acad. Sci. USA, 77:4030 (1980); and U.S. Pat. Nos. 4,485,045
and 4,544,545. Liposomes with enhanced circulation time are
disclosed in U.S. Pat. No. 5,013,556.
[0337] Particularly useful liposomes can be generated by the
reverse-phase evaporation method with a lipid composition
comprising phosphatidylcholine, cholesterol, and PEG-derivatized
phosphatidylethanolamine (PEG-PE). Liposomes are extruded through
filters of defined pore size to yield liposomes with the desired
diameter. Fab' fragments of the antibody of the present invention
can be conjugated to the liposomes as described in Martin et al.,
J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange
reaction. A chemotherapeutic agent (such as Doxorubicin) is
optionally contained within the liposome. See Gabizon et al., J.
National Cancer Inst., 81(19):1484 (1989).
[0338] 9. Uses for anti-PRO842 Antibodies
[0339] The anti-PRO842 antibodies of the invention have various
utilities. For example, anti-PRO842 antibodies may be used in
diagnostic assays for PRO842, e.g., detecting its expression (and
in some cases, differential expression) in specific cells, tissues,
or serum. Various diagnostic assay techniques known in the art may
be used, such as competitive binding assays, direct or indirect
sandwich assays and immunoprecipitation assays conducted in either
heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A
Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158]. The
antibodies used in the diagnostic assays can be labeled with a
detectable moiety. The detectable moiety should be capable of
producing, either directly or indirectly, a detectable signal. For
example, the detectable moiety may be a radioisotope, such as
.sup.3H, .sup.14C, .sup.32P, .sup.35S, or .sup.125I, a fluorescent
or chemiluminescent compound, such as fluorescein isothiocyanate,
rhodamine, or luciferin, or an enzyme, such as alkaline
phosphatase, beta-galactosidase or horseradish peroxidase. Any
method known in the art for conjugating the antibody to the
detectable moiety may be employed, including those methods
described by Hunter et al., Nature, 144:945 (1962): David et al.,
Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth. 40:219
(1981); and Nygren, J. Histochem, and Cytochem., 30:407 (1982).
[0340] Anti-PRO842 antibodies also are useful for the affinity
purification of PRO842 from recombinant cell culture or natural
sources. In this process, the antibodies against PRO842 are
immobilized on a suitable support, such a Sephadex resin or filter
paper, using methods well known in the art. The immobilized
antibody then is contacted with a sample containing the PRO842 to
be purified, and thereafter the support is washed with a suitable
solvent that will remove substantially all the material in the
sample except the PRO842, which is bound to the immobilized
antibody. Finally, the support is washed with another suitable
solvent that will release the PRO842 from the antibody.
[0341] The following examples are offered for illustrative purposes
only, and are not intended to limit the scope of the present
invention in any way.
[0342] All patent and literature references cited in the present
specification are hereby incorporated by reference in their
entirety.
[0343] N. Pharmaceutical Compositions
[0344] The active PRO842 molecules of the invention (e.g., PRO842
polypeptides, anti-PRO842 antibodies, and/or variants of each) as
well as other molecules identified by the screening assays
disclosed above, can be administered for the treatment of immune
related diseases, in the form of pharmaceutical compositions.
Therapeutic formulations of the active PRO842 molecule, preferably
a polypeptide or antibody of the invention, are prepared for
storage by mixing the active molecule having the desired degree of
purity with optional pharmaceutically acceptable carriers,
excipients or stabilizers (Remington's Pharmaceutical Sciences 16th
edition, Osol, A. Ed. [1980]), in the form of lyophilized
formulations or aqueous solutions. Acceptable carriers, excipients,
or stabilizers are nontoxic to recipients at the dosages and
concentrations employed, and include buffers such as phosphate,
citrate, and other organic acids; antioxidants including ascorbic
acid and methionine; preservatives (such as octadecyldimethylbenzyl
ammonium chloride; hexamethonium chloride; benzalkonium chloride,
benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl
parabens such as methyl or propyl paraben; catechol; resorcinol;
cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less
than about 10 residues) polypeptides; proteins, such as serum
albumin, gelatin, or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides, and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g., Zn-protein complexes); and/or
non-ionic surfactants such as TWEEN.TM., PLURONICS.TM. or
polyethylene glycol (PEG).
[0345] Compounds identified by the screening assays disclosed
herein can be formulated in an analogous manner, using standard
techniques well known in the art.
[0346] Lipofections or liposomes can also be used to deliver the
PRO842 molecule into cells. Where antibody fragments are used, the
smallest inhibitory fragment which specifically binds to the
binding domain of the target protein is preferred. For example,
based upon the variable region sequences of an antibody, peptide
molecules can be designed which retain the ability to bind the
target protein sequence. Such peptides can be synthesized
chemically and/or produced by recombinant DNA technology (see,
e.g., Marasco et al., Proc. Natil. Acad. Sci. USA. 90:7889-7893
[1993]).
[0347] The formulation herein may also contain more than one active
compound as necessary for the particular indication being treated,
preferably those with complementary activities that do not
adversely affect each other. Alternatively, or in addition, the
composition may comprise a cytotoxic agent, cytokine or growth
inhibitory agent. Such molecules are suitably present in
combination in amounts that are effective for the purpose
intended.
[0348] The active PRO842 molecules may also be entrapped in
microcapsules prepared, for example, by coacervation techniques or
by interfacial polymerization, for example, hydroxymethylcellulose
or gelatin-microcapsules and poly-(methylmethacylate)
microcapsules, respectively, in colloidal drug delivery systems
(for example, liposomes, albumin microspheres, microemulsions,
nano-particles and nanocapsules) or in macroemulsions. Such
techniques are disclosed in Remington's Pharmaceutical Sciences
16th edition, Osol, A. Ed. (1980).
[0349] The formulations to be used for in vivo administration must
be sterile. This is readily accomplished by filtration through
sterile filtration membranes.
[0350] Sustained-release preparations or the PRO842 molecules may
be prepared. Suitable examples of sustained-release preparations
include semipermeable matrices of solid hydrophobic polymers
containing the antibody, which matrices are in the form of shaped
articles, e.g., films, or microcapsules. Examples of
sustained-release matrices include polyesters, hydrogels (for
example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)),
polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic
acid and .gamma.-ethyl-L-glutamate, non-degradable ethylene-vinyl
acetate, degradable lactic acid-glycolic acid copolymers such as
the LUPRON DEPOT.TM. (injectable microspheres composed of lactic
acid-glycolic acid copolymer and leuprolide acetate), and
poly-D-(-)-3-hydroxybutyric acid. While polymers such as
ethylene-vinyl acetate and lactic acid-glycolic acid enable release
of molecules for over 100 days, certain hydrogels release proteins
for shorter time periods. When encapsulated antibodies remain in
the body for a long time, they may denature or aggregate as a
result of exposure to moisture at 37.degree. C., resulting in a
loss of biological activity and possible changes in immunogenicity.
Rational strategies can be devised for stabilization depending on
the mechanism involved. For example, if the aggregation mechanism
is discovered to be intermolecular S--S bond formation through
thio-disulfide interchange, stabilization may be achieved by
modifying sulfhydryl residues, lyophilizing from acidic solutions,
controlling moisture content, using appropriate additives, and
developing specific polymer matrix compositions.
[0351] O. Methods of Treatment
[0352] It is contemplated that the polypeptides, antibodies and
other active compounds of the present invention may be used to
treat various immune related diseases and conditions, such as T
cell mediated diseases, including those characterized by
infiltration of inflammatory cells into a tissue, stimulation of
T-cell proliferation, inhibition of T-cell proliferation, increased
or decreased vascular permeability or the inhibition thereof.
[0353] Exemplary conditions or disorders to be treated with the
polypeptides, antibodies and other compounds of the invention,
include, but are not limited to systemic lupus erythematosis,
rheumatoid arthritis, juvenile chronic arthritis, osteoarthritis,
spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic
inflammatory myopathies (dermatomyositis, polymyositis), Sjogren's
syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic
anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria),
autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura,
immune-mediated thrombocytopenia), thyroiditis (Grave's disease,
Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic
thyroiditis), diabetes mellitus, immune-mediated renal disease
(glomerulonephritis, tubulointerstitial nephritis), demyelinating
diseases of the central and peripheral nervous systems such as
multiple sclerosis, idiopathic demyelinating polyneuropathy or
Guillain-Barre syndrome, and chronic inflammatory demyelinating
polyneuropathy, hepatobiliary diseases such as infectious hepatitis
(hepatitis A, B, C, D, E and other non-hepatotropic viruses),
autoimmune chronic active hepatitis, primary biliary cirrhosis,
granulomatous hepatitis, and sclerosing cholangitis, inflammatory
bowel disease (ulcerative colitis: Crohn's disease),
gluten-sensitive enteropathy, and Whipple's disease, autoimmune or
immune-mediated skin diseases including bullous skin diseases,
erythema multiforme and contact dermatitis, psoriasis, allergic
diseases such as asthma, allergic rhinitis, atopic dermatitis, food
hypersensitivity and urticaria, immunologic diseases of the
ovaries, immunologic diseases of the lung such as eosinophilic
pneumonia, idiopathic pulmonary fibrosis and hypersensitivity
pneumonitis, transplantation associated diseases including graft
rejection and graft-versus-host-disease.
[0354] In systemic lupus erythematosus, the central mediator of
disease is the production of auto-reactive antibodies to self
proteins/tissues and the subsequent generation of immune-mediated
inflammation. Antibodies either directly or indirectly mediate
tissue injury. Though T lymphocytes have not been shown to be
directly involved in tissue damage, T lymphocytes are required for
the development of auto-reactive antibodies. The genesis of the
disease is thus T lymphocyte dependent. Multiple organs and systems
are affected clinically including kidney, lung, musculoskeletal
system, mucocutaneous, eye, central nervous system, cardiovascular
system, gastrointestinal tract, bone marrow and blood.
[0355] Rheumatoid arthritis (RA) is a chronic systemic autoimmune
inflammatory disease that mainly involves the synovial membrane of
multiple joints with resultant injury to the articular cartilage.
The pathogenesis is T lymphocyte dependent and is associated with
the production of rheumatoid factors, auto-antibodies directed
against self IgG, with the resultant formation of immune complexes
that attain high levels in joint fluid and blood. These complexes
in the joint may induce the marked infiltrate of lymphocytes and
monocytes into the synovium and subsequent marked synovial changes;
the joint space/fluid if infiltrated by similar cells with the
addition of numerous neutrophils. Tissues affected are primarily
the joints, often in symmetrical pattern. However, extra-articular
disease also occurs in two major forms. One form is the development
of extra-articular lesions with ongoing progressive joint disease
and typical lesions of pulmonary fibrosis, vasculitis, and
cutaneous ulcers. The second form of extra-articular disease is the
so called Felty's syndrome which occurs late in the RA disease
course, sometimes after joint disease has become quiescent, and
involves the presence of neutropenia, thrombocytopenia and
splenomegaly. This can be accompanied by vasculitis in multiple
organs with formations of infarcts, skin ulcers and gangrene.
Patients often also develop rheumatoid nodules in the subcutis
tissue overlying affected joints; the nodules late stage have
necrotic centers surrounded by a mixed inflammatory cell
infiltrate. Other manifestations which can occur in RA include:
pericarditis, pleuritis, coronary arteritis, interstitial
pneumonitis with pulmonary fibrosis, keratoconjunctivitis sicca,
and rheumatoid nodules.
[0356] Juvenile chronic arthritis is a chronic idiopathic
inflammatory disease which begins often at less than 16 years of
age. Its phenotype has some similarities to RA; some patients which
are rheumatoid factor positive are classified asjuvenile rheumatoid
arthritis. The disease is sub-classified into three
majorcategories: pauciarticular, polyarticular, and systemic. The
arthritis can be severe and is typically destructive and leads to
joint ankylosis and retarded growth. Other manifestations can
include chronic anterior uveitis and systemic amyloidosis.
[0357] Spondyloarthropathies are a group of disorders with some
common clinical features and the common association with the
expression of HLA-B27 gene product. The disorders include:
ankylosing spondylitis, Reiter's syndrome (reactive arthritis),
arthritis associated with inflammatory bowel disease, spondylitis
associated with psoriasis, juvenile onset spondyloarthropathy and
undifferentiated spondyloarthropathy. Distinguishing features
include sacroileitis with or without spondylitis; inflammatory
asymmetric arthritis; association with HLA-B27 (a serologically
defined allele of the HLA-B locus of class I MHC); ocular
inflammation, and absence of autoantibodies associated with other
rheumatoid disease. The cell most implicated as key to induction of
the disease is the CD8.sup.+ T lymphocyte, a cell which targets
antigen presented by class I MHC molecules. CD8.sup.+ T cells may
react against the class I MHC allele HLA-B27 as if it were a
foreign peptide expressed by MHC class I molecules. It has been
hypothesized that an epitope of HLA-B27 may mimic a bacterial or
other microbial antigenic epitope and thus induce a CD8.sup.+ T
cells response.
[0358] Systemic sclerosis (scleroderma) has an unknown etiology. A
hallmark of the disease is induration of the skin; likely this is
induced by an active inflammatory process. Scleroderma can be
localized or systemic, vascular lesions are common and endothelial
cell injury in the microvasculature is an early and important event
in the development of systemic sclerosis; the vascular injury may
be immune mediated. An immunologic basis is implied by the presence
of mononuclear cell infiltrates in the cutaneous lesions and the
presence of anti-nuclear antibodies in many patients. ICAM-1 is
often upregulated on the cell surface of fibroblasts in skin
lesions suggesting that T cell interaction with these cells may
have a role in the pathogenesis of the disease. Other organs
involved include: the gastrointestinal tract: smooth muscle atrophy
and fibrosis resulting in abnormal peristalsis/motility; kidney:
concentric subendothelial intimal proliferation affecting small
arcuate and interlobular arteries with resultant reduced renal
cortical blood flow, results in proteinuria, azotemia and
hypertension; skeletal muscle: atrophy, interstitial fibrosis;
inflammation; lung: interstitial pneumonitis and interstitial
fibrosis; and heart: contraction band necrosis,
scarring/fibrosis.
[0359] Idiopathic inflammatory myopathies including
dermatomyositis, polymyositis and others are disorders of chronic
muscle inflammation of unknown etiology resulting in muscle
weakness. Muscle injury/inflammation is often symmetric and
progressive. Autoantibodies are associated with most forms. These
myositis-specific autoantibodies are directed against and inhibit
the function of components, proteins and RNA's, involved in protein
synthesis.
[0360] Sjogren's syndrome is due to immune-mediated inflammation
and subsequent functional destruction of the tear glands and
salivary glands. The disease can be associated with or accompanied
by inflammatory connective tissue diseases. The disease is
associated with autoantibody production against Ro and La antigens,
both of which are small RNA-protein complexes. Lesions result in
keratoconjunctivitis sicca, xerostomia, with other manifestations
or associations including biliary cirrhosis, peripheral or sensory
neuropathy, and palpable purpura.
[0361] Systemic vasculitis are diseases in which the primary lesion
is inflammation and subsequent damage to blood vessels which
results in ischemia/necrosis/degeneration to tissues supplied by
the affected vessels and eventual end-organ dysfunction in some
cases. Vasculitides can also occur as a secondary lesion or
sequelae to other immune-inflammatory mediated diseases such as
rheumatoid arthritis, systemic sclerosis, etc., particularly in
diseases also associated with the formation of immune complexes.
Diseases in the primary systemic vasculitis group include: systemic
necrotizing vasculitis: polyarteritis nodosa, allergic angiitis and
granulomatosis, polyangiitis; Wegener's granulomatosis;
lymphomatoid granulomatosis; and giant cell arteritis.
Miscellaneous vasculitides include: mucocutaneous lymph node
syndrome (MLNS or Kawasaki's disease), isolated CNS vasculitis,
Behet's disease, thromboangiitis obliterans (Buerger's disease) and
cutaneous necrotizing venulitis. The pathogenic mechanism of most
of the types of vasculitis listed is believed to be primarily due
to the deposition of immunoglobulin complexes in the vessel wall
and subsequent induction of an inflammatory response either via
ADCC, complement activation, or both.
[0362] Sarcoidosis is a condition of unknown etiology which is
characterized by the presence of epithelioid granulomas in nearly
any tissue in the body; involvement of the lung is most common. The
pathogenesis involves the persistence of activated macrophages and
lymphoid cells at sites of the disease with subsequent chronic
sequelae resultant from the release of locally and systemically
active products released by these cell types.
[0363] Autoimmune hemolytic anemia including autoimmune hemolytic
anemia, immune pancytopenia, and paroxysmal noctural hemoglobinuria
is a result of production of antibodies that react with antigens
expressed on the surface of red blood cells (and in some cases
other blood cells including platelets as well) and is a reflection
of the removal of those antibody coated cells via complement
mediated lysis and/or ADCC/Fc-receptor-mediated mechanisms.
[0364] In autoimmune thrombocytopenia including thrombocytopenic
purpura, and immune-mediated thrombocytopenia in other clinical
settings, platelet destruction/removal occurs as a result of either
antibody or complement attaching to platelets and subsequent
removal by complement lysis, ADCC or FC-receptor mediated
mechanisms.
[0365] Thyroiditis including Grave's disease, Hashimoto's
thyroiditis, juvenile lymphocytic thyroiditis, and atrophic
thyroiditis, are the result of an autoimmune response against
thyroid antigens with production of antibodies that react with
proteins present in and often specific for the thyroid gland.
Experimental models exist including spontaneous models: rats (BUF
and BB rats) and chickens (obese chicken strain); inducible models:
immunization of animals with either thyroglobulin, thyroid
microsomal antigen (thyroid peroxidase).
[0366] Type I diabetes mellitus or insulin-dependent diabetes is
the autoimmune destruction of pancreatic islet cells; this
destruction is mediated by auto-antibodies and auto-reactive T
cells. Antibodies to insulin or the insulin receptor can also
produce the phenotype of insulin-non-responsiveness.
[0367] Immune mediated renal diseases, including glomerulonephritis
and tubulointerstitial nephritis, are the result of antibody or T
lymphocyte mediated injury to renal tissue either directly as a
result of the production of autoreactive antibodies or T cells
against renal antigens or indirectly as a result of the deposition
of antibodies and/or immune complexes in the kidney that are
reactive against other, non-renal antigens. Thus other
immune-mediated diseases that result in the formation of
immune-complexes can also induce immune mediated renal disease as
an indirect sequelae. Both direct and indirect immune mechanisms
result in inflammatory response that produces/induces lesion
development in renal tissues with resultant organ function
impairment and in some cases progression to renal failure. Both
humoral and cellular immune mechanisms can be involved in the
pathogenesis of lesions.
[0368] Demyelinating diseases of the central and peripheral nervous
systems, including multiple sclerosis; idiopathic demyelinating
polyneuropathy or Guillain-Barre syndrome; and chronic inflammatory
demyelinating polyneuropathy, are believed to have an autoimmune
basis and result in nerve demyelination as a result of damage
caused to oligodendrocytes or to myelin directly. In MS there is
evidence to suggest that disease induction and progression is
dependent on T lymphocytes. Multiple sclerosis is a demyelinating
disease that is T lymphocyte-dependent and has either a
relapsing-remitting course or a chronic progressive course. The
etiology is unknown; however, viral infections, genetic
predisposition, environment, and autoimmunity all contribute.
Lesions contain infiltrates of predominantly T lymphocyte mediated,
microglial cells and infiltrating macrophages; CD4.sup.+ T
lymphocytes are the predominant cell type at lesions. The mechanism
of oligodendrocyte cell death and subsequent demyelination is not
known but is likely T lymphocyte driven.
[0369] Inflammatory and fibrotic lung disease, including
eosinophilic pneumonia; idiopathic pulmonary fibrosis, and
hypersensitivity pneumonitis may involve a disregulated
immune-inflammatory response. Inhibition of that response would be
of therapeutic benefit.
[0370] Autoimmune or immune-mediated skin disease including bullous
skin diseases, erythema multiforme, and contact dermatitis are
mediated by auto-antibodies, the genesis of which is T
lymphocyte-dependent.
[0371] Psoriasis is a T lymphocyte-mediated inflammatory disease.
Lesions contain infiltrates of T lymphocytes, macrophages and
antigen processing cells, and some neutrophils.
[0372] Allergic diseases, including asthma; allergic rhinitis;
atopic dermatitis; food hypersensitivity; and urticaria are T
lymphocyte dependent. These diseases are predominantly mediated by
T lymphocyte induced inflammation, IgE mediated-inflamrdation or a
combination of both.
[0373] Transplantation associated diseases, including graft
rejection and graft-versus-host-disease (GVHD) are T
lymphocyte-dependent; inhibition of T lymphocyte function is
ameliorative.
[0374] Other diseases in which intervention of the immune and/or
inflammatory response have benefit are infectious disease including
but not limited to viral infection (including but not limited to
AIDS, hepatitis A, B, C, D, E and herpes) bacterial infection,
fungal infections, and protozoal and parasitic infections
(molecules (or derivatives/agonists) which stimulate the MLR can be
utilized therapeutically to enhance the immune response to
infectious agents), diseases of immunodeficiency
(molecules/derivatives/agonists) which stimulate the MLR can be
utilized therapeutically to enhance the immune response for
conditions of inherited, acquired, infectious induced (as in HIV
infection), or iatrogenic (i.e., as from chemotherapy)
immunodeficiency, and neoplasia.
[0375] It has been demonstrated that some human cancer patients
develop an antibody and/or T lymphocyte response to antigens on
neoplastic cells. It has also been shown in animal models of
neoplasia that enhancement of the immune response can result in
rejection or regression of that particular neoplasm. Molecules that
enhance the T lymphocyte response in the MLR have utility in vivo
in enhancing the immune response against neoplasia. Molecules which
enhance the T lymphocyte proliferative response in the MLR (or
small molecule agonists or antibodies that affected the same
receptor in an agonistic fashion) can be used therapeutically to
treat cancer. Molecules that inhibii the lymphocyte response in the
MLR also function in vivo during neoplasia to suppress the immune
response to a neoplasm; such molecules can either be expressed by
the neoplastic cells themselves or their expression can be induced
by the neoplasm in other cells. Antagonism of such inhibitory
molecules (either with antibody, small molecule antagonists or
other means) enhances immune-mediated tumor rejection.
[0376] Additionally, inhibition of molecules with proinflammatory
properties may have therapeutic benefit in reperfusion injury;
stroke; myocardial infarction; atherosclerosis; acute lung injury;
hemorrhagic shock; burn; sepsis/septic shock; acute tubular
necrosis; endometriosis; degenerative joint disease and
pancreatitis. The compounds of the present invention, e.g.,
polypeptides or antibodies, are administered to a mammal,
preferably a human, in accord with known methods, such as
intravenous administration as a bolus or by continuous infusion
over a period of time, by intramuscular, intraperitoneal,
intracerebral spinal, subcutaneous, intra-articular, intra
synovial, intrathecal, oral, topical, or inhalation (intranasal,
intrapulmonary) routes. Intravenous or inhaled administration of
polypeptides and antibodies is preferred.
[0377] In immunoadjuvant therapy, other therapeutic regimens, such
administration of an anti-cancer agent, may be combined with the
administration of the proteins, antibodies or compounds of the
instant invention. For example, the patient to be treated with a
the immunoadjuvant of the invention may also receive an anti-cancer
agent (chemotherapeutic agent) or radiation therapy. Preparation
and dosing schedules for such chemotherapeutic agents may be used
according to manufacturers' instructions or as determined
empirically by the skilled practitioner. Preparation and dosing
schedules for such chemotherapy are also described in Chemotherapy
Service. Ed., M. C. Perry, Williams & Wilkins, Baltimore, Md.
(1992). The chemotherapeutic agent may precede, or follow
administration of the immunoadjuvant or may be given simultaneously
therewith. Additionally, an anti-oestrogen compound such as
tamoxifen or an anti-progesterone such as onapristone (see, EP
616812) may be given in dosages known for such molecules.
[0378] It may be desirable to also administer antibodies against
other immune disease associated or tumor associated antigens, such
as antibodies which bind to CD20, CD11a, CD 18, ErbB2, EGFR, ErbB3,
ErbB4, or vascular endothelial factor (VEGF). Alternatively, or in
addition, two or more antibodies binding the same or two or more
different antigens disclosed herein may be coadministered to the
patient. Sometimes, it may be beneficial to also administer one or
more cytokines to the patient. In one embodiment, the PRO842
polypeptides are coadministered with a growth inhibitory agent. For
example, the growth inhibitory agent may be administered first,
followed by a PRO842 polypeptide. However, simultaneous
administration or administration first is also contemplated.
Suitable dosages for the growth inhibitory agent are those
presently used and may be lowered due to the combined action
(synergy) of the growth inhibitory agent and the PRO842
polypeptide. For the treatment or reduction in the severity of
immune related disease, the appropriate dosage of an a compound of
the invention will depend on the type of disease to be treated, as
defined above, the severity and course of the disease, whether the
agent is administered for preventive or therapeutic purposes,
previous therapy, the patient's clinical history and response to
the compound, and the discretion of the attending physician. The
compound is suitably administered to the patient at one time or
over a series of treatments.
[0379] For example, depending on the type and severity of the
disease, about 1 mg/kg to 15 mg/kg (e.g., 0.1-20 mg/kg) of
polypeptide or antibody is an initial candidate dosage for
administration to the patient, whether, for example, byone or more
separate administrations, or by continuous infusion. A typical
daily dosage might range from about 1 mg/kg to 100 mg/kg or more,
depending on the factors mentioned above. For repeated
administrations over several days or longer, depending on the
condition, the treatment is sustained until a desired suppression
of disease symptoms occurs. However, other dosage regimens may be
useful. The progress of this therapy is easily monitored by
conventional techniques and assays.
[0380] P. Articles of Manufacture
[0381] In another embodiment of the invention, an article of
manufacture containing materials (e.g., comprising a PRO842
molecule) useful for the diagnosis or treatment of the disorders
described above is provided. The article of manufacture comprises a
container and an instruction. Suitable containers include, for
example, bottles, vials, syringes, and test tubes. The containers
may be formed from a variety of materials such as glass or plastic.
The container holds a composition which is effective for diagnosing
or treating the condition and may have a sterile access port (for
example the container may be an intravenous solution bag or a vial
having a stopper pierceable by a hypodermic injection needle). The
active agent in the composition is usually a polypeptide or an
antibody of the invention. An instruction or label on, or
associated with, the container indicates that the composition is
used for diagnosing or treating the condition of choice. The
article of manufacture may further comprise a second container
comprising a pharmaceutically-acceptable buffer, such as
phosphate-buffered saline, Ringer's solution and dextrose solution.
It may further include other materials desirable from a commercial
and user standpoint, including other buffers, diluents, filters,
needles, syringes, and package inserts with instructions for
use.
[0382] Q. Diagnosis and Prognosis of Immune Related Disease
[0383] Cell surface proteins, such as proteins which are
overexpressed in certain immune related diseases, are excellent
targets for drug candidates or disease treatment. The same proteins
along with secreted proteins encoded by the genes amplified in
immune related disease states find additional use in the diagnosis
and prognosis of these diseases. For example, antibodies directed
against the protein products of genes amplified in multiple
sclerosis, rheumatoid arthritis, inflammatory bowel disorder, or
another immune related disease, can be used as diagnostics or
prognostics.
[0384] For example, antibodies, including antibody fragments, can
be used to qualitatively or quantitatively detect the expression of
proteins encoded by amplified or overexpressed genes ("marker gene
products"). The antibody preferably is equipped with a detectable,
e.g., fluorescent label, and binding can be monitored by light
microscopy, flow cytometry, fluorimetry, or other techniques known
in the art. These techniques are particularly suitable, if the
overexpressed gene encodes a cell surface protein Such binding
assays are performed essentially as described above.
[0385] In situ detection of antibody binding to the marker gene
products can be performed, for example, by immunofluorescence or
immunoelectron microscopy. For this purpose, a histological
specimen is removed from the patient, and a labeled antibody is
applied to it, preferably by overlaying the antibody on a
biological sample. This procedure also allows for determining the
distribution of the marker gene product in the tissue examined. It
will be apparent for those skilled in the art that a wide variety
of histological methods are readily available for in situ
detection.
[0386] The following examples are offered for illustrative purposes
only, and are not intended to limit the scope of the present
invention in any way.
[0387] All patent and literature references cited in the present
specification are hereby incorporated by reference in their
entirety.
EXAMPLES
[0388] Commercially available reagents referred to in the examples
were used according to manufacturer's instructions unless otherwise
indicated. The source of those cells identified in the following
examples, and throughout the specification, by ATCC accession
numbers is the American Type Culture Collection, Manassas, Va.
Example 1
Isolation of cDNA Clones Encoding Human PRO842
[0389] PRO842 polypeptide-encoding nucleic acid sequences were
identified by applying a proprietary signal sequence finding
algorithm developed by Genentech, Inc. (South San Francisco,
Calif.) upon ESTs as well as clustered and assembled EST fragments
from public (e.g., GenBank) and/or private (LIFESEQ.RTM., Incyte
Pharmaceuticals, Inc., Palo Alto, Calif.) databases. The signal
sequence algorithm computes a secretion signal score based on the
character of the DNA nucleotides surrounding the first and
optionally the second methionine codon(s) (ATG) at the 5'-end of
the sequence or sequence fragment under consideration. The
nucleotides following the first ATG must code for at least 35
unambiguous amino acids without any stop codons. If the first ATG
has the required amino acids, the second is not examined. If
neither meets the requirement, the candidate sequence is not
scored. In order to determine whether the EST sequence contains an
authentic signal sequence, the DNA and corresponding amino acid
sequences surrounding the ATG codon are scored using a set of seven
sensors (evaluation parameters) known to be associated with
secretion signals. Use of this algorithm resulted in identification
of a single Incyte EST cluster sequence designated herein as Incyte
EST cluster sequence no. 69572. This EST cluster sequence was then
compared to a variety of expressed sequence tag (EST) databases
which included public EST databases (e.g., GenBank) and a
proprietary EST DNA database (LIFESEQ.RTM., Incyte Pharmaceuticals,
Palo Alto, Calif.) to identify existing homologies. The homology
search was performed using the computer program BLAST or BLAST2
(Altshul et al., Methods in Enzymology 266:460-480 (1996)). Those
comparisons resulting in a BLAST score of 70 (or in some cases 90)
or greater that did not encode known proteins were clustered and
assembled into a consensus DNA sequence with the program "phrap"
(Phil Green, University of Washington, Seattle, Wash.). The
consensus sequence obtained therefrom is herein designated
DNA54230.
[0390] In light of an observed sequence homology between the
consensus sequence and an EST sequence encompassed within the Merck
EST clone no. AA477092, the Merck EST clone AA477092 was purchased
and the cDNA insert was obtained and sequenced. It was found that
this insert encoded a full-length protein. The sequence of this
cDNA insert is shown in FIG. 98 and is herein designated as
DNA56855-1447.
[0391] The full length clone shown in FIG. 98 contained a single
open reading frame with an apparent translational initiation site
at nucleotide positions 153-155 and ending at the stop codon found
at nucleotide positions 510-512 (FIG. 98; SEQ ID NO:164). The
predicted polypeptide precursor (FIG. 99, SEQ ID NO:165) is 119
amino acids long. PRO842 has a calculated molecular weight of
approximately 13,819 Daltons and an estimated p1 of approximately
11.16. Other features of PRO842 include a signal peptide at about
amino acids 1-22, a potential protein kinase C phosphorylation site
at about amino acids 39-41 and two potential N-myristoylation sites
at about amino acids 27-32 and about amino acids 46-51.
[0392] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using a WU-BLAST-2 sequence alignment analysis of the
full-length sequence shown in FIG. 98 (SEQ ID NO:164), evidenced
some homology between the PRO842 amino acid sequence and the
following Dayhoff sequences: CEZK131.sub.--11, P_R80843,
RAT5HT2X.sub.--1, S81882.sub.--1, A60912, MCU60315.sub.--137MC137L,
U93422.sub.--1, p_P91996, U93462.sub.--1, and ZN18_HUMAN.
Example 2
Expression of PRO842 in E. coli
[0393] This example illustrates preparation of an un glycosylated
form of PRO842 polypeptides by recombinant expression in E.
coli.
[0394] The DNA sequence encoding a PRO842 polypeptide is initially
amplified using selected PCR primers. The primers should contain
restriction enzyme sites which correspond to the restriction enzyme
sites on the selected expression vector. A variety of expression
vectors may be employed. An example of a suitable vector is pBR322
(derived from E. coli; see Bolivar et al., Gene, 2:95 (1977)) which
contains genes for ampicillin and tetracycline resistance. The
vector is digested with restriction enzyme and dephosphorylated.
The PCR amplified sequences are then ligated into the vector. The
vector will preferably include sequences which encode for an
antibiotic resistance gene, a trp promoter, a polyHis leader
(including the first six STII codons, polyHis sequence, and
enterokinase cleavage site), the PRO842 polypeptide coding region,
lambda transcriptional terminator, and an argu gene.
[0395] The ligation mixture is then used to transform a selected E.
coli strain using the methods described in Sambrook et al., supra.
Transformants are identified by their ability to grow on LB plates
and antibiotic resistant colonies are then selected. Plasmid DNA
can be isolated and confirmed by restriction analysis and DNA
sequencing.
[0396] Selected clones can be grown overnight in liquid culture
medium such as LB broth supplemented with antibiotics. The
overnight culture may subsequently be used to inoculate a larger
scale culture. The cells are then grown to a desired optical
density, during which the expression promoter is turned on.
[0397] After culturing the cells for several more hours, the cells
can be harvested by centrifugation. The cell pellet obtained by the
centrifugation can be solubilized using various agents known in the
art, and the solubilized PRO842 protein can then be purified using
a metal chelating column under conditions that allow tight binding
of the protein.
[0398] PRO842 polypeptides may be expressed in E. coli in a
poly-His tagged form, using the following procedure. The DNA
encoding a PRO842 polypeptide is initially amplified using selected
PCR primers. The primers will contain restriction enzyme sites
which correspond to the restriction enzyme sites on the selected
expression vector, and other useful sequences providing for
efficient and reliable translation initiation, rapid purification
on a metal chelation column, and proteolytic removal with
enterokinase. The PCR-amplified, poly-His tagged sequences are then
ligated into an expression vector, which is used to transform an E.
coli host based on strain 52 (W3110 fuhA(tonA) Ion galE
rpoHts(htpRts) clpP(lacIq). Transformants are first grown in LB
containing 50 mg/ml carbenicillin at 30.degree. C. with shaking
until an O.D.600 of 3-5 is reached. Cultures are then diluted
50-100 fold into CRAP media (prepared by mixing 3.57 g
(NH.sub.4).sub.2SO.sub.4, 0.71 g sodium citrate.2H2O, 1.07 g KCl,
5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL
water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM
MgSO.sub.4) and grown for approximately 20-30 hours at 30.degree.
C. with shaking. Samples are removed to verify expression by
SDS-PAGE analysis, and the bulk culture is centrifuged to pellet
the cells. Cell pellets are frozen until purification and
refolding.
[0399] E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets)
is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH
8 buffer. Solid sodium sulfite and sodium tetrathionate is added to
make final concentrations of 0.1M and 0.02 M, respectively, and the
solution is stirred overnight at 4.degree. C. This step results in
a denatured protein with all cysteine residues blocked by
sulfitolization. The solution is centrifuged at 40,000 rpm in a
Beckman Ultracentrifuge for 30 min. The supernatant is diluted with
3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM
Tris, pH 7.4) and filtered through 0.22 micron filters to clarify.
The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal
chelate column equilibrated in the metal chelate column buffer. The
column is washed with additional buffer containing 50 mM imidazole
(Calbiochem, Utrol grade), pH 7.4. The protein is eluted with
buffer containing 250 mM imidazole. Fractions containing the
desired protein are pooled and stored at 4.degree. C. Protein
concentration is estimated by its absorbance at 280 nm using the
calculated extinction coefficient based on its amino acid
sequence.
[0400] The proteins are refolded by diluting the sample slowly into
freshly prepared refolding buffer consisting of: 20 mM Tris, pH
8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM
EDTA. Refolding volumes are chosen so that the final protein
concentration is between 50 to 100 micrograms/ml. The refolding
solution is stirred gently at 4.degree. C. for 12-36 hours. The
refolding reaction is quenched by the addition of TFA to a final
concentration of 0.4% (pH of approximately 3). Before further
purification of the protein, the solution is filtered through a
0.22 micron filter and acetonitrile is added to 2-10% final
concentration. The refolded protein is chromatographed on a Poros
R1/H reversed phase column using a mobile buffer of 0.1% TFA with
elution with a gradient of acetonitrile from 10 to 80%. Aliquots of
fractions with A280 absorbance are analyzed on SDS polyacrylamide
gels and fractions containing homogeneous refolded protein are
pooled. Generally, the properly refolded species of most proteins
are eluted at the lowest concentrations of acetonitrile since those
species are the most compact with their hydrophobic interiors
shielded from interaction with the reversed phase resin. Aggregated
species are usually eluted at higher acetonitrile concentrations.
In addition to resolving misfolded forms of proteins from the
desired form, the reversed phase step also removes endotoxin from
the samples.
[0401] Fractions containing the desired folded PRO842 polypeptide
are pooled and the acetonitrile removed using a gentle stream of
nitrogen directed at the solution. Proteins are formulated into 20
mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by
dialysis or by gel filtration using G25 Superfine (Pharmacia)
resins equilibrated in the formulation buffer and sterile
filtered.
[0402] PRO842 polypeptides were successfully expressed as described
above.
Example 3
Expression of PRO842 in Mammalian Cells
[0403] This example illustrates preparation of a potentially
glycosylated form of PRO842 polypeptides by recombinant expression
in mammalian cells.
[0404] The vector, pRK5 (see EP 307,247, published Mar. 15, 1989),
is employed as the expression vector. Optionally, the PRO842 DNA is
ligated into pRK5 with selected restriction enzymes to allow
insertion of the PRO842 DNA using ligation methods such as
described in Sambrook et al., supra. The resulting vector is called
pRK5-PRO842.
[0405] In one embodiment, the selected host cells may be 293 cells.
Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue
culture plates in medium such as DMEM supplemented with fetal calf
serum and optionally, nutrient components and/or antibiotics. About
10 .mu.g pRK5-PRO842 DNA is mixed with about 1 .mu.g DNA encoding
the VA RNA gene [Thimmappaya et al., Cell, 31:543 (1982)] and
dissolved in 500 .mu.l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M
CaCl.sub.2. To this mixture is added, dropwise, 500/1 of 50 mM
HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO.sub.4, and a precipitate
is allowed to form for 10 minutes at 25.degree. C. The precipitate
is suspended and added to the 293 cells and allowed to settle for
about four hours at 37.degree. C. The culture medium is aspirated
off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The
293 cells are then washed with serum free medium, fresh medium is
added and the cells are incubated for about 5 days.
[0406] Approximately 24 hours after the transfections, the culture
medium is removed and replaced with culture medium (alone) or
culture medium containing 200 .mu.Ci/ml .sup.35S-cysteine and 200
.mu.Ci/ml .sup.35S-methionine. After a 12 hour incubation, the
conditioned medium is collected, concentrated on a spin filter, and
loaded onto a 15% SDS gel. The processed gel may be dried and
exposed to film for a selected period of time to reveal the
presence of the PRO842 polypeptide. The cultures containing
transfected cells may undergo further incubation (in serum free
medium) and the medium is tested in selected bioassays.
[0407] In an alternative technique, PRO842 may be introduced into
293 cells transiently using the dextran sulfate method described by
Somparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (1981). 293
cells are grown to maximal density in a spinner flask and 700 .mu.g
pRK5-PRO842 DNA is added. The cells are first concentrated from the
spinner flask by centrifugation and washed with PBS. The
DNA-dextran precipitate is incubated on the cell pellet for four
hours. The cells are treated with 20% glycerol for 90 seconds,
washed with tissue culture medium, and re-introduced into the
spinner flask containing tissue culture medium, 5 .mu.g/ml bovine
insulin and 0.1 .mu.g/ml bovine transferrin. After about four days,
the conditioned media is centrifuged and filtered to remove cells
and debris. The sample containing the expressed PRO842 polypeptide
can then be concentrated and purified by any selected method, such
as dialysis and/or column chromatography.
[0408] In another embodiment, PRO842 polypeptides can be expressed
in CHO cells. The pRK5-PRO842 can be transfected into CHO cells
using known reagents such as CaPO, or DEAE-dextran. As described
above, the cell cultures can be incubated, and the medium replaced
with culture medium (alone) or medium containing a radiolabel such
as .sup.35S-methionine. After determining the presence of the
PRO842 polypeptide, the culture medium may be replaced with serum
free medium. Preferably, the cultures are incubated for about 6
days, and then the conditioned medium is harvested. The medium
containing the expressed PRO842 polypeptide can then be
concentrated and purified by any selected method.
[0409] Epitope-tagged PRO842 may also be expressed in host CHO
cells. The PRO842 may be subcloned out of the pRK5 vector. The
subclone insert can undergo PCR to fuse in frame with a selected
epitope tag such as a poly-His tag into a Baculovirus expression
vector. The poly-His tagged PRO842 insert can then be subcloned
into a SV40 driven vector containing a selection marker such as
DHFR for selection of stable clones. Finally, the CHO cells can be
transfected (as described above) with the SV40 driven vector.
Labeling may be performed, as described above, to verify
expression. The culture medium containing the expressed poly-His
tagged PRO842 can then be concentrated and purified by any selected
method, such as by Ni.sup.2+-chelate affinity chromatography.
[0410] PRO842 polypeptides may also be expressed in CHO and/or COS
cells by a transient expression procedure or in CHO cells by
another stable expression procedure.
[0411] Stable expression in CHO cells is performed using the
following procedure. The proteins are expressed as an IgG construct
(immunoadhesin), in which the coding sequences for the soluble
forms (e.g., extracellular domains) of the respective proteins are
fused to an IgG1 constant region sequence containing the hinge, CH2
and CH2 domains, and/or as a poly-His tagged form.
[0412] Following PCR amplification, the respective DNAs are
subcloned in a CHO expression vector using standard techniques as
described in Ausubel et al., Current Protocols of Molecular
Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression
vectors are constructed to have compatible restriction sites 5' and
3' of the DNA of interest to allow the convenient shuttling of
cDNA's. The vector used in expression in CHO cells is as described
in Lucas et al., Nucl. Acids Res., 24:9 (1774-1779 (1996), and uses
the SV40 early promoter/enhancer to drive expression of the cDNA of
interest and dihydrofolate reductase (DHFR). DHFR expression
permits selection for stable maintenance of the plasmid following
transfection.
[0413] Twelve micrograms of the desired plasmid DNA is introduced
into approximately 10 million CHO cells using commercially
available transfection reagents Superfect.RTM. (Qiagen),
Dosper.RTM. or Fugene.RTM. (Boehringer Mannheim). The cells are
grown as described in Lucas et al., supra. Approximately
3.times.10.sup.7 cells are frozen in an ampule for further growth
and production as described below.
[0414] The ampules containing the plasmid DNA are thawed by
placement into water bath and mixed by vortexing. The contents are
pipetted into a centrifuge tube containing 10 mLs of media and
centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated
and the cells are resuspended in 10 mL of selective media (0.2
.mu.m filtered PS20 with 5% 0.2 .mu.m diafiltered fetal bovine
serum). The cells are then aliquoted into a 100 mL spinner
containing 90 mL of selective media. After 1-2 days, the cells are
transferred into a 250 mL spinner filled with 150 mL selective
growth medium and incubated at 37.degree. C. After another 2-3
days, 250 mL, 500 mL and 2000 mL spinners are seeded with
3.times.10.sup.5 cells/mL. The cell media is exchanged with fresh
media by centrifugation and resuspension in production medium.
Although any suitable CHO media may be employed, a production
medium described in U.S. Pat. No. 5,122,469, issued Jun. 16, 1992
may actually be used. A 3L production spinner is seeded at
1.2.times.10.sup.6 cells/mL. On day 0, the cell number pH ie
determined. On day 1, the spinner is sampled and sparging with
filtered air is commenced. On day 2, the spinner is sampled, the
temperature shifted to 33.degree. C., and 30 mL of 500 g/L glucose
and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane
emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout
the production, the pH is adjusted as necessary to keep it at
around 7.2. After 10 days, or until the viability dropped below
70%, the cell culture is harvested by centrifugation and filtering
through a 0.22 .mu.m filter. The filtrate was either stored at
4.degree. C. or immediately loaded onto columns for
purification.
[0415] For the poly-His tagged constructs, the proteins are
purified using a Ni-NTA column (Qiagen). Before purification,
imidazole is added to the conditioned media to a concentration of 5
mM. The conditioned media is pumped onto a 6 ml Ni-NTA column
equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl
and 5 mM imidazole at a flow rate of 4-5 ml/min, at 4.degree. C.
After loading, the column is washed with additional equilibration
buffer and the protein eluted with equilibration buffer containing
0.25 M imidazole. The highly purified protein is subsequently
desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl
and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia)
column and stored at -80.degree. C.
[0416] Immunoadhesin (Fc-containing) constructs are purified from
the conditioned media as follows. The conditioned medium is pumped
onto a 5 ml Protein A column (Pharmacia) which had been
equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading,
the column is washed extensively with equilibration buffer before
elution with 100 mM citric acid, pH 3.5. The eluted protein is
immediately neutralized by collecting 1 ml fractions into tubes
containing 275 .mu.L of 1 M Tris buffer, pH 9. The highly purified
protein is subsequently desalted into storage buffer as described
above for the poly-His tagged proteins. The homogeneity is assessed
by SDS polyacrylamide gels and by N-terminal amino acid sequencing
by Edman degradation.
[0417] PRO842 polypeptides were successfully expressed as described
above.
Example 4
Expression of PRO842 in Yeast
[0418] The following method describes recombinant expression of
PRO842 polypeptides in yeast.
[0419] First, yeast expression vectors are constructed for
intracellular production or secretion of PRO842 from the ADH2/GAPDH
promoter. DNA encoding the PRO842 polypeptide and the promoter is
inserted into suitable restriction enzyme sites in the selected
plasmid to direct intracellular expression of the PRO842
polypeptide. For secretion, DNA encoding PRO842 can be cloned into
the selected plasmid, together with DNA encoding the ADH2/GAPDH
promoter, a native PRO842 signal peptide or other mammalian signal
peptide, or, for example, a yeast alpha-factor or invertase
secretory signal/leader sequence, and linker sequences (if needed)
for expression of PRO842.
[0420] Yeast cells, such as yeast strain AB110, can then be
transformed with the expression plasmids described above and
cultured in selected fermentation media. The transformed yeast
supernatants can be analyzed by precipitation with 10%
trichloroacetic acid and separation by SDS-PAGE, followed by
staining of the gels with Coomassie Blue stain.
[0421] Recombinant PRO842 polypeptides can subsequently be isolated
and purified by removing the yeast cells from the fermentation
medium by centrifugation and then concentrating the medium using
selected cartridge filters. The concentrate containing the PRO842
polypeptide may further be purified using selected column
chromatography resins.
Example 5
Expression of PRO842 in Baculovirus-Infected Insect Cells
[0422] The following method describes recombinant expression of
PRO842 polypeptides in Baculovirus-infected insect cells.
[0423] The sequence coding for PRO842 is fused upstream of an
epitope tag contained within a Raculovirus expression vector. Such
epitope tags include poly-His tags and immunoglobulin tags (like Fc
regions of IgG) A variety of plasmids may be employed, including
plasmids derived from commercially available plasmids such as
pVL1393 (Novagen). Briefly, the sequence encoding PRO842 or the
desired portion of the coding sequence of PRO842 such as the
sequence encoding the extracellular domain of a transmembrane
protein or the sequence encoding the mature protein if the protein
is extracellular is amplified by PCR with primers complementary to
the 5' and 3' regions. The 5' printer may incorporate flanking
(selected) restriction enzyme sites. The product is then digested
with those selected restriction enzymes and subcloned into the
expression vector.
[0424] Recombinant baculovirus is generated by co-transfecting the
above plasmid and BaculoGoldt.TM. virus DNA (Pharmingen) into
Spodoptera frugiperda ("Sf9") cells (ATCC CRL 1711) using
lipofectin (commercially available from GIBCO-BRL). After 4-5 days
of incubation at 28.degree. C., the released viruses are harvested
and used for further amplifications. Viral infection and protein
expression are performed as described by O'Reilley et al.,
Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford
University Press (1994).
[0425] Expressed poly-His tagged PRO842 can then be purified, for
example, by Ni.sup.2+ chelate affinity chromatography as follows.
Extracts are prepared from recombinant virus-infected Sf9 cells as
described by Rupert et al., Nature, 3: 175-179 (1993). Briefly, Sf9
cells are washed, resuspended in sonication buffer (25 mL Hepes, pH
7.9; 12.5 mM MgCl.sub.2; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40: 0.4
M KCl), and sonicated twice for 20 seconds on ice. The sonicates
are cleared by centrifugation, and the supernatant is diluted
50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10%
glycerol, pH 7.8) and filtered through a 0.45 .mu.m filter. A
Ni.sup.2+-NTA agarose column (commercially available from Qiagen)
is prepared with a bed volume of 5 mL, washed with 25 mL of water
and equilibrated with 25 mL of loading buffer. The filtered cell
extract is loaded onto the column at 0.5 mL per minute. The column
is washed to baseline A.sub.280 with loading buffer, at which point
fraction collection is started. Next, the column is washed with a
secondary wash buffer (50 mM phosphate; 300 mM NaCl. 10% glycerol,
pH 6.0), which elutes nonspecifically bound protein. After reaching
A.sub.280 baseline again, the column is developed with a 0 to 500
mM Imidazole gradient in the secondary wash buffer. One mL
fractions are collected and analyzed by S DS-PAGE and silver
staining or Western blot with Ni.sup.2+-NTA-conjugated to alkaline
phosphatase (Qiagen). Fractions containing the eluted
His.sub.10-tagged PRO842 are pooled and dialyzed against loading
buffer.
[0426] Alternatively, purification of the IgG tagged (or Fc tagged)
PRO842 can be performed using known chromatography techniques,
including for instance. Protein A or Protein G column
chromatography.
[0427] PRO842 polypeptides were successfully expressed as described
above.
Example 6
Preparation of Antibodies that Bind PRO842
[0428] This example illustrates preparation of monoclonal
antibodies which can specifically bind PRO842.
[0429] Techniques for producing the monoclonal antibodies are known
in the art and are described, for instance, in Goding, supra.
Immunogens that may be employed include purified PRO842
polypeptides, fusion proteins containing PRO842 polypeptides, and
cells expressing recombinant PRO842 polypeptides on the cell
surface. Selection of the immunogen can be made by the skilled
artisan without undue experimentation.
[0430] Mice, such as BALB/c, are immunized with the PRO842
immunogen emulsified in complete Freund's adjuvant and injected
subcutaneously or intraperitoneally in an amount from 1-100
micrograms. Alternatively, the immunogen is emulsified in MPL-TDM
adjuvant (Ribi Immunochemical Research, Hamilton, Mont.) and
injected into the animal's hind foot pads. The immunized mice are
then boosted 10 to 12 days later with additional immunogen
emulsified in the selected adjuvant. Thereafter, for several weeks,
the mice may also be boosted with additional immunization
injections. Serum samples may be periodically obtained from the
mice by retro-orbital bleeding for testing in ELISA assays to
detect anti-PRO842 antibodies.
[0431] After a suitable antibody titer has been detected, the
animals "positive" for antibodies can be injected with a final
intravenous injection of PRO842. Three to four days later, the mice
are sacrificed and the spleen cells are harvested. The spleen cells
are then fused (using 35% polyethylene glycol) to a selected murine
myeloma cell line such as P3X63AgU. 1, available from ATCC, No. CRL
1597. The fusions generate hybridoma cells which can then be plated
in 96 well tissue culture plates containing HAT (hypoxanthine,
aminopterin, and thymidine) medium to inhibit proliferation of
non-fused cells, myeloma hybrids, and spleen cell hybrids.
[0432] The hybridoma cells will be screened in an ELISA for
reactivity against PRO842. Determination of "positive" hybridoma
cells secreting the desired monoclonal antibodies against PRO842 is
within the skill in the art.
[0433] The positive hybridoma cells can be injected
intraperitoneally into syngeneic BALB/c mice to produce ascites
containing the anti-PRO842 monoclonal antibodies. Alternatively,
the hybridoma cells can be grown in tissue culture flasks or roller
bottles. Purification of the monoclonal antibodies produced in the
ascites can be accomplished using ammonium sulfate precipitation,
followed by gel exclusion chromatography. Alternatively, affinity
chromatography based upon binding of antibody to Protein A or
Protein G can be employed.
Example 7
Purification of PRO842 Polypeptides Using Specific Antibodies
[0434] Native or recombinant PRO842 polypeptides may be purified by
a variety of standard techniques in the art of protein
purification. For example, pro-PRO842 polypeptide, mature PRO842
polypeptide, or pre-PRO842 polypeptide is purified by
immunoaffinity chromatography using antibodies specific for the
PRO842 polypeptide of interest. In general, an immunoaffinity
column is constructed by covalently coupling the anti-PRO842
polypeptide antibody to an activated chromatographic resin.
[0435] Polyclonal immunoglobulins are prepared from immune sera
either by precipitation with ammonium sulfate or by purification on
immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway,
N.J.). Likewise, monoclonal antibodies are prepared from mouse
ascites fluid by ammonium sulfate precipitation or chromatography
on immobilized Protein A. Partially purified immunoglobulin is
covalently attached to a chromatographic resin such as
CnBr-activated SEPHAROSE.TM. (Pharmacia LKB Biotechnology). The
antibody is coupled to the resin, the resin is blocked, and the
derivative resin is washed according to the manufacturer's
instructions.
[0436] Such an immunoaffinity column is utilized in the
purification of PRO842 polypeptide by preparing a fraction from
cells containing PRO842 polypeptide in a soluble form. This
preparation is derived by solubilization of the whole cell or of a
subcellular fraction obtained via differential centrifugation by
the addition of detergent or by other methods well known in the
art. Alternatively, soluble PRO842 polypeptide containing a signal
sequence may be secreted in useful quantity into the medium in
which the cells are grown.
[0437] A soluble PRO842 polypeptide-containing preparation is
passed over the immunoaffinity column, and the column is washed
under conditions that allow the preferential absorbance of PRO842
polypeptide (e.g., high ionic strength buffers in the presence of
detergent). Then, the column is eluted under conditions that
disrupt antibody/PRO842 polypeptide binding (e.g., a low pH buffer
such as approximately pH 2-3, or a high concentration of a
chaotrope such as urea or thiocyanate ion), and PRO842 polypeptide
is collected.
Example 8
Drug Screening
[0438] This invention is particularly useful for screening
compounds by using PRO842 polypeptides or binding fragment thereof
in any of a variety of drug screening techniques. The PRO842
polypeptide or fragment employed in such a test may either be free
in solution, affixed to a solid support, borne on a cell surface,
or located intracellularly. One method of drug screening utilizes
eukaryotic or prokaryotic host cells which are stably transformed
with recombinant nucleic acids expressing the PRO842 polypeptide or
fragment. Drugs are screened against such transformed cells in
competitive binding assays. Such cells, either in viable or fixed
form, can be used for standard binding assays. One may measure, for
example, the formation of complexes between PRO842 polypeptide or a
fragment and the agent being tested. Alternatively, one can examine
the diminution in complex formation between the PRO842 polypeptide
and its target cell or target receptors caused by the agent being
tested.
[0439] Thus, the present invention provides methods of screening
for drugs or any other agents which can affect a PRO842
polypeptide-associated disease or disorder. These methods comprise
contacting such an agent with an PRO842 polypeptide or fragment
thereof and assaying (i) for the presence of a complex between the
agent and the PRO842 polypeptide or fragment, or (ii) for the
presence of a complex between the PRO842 polypeptide or fragment
and the cell, by methods well known in the art. In such competitive
binding assays, the PRO842 polypeptide or fragment is typically
labeled. After suitable incubation, free PRO842 polypeptide or
fragment is separated from that present in bound form, and the
amount of free or uncomplexed label is a measure of the ability of
the particular agent to bind to PRO842 polypeptide or to interfere
with the PRO842 polypeptide/cell complex.
[0440] Another technique for drug screening provides high
throughput screening for compounds having suitable binding affinity
to a polypeptide and is described in detail in WO 84/03564,
published on Sep. 13, 1984. Briefly stated, large numbers of
different small peptide test compounds are synthesized on a solid
substrate, such as plastic pins or some other surface. As applied
to a PRO842 polypeptide, the peptide test compounds are reacted
with PRO842 polypeptide and washed. Bound PRO842 polypeptide is
detected by methods well known in the art. Purified PRO842
polypeptide can also be coated directly onto plates for use in the
aforementioned drug screening techniques. In addition,
non-neutralizing antibodies can be used to capture the peptide and
immobilize it on the solid support.
[0441] This invention also contemplates the use of competitive drug
screening assays in which neutralizing antibodies capable of
binding PRO842 polypeptide specifically compete with a test
compound for binding to PRO842 polypeptide or fragments thereof. In
this manner, the antibodies can be used to detect the presence of
any peptide which shares one or more antigenic determinants with
PRO842 polypeptide.
Example 9
Rational Drug Design
[0442] The goal of rational drug design is to produce structural
analogs of biologically-active polypeptide of interest (i.e., a
PRO842 polypeptide) or of small molecules with which they interact,
e.g., agonists, antagonists, or inhibitors. Any of these examples
can be used to fashion drugs which are more active or stable forms
of the PRO842 polypeptide or which enhance or interfere with the
function of the PRO842 polypeptide in vivo (c.f., Hodgson,
Bio/Technology, 2: 19-21 (1991)).
[0443] In one approach, the three-dimensional structure of the
PRO842 polypeptide, or of an PRO842 polypeptide-inhibitor complex,
is determined by x-ray crystallography, by computer modeling or,
most typically, by a combination of the two approaches. Both the
shape and charges of the PRO842 polypeptide must be ascertained to
elucidate the structure and to determine active site(s) of the
molecule. Less often, useful information regarding the structure of
the PRO842 polypeptide may be gained by modeling based on the
structure of homologous proteins. In both cases, relevant
structural information is used to design analogous PRO842
polypeptide-like molecules or to identify efficient inhibitors.
Useful examples of rational drug design may include molecules which
have improved activity or stability as shown by Braxton and Wells,
Biochemistry. 31:7796-7801 (1992) or which act as inhibitors,
agonists, or antagonists of native peptides as shown by Athauda et
al., J. Biochem., 113:742-746 (1993).
[0444] It is also possible to isolate a target-specific antibody,
selected by functional assay, as described above, and then to solve
its crystal structure. This approach, in principle, yields a
pharmacore upon which subsequent drug design can be based. It is
possible to bypass protein crystallography altogether by generating
anti-idiotypic antibodies (anti-ids) to a functional,
pharmacologically active antibody. As a mirror image of a mirror
image, the binding site of the anti-ids would be expected to be an
analog of the original receptor. The anti-id could then be used to
identify and isolate peptides from banks of chemically or
biologically produced peptides. The isolated peptides would then
act as the pharmacore.
[0445] By virtue of the present invention, sufficient amounts of
the PRO842 polypeptide may be made available to perform such
analytical studies as X-ray crystallography. In addition, knowledge
of the PRO842 polypeptide amino acid sequence provided herein will
provide guidance to those employing computer modeling techniques in
place of or in addition to x-ray crystallography.
Example 10
Microarray Analysis to Detect Overexpression of PRO842 Polypeptides
in Cancerous Tumors
[0446] Nucleic acid microarrays, often containing thousands of gene
sequences, are useful for identifying differentially expressed
genes in diseased tissues as compared to their normal counterparts.
Using nucleic acid microarrays, test and control mRNA samples from
test and control tissue samples are reverse transcribed and labeled
to generate cDNA probes. The cDNA probes are then hybridized to an
array of nucleic acids immobilized on a solid support. The array is
configured such that the sequence and position of each member of
the array is known. For example, a selection of genes known to be
expressed in certain disease states may be arrayed on a solid
support. Hybridization of a labeled probe with a particular array
member indicates that the sample from which the probe was derived
expresses that gene. If the hybridization signal of a probe from a
test (disease tissue) sample is greater than hybridization signal
of a probe from a control (normal tissue) sample, the gene or genes
overexpressed in the disease tissue are identified. The implication
of this result is that an overexpressed protein in a diseased
tissue is useful not only as a diagnostic marker for the presence
of the disease condition, but also as a therapeutic target for
treatment of the disease condition.
[0447] The methodology of hybridization of nucleic acids and
microarray technology is well known in the art. In the present
example, the specific preparation of nucleic acids for
hybridization and probes, slides, and hybridization conditions are
all detailed in U.S. Provisional Patent Application Ser. No.
60/193,767, filed on Mar. 31, 2000 and which is herein incorporated
by reference.
[0448] In the present example, cancerous tumors derived from
various human tissues were studied for PRO842 polypeptide-encoding
gene expression relative to non-cancerous human tissue in an
attempt to identify those PRO842 polypeptides which are
overexpressed in cancerous tumors. Two sets of experimental data
were generated. In one set, cancerous human colon tumor tissue and
matched non-cancerous human colon tumor tissue from the same
patient ("matched colon control") were obtained and analyzed for
PRO842 polypeptide expression using the above described microarray
technology. In the second set of data, cancerous human tumor tissue
from any of a variety of different human tumors was obtained and
compared to a "universal" epithelial control sample which was
prepared by pooling non-cancerous human tissues of epithelial
origin, including liver, kidney, and lung, mRNA isolated from the
pooled tissues represents a mixture of expressed gene products from
these different tissues. Microarray hybridization experiments using
the pooled control samples generated a linear plot in a 2-color
analysis. The slope of the line generated in a 2-color analysis was
then used to normalize the ratios of (test:control detection)
within each experiment. The normalized ratios from various
experiments were then compared and used to identify clustering of
gene expression. Thus, the pooled "universal control" sample not
only allowed effective relative gene expression determinations in a
simple 2-sample comparison, it also allowed multi-sample
comparisons across several experiments.
[0449] In the present experiments, nucleic acid probes derived from
the herein described PRO842 polypeptide-encoding nucleic acid
sequences were used in the creation of the microarray and RNA from
the tumor tissues listed above were used for the hybridization
thereto. A value based upon the normalized ratio:experimental ratio
was designated as a "cutoff ratio". Only values that were above
this cutoff ratio were determined to be significant. Table 7 below
shows the results of these experiments, demonstrating that various
PRO842 polypeptides of the present invention are significantly
overexpressed in various human tumor tissues as compared to a
non-cancerous human tissue control. As described above, these data
demonstrate that the PRO842 polypeptides of the present invention
are useful not only as diagnostic markers for the presence of one
or more cancerous tumors, but also serve as therapeutic targets for
the treatment of those tumors. TABLE-US-00006 TABLE 7 Molecule is
overexpressed in: as compared to: PRO842 colon tumor universal
normal control PRO842 lung tumor universal normal control PRO842
breast tumor universal normal control
Example 11
In Situ Hybridization
[0450] In situ hybridization is a powerful and versatile technique
for the detection and localization of nucleic acid sequences within
cell or tissue preparations. It may be useful, for example, to
identify sites of gene expression, analyze the tissue distribution
of transcription, identify and localize viral infection, follow
changes in specific mRNA synthesis and aid in chromosome
mapping.
[0451] In situ hybridization was performed following an optimized
version of the protocol by Lu and Gillett, Cell Vision, 1:169-176
(1994), using PCR-generated .sup.33P-labeled riboprobes. Briefly,
formalin-fixed, paraffin-embedded human tissues were sectioned,
deparaffinized, deproteinated in proteinase K (20 .mu.g/ml) for 15
minutes at 37.degree. C., and further processed for in situ
hybridization as described by Lu and Gillett, supra. A [.sup.33-P]
UTP-labeled antisense riboprobe was generated from a PCR product
and hybridized at 55.degree. C. overnight. The slides were dipped
in Kodak NTB2 nuclear track emulsion and exposed for 4 weeks.
.sup.33P-Riboprobe Synthesis
[0452] 6.0 .mu.l (125 mCi) of .sup.33P-UTP (Amersham BF 1002,
SA<2000 Ci/mmol) were speed vac dried. To each tube containing
dried .sup.33P-UTP, the following ingredients were added: [0453]
2.0 .mu.l 5.times. transcription buffer [0454] 1.0 .mu.l DTT (100
mM) [0455] 2.0 .mu.l NTP mix (2.5 mM 10 .mu.l: each of 10 mM GTP,
CTP & ATP+10 .mu.l H.sub.2O) [0456] 1.0 .mu.l UTP (50 .mu.M)
[0457] 1.0 .mu.l Rnasin [0458] 1.0 .mu.l DNA template (1 .mu.g)
[0459] 1.0 .mu.l H.sub.2O [0460] 1.0 .mu.l RNA polymerase (for PCR
products T3=AS, T7=S, usually)
[0461] The tubes were incubated at 37.degree. C. for one hour. 10.0
.mu.l RQ1 DNase were added, followed by incubation at 37.degree. C.
for 15 minutes. 90 .mu.l TE (10 mM Tris pH 7.6/1 mM EDTA pH 8.0)
were added, and the mixture was pipetted onto DE81 paper. The
remaining solution was loaded in a Microcon-50 ultrafiltration
unit, and spun using program 10 (6 minutes). The filtration unit
was inverted over a second tube and spun using program 2 (3
minutes). After the final recovery spin, 100 .mu.l TE were added. 1
.mu.L of the final product was pipetted on DE81 paper and counted
in 6 ml of Biofluor 11.
[0462] The probe was run on a TBE/urea gel. 1-3 .mu.l of the probe
or 5 .mu.l of RNA Mrk III were added to 3 .mu.l of loading buffer.
After heating on a 95.degree. C. heat block for three minutes, the
gel was immediately placed on ice. The wells of gel were flushed,
the sample loaded, and run at 180-250 volts for 45 minutes. The gel
was wrapped in saran wrap and exposed to XAR film with an
intensifying screen in -70.degree. C. freezer one hour to
overnight. .sup.33P-Hybridization
[0463] A. Pretreatment of Frozen Sections
[0464] The slides were removed from the freezer, placed on
aluminium trays and thawed at room temperature for 5 minutes. The
trays were placed in 55.degree. C. incubator for five minutes to
reduce condensation. The slides were fixed for 10 minutes in 4%
paraformaldehyde on ice in the fume hood, and washed in
0.5.times.SSC for 5 minutes, at room temperature (25 ml
20.times.SSC+975 ml SQ H.sub.2O). After deproteination in 0.5
.mu.g/nd proteinase K for 10 minutes at 37.degree. C. (12.5 .mu.l
of 10 mg/ml stock in 250 ml prewarmed RNase-free RNAse buffer), the
sections were washed in 0.5.times.SSC for 10 minutes at room
temperature. The sections were dehydrated in 70%, 95%, 100%
ethanol, 2 minutes each.
[0465] B. Pretreatment of Paraffin-Embedded Sections
[0466] The slides were deparaffinized, placed in SQ H.sub.2O, and
rinsed twice in 2.times.SSC at room temperature, for 5 minutes each
time. The sections were deproteinated in 20 .mu.g/ml proteinase K
(500 .mu.l of 10 mg/ml in 250 ml RNase-free RNase buffer;
37.degree. C., 15 minutes)--human embryo, or 8.times. proteinase K
(100 .mu.l in 250 ml Rnase buffer, 37.degree. C., 30
minutes)--formalin tissues. Subsequent rinsing in 0.5.times.SSC and
dehydration were performed as described above.
[0467] C. Prehybridization
[0468] The slides were laid out in a plastic box lined with Box
buffer (4.times.SSC, 50% formamide)--saturated filter paper. The
tissue was covered with 50 .mu.l of hybridization buffer (3.75 g
Dextran Sulfate+6 ml SQ H.sub.2O), vortexed and heated in the
microwave for 2 minutes with the cap loosened. After cooling on
ice, 18.75 ml formamide, 3.75 ml 20.times.SSC and 9 ml SQ H2O were
added, the tissue was vortexed well, and incubated at 42.degree. C.
for 1-4 hours.
[0469] D. Hybridization
[0470] 1.0.times.10.sup.6 cpm probe and 1.0 .mu.l tRNA (50 mg/ml
stock) per slide were heated at 95.degree. C. for 3 minutes. The
slides were cooled on ice, and 48 .mu.l hybridization buffer were
added per slide. After vortexing. 50 .mu.l .sup.33P mix were added
to 50 .mu.l prehybridization on slide. The slides were incubated
overnight at 55.degree. C.
[0471] E. Washes
[0472] Washing was done 2.times.10 minutes with 2.times.SSC, EDTA
at room temperature (400 ml 20.times.SSC+16 ml 0.25M EDTA,
V.sub.f=4L), followed by RNaseA treatment at 37.degree. C. for 30
minutes (500 .mu.l of 10 mg/ml in 250 ml Rnase buffer=20 .mu.g/ml),
The slides were washed 2.times.10 minutes with 2.times.SSC, EDTA at
room temperature. The stringency wash conditions were as follows: 2
hours at 55.degree. C., 0.1.times.SSC, EDTA (20 ml 20.times.SSC+16
ml EDTA, V.sub.f=4L).
[0473] F. Oligonucleotides
[0474] In situ analysis was performed on DNA59294-1381 disclosed
herein. The oligonucleotides employed for this analysis were
derived from the nucleotide sequences disclosed herein and
generally range from about 40 to 55 nucleotides in length.
[0475] G. Results
[0476] In situ analysis was performed on DNA59294-1381 as disclosed
herein. The results from this analysis is as follows.
[0477] Expression of DNA56855 in Tissue Screen: Adult Inflamed Lung
and Ovary
[0478] Sections show an intense signal associated with bronchial
epithelium in normal and inflamed adult lungs, including asthma and
interstitial pneumonitis blocks. The lung tumor multiblock has
intense signal over epithelial cells lining glandular structures
that comprise the neoplasm. The fetal lung showed negative results.
In a section of ovary, tubal epithelium adjacent to the ovarian
stroma is positive.
Example 12
Threading Analysis of PRO842 (CK27) Suggests Structural Homology to
Interleukin-8
[0479] Threading methods have demonstrated high sensitivity on
prediction of structure for novel sequences. These techniques are
able to detect if a protein sequence resembles known structures
without relying on sequence comparison, thus being able to identify
relationships amoung proteins even if the sequence similarity
between them is low. The present study demonstrated that threading
techniques can detect lower sequence similarity than standard
sequence similarity methods in particular for a novel chemokine
PRO842 (designated CK27) encoded by DNA56855-1447.
[0480] The fold recognition program ProCeryon was used for this
analysis (ProCeryon Biosciences, Inc.). The fold library used
consisted of 4,749 known 3D structures filtered at 95% sequence
identity from the Protein Data Bank. Two mean force potentials
describing the energetic forces between the residues of a fold and
the energetic forces between the residues of the fold and the
surrounding solvent were used to calculate the sequence-structure
fitness (Domingues, et al., Proteins, 37:112-120 (1999); Sippl, M.
J., J. Comput Aided Mol. Des, 7:473-501 (1993); and Sippl, M. J.,
Curr Opin Struct Biol, 5:229-235 (1995)). Gap restrictions were
used to control the number, size and placement of deletions and
insertions in the query sequence and the fold library entries: fold
and sequence deletion penalty, 300; fold and sequence penalty, 15;
and fold and sequence maximum gap length, 30. Fold information was
used as gap restraints: gaps were not allowed to be placed in
secondary structure elements and in the core of the fold. A gap
between adjacent residues in sequence was only accepted if the
distance bewteen them in the structure is less than 7 .ANG.. To
suppress the fragmentation on the sequence-structure alignment, a
minimum fragment size of 3 residues between two adjacent gaps was
used. The BLOSUM40 amino acid substitution matrix was used for
sequence comparison and scoring (Henrikoff, S. and Henrikoff. J.
G., Proc. Natl. Acad. Sci USA, 89:10915-10919(1995)).
[0481] A combination of four different scoring strategies was used
for final scoring and ranking: i) a combined energy score derived
from residue-residue and residue-solvent interactions (pair/surf);
ii) a sequence similarity score (seq); iii) a normalized
combination of both, pair/surf ands seq (Threading index; Th ldx.);
and iv) the ratio between the length of the fold (foldlength) and
the number of aligned residues that took part in the
sequence-structure alignment (pathlength).
[0482] The 3D models generated for the high scoring hits and their
respective sequence-structure alignments were analyzed graphically
by using the Peep module in ProCeryon (ProCeryon Biosciences,
Inc.). Structural classification schemes SCOP (Murzin et al., J.
Mol. Biol., 247:536-540 (1995)) and CATH (Orengo et al., Structure,
5:1093-1108 (1997)) were used to find all members of a fold and
look for the scoring of those in the ProFit output. Similar
structures of a fold were checked in the top-ranking hits in order
to confirm a fold annotation and to generate structure-based
protein function hypothesis.
[0483] Using the above described threading analysis, PRO842 (CK27)
encoded by DNA56855-1447 suggested structural homology to the
chemokine interleukin-8 (IL-8). Amino acid sequence identity
between the two proteins is low, however they both have a CXC
motif, which classifies IL-8 as a member of the CXC chemokine
family.
Example 13
Novel Cvtokine PRO842 (CK27) Plays a Role in the Inflammatory
Response
A. Expression Patterns of DNA56855 (CK27)
[0484] The expression pattern of CK27 was investigated in both
human and mouse multiple tissues. FIGS. 3 and 4 show the expression
pattern of CK27 as demonstrated by hybridization to a human
multiple tissue expression array. CK27 was highly expressed in
lung, stomach, and the trachea. In ovary, prostate, colon and fetal
lung, weak expression of CK27 was detected. In situ analysis
confirmed high expression of CK27 in normal lung and also showed
expression in tissue samples from patients with inflammed lungs and
asthma. The expression pattern of murine DNA56855 (CK27) is shown
in FIG. 5. In the mouse, significant levels of expression was
observed in the lung, thyroid, submaxillary gland and the
uterus.
B. PRO842 Chemoattracts Monocytes and Dendritic Cells
[0485] (1) Methods
[0486] Threading analysis of PRO842 (designated herein as CK27)
suggested a functional role for this novel chemokine similar to
IL-8. Interleukin-8 has long been characterized as a
proinflammatory cytokine and chemoattractant for neutrophils.
Accordingly, transwell migration assays were performed to
demonstrate the role of PRO842 (CK27) as a potential chemokine.
Peripheral blood mononuclear cells (PBMC) were isolated from human
peripheral blood by Hypaque-Ficoll density centrifugation.
Migration of PMBC towards PRO842 (CK27) was tested in 24-well
Transwell migration plates containing filters with 5 .mu.m pores.
10.sup.6 PBMC per well were used. After a 2.5 hour incubation at
37.degree. C. and 5% CO.sub.2, the number of cells and cell
populations migrated were analyzed by flow cytometry.
[0487] It is interesting to note that threading analysis of PRO842
(CK27) demonstrated the possession of a CXC motif, suggesting that
CK27 belongs to the family of CXC chemokines (see EXAMPLE 13).
Structural homology was also found to DNA39523, which has been
published as a novel chemokine (named MIP2-y) that also attracts
dendritic cells (Cao et al., Journal of Immunology, 165:2588-2595
(2000)). In addition to the presently identified chemokine PRO842
(CK27), MIP2-.gamma. and another related chemokine known as
SDF-.alpha. are the only CXC chemokines that attract dendritic
cells.
[0488] (2) Results
[0489] As described above, threading analysis of CK27 prompted
investigation of the chemoattractant properties of PRO842 (CK27).
Results of transwell migration assays are shown in FIGS. 6 through
8. These studies demonstrate that PRO842 (CK27) specifically
chemoattracts monocytes and dendritic cells (see FIG. 6). Different
lots of CK27 show similar chemoattractant activity (FIG. 7). Heat
treatment reduces the chemoattraction of CD11c.sup.+ (dendritic
cells) and CD14.sup.+ (monocytes) (FIG. 8). These data show that
CK27 specifically attracts monocytes and dendritic cells. However,
similar attraction of T-cells, B-cells or neutrophils was not
observed. Both cell types (monocytes and dendritic cells) play an
important role in the initiation of an immune response. Monocytes
and dendritic cells have the ability of phagocytosing antigens,
presenting antigens on their cell surface and activating T-cells by
direct cell-cell interactions and secretion of cytokines. The
present studies demonstrate that the novel chemokine PRO842 (CK27)
identified herein plays an important role in leukocyte trafficking
and may also function in the regulation of inflammatory responses.
In addition, CK27 may play a role similar to interleukin-8 in a
variety of homostatic and disease processes, including development,
hematopoiesis, allergies, angiogenesis, and oncogenesis. As
discussed below, studies involving human DNA56855 transgenic mice
suggest that CK27 plays an important role in the development of
ovarian cystic pathology.
C. Human DNA56855 (CK27) Transgenic Mouse Model Develop Cystic
Ovaries
[0490] Human 56855 cDNA was ligated 3' to the pRK splice
donor/acceptor site that was preceded by the myosin light chain
using the protocol described by Shani, M., Nature, 314:283-286
(1985). The 56855 cDNA was also followed by the splice
donor/acceptor sites present between the fourth and fifth exons of
the human growth hormone gene (Stewart, T. A. et al.,
Endocrinology, 130:405-14 (1992)). The entire expression fragment
was purified free from contaminating vector sequences and injected
into one cell mouse eggs derived from FVB.times.FVB matings. CK27
transgenic mice were identified by PCR analysis of DNA extracted
from tail biopsies. Expression was determined by real-time RT-PCR
(TaqMan.RTM.; Perkin Elmer) on total RNA from skeletal muscle
biopsies.
[0491] Mice expressing human DNA56855 (CK27) as a transgene under
the control of the MLCH promoter developed cystic ovaries by 12
weeks of age (see FIG. 9). Although in situ analysis showed
relatively specific expression in lung bronchial epithelium (see
EXAMPLE 12), CK27 transgenic mice had histologically normal lungs.
In addition, expression in tubule epithelium adjacent to the ovary
(human tissue) has been observed in situ, which may be relevant to
the changes seen in CK27 transgenic mice.
Deposit of Material
[0492] The following materials have been deposited with the
American Type Culture Collection, 10801 University Blvd., Manassas,
Va. 20110-2209, USA (ATCC): TABLE-US-00007 Material ATCC Dep. No.
Deposit Date DNA56855-1447 203004 Jun. 23, 1998
[0493] These deposits were made under the provisions of the
Budapest Treaty on the International Recognition of the Deposit of
Microorganisms for the Purpose of Patent Procedure and the
Regulations thereunder (Budapest Treaty). This assures maintenance
of a viable culture of the deposit for 30 years from the date of
deposit. The deposits will be made available by ATCC under the
terms of the Budapest Treaty, and subject to an agreement between
Genentech, Inc. and ATCC, which assures permanent and unrestricted
availability of the progeny of the culture of the deposit to the
public upon issuance of the pertinent U.S. patent or upon laying
open to the public of any U.S. or foreign patent application,
whichever comes first, and assures availability of the progeny to
one determined by the U.S. Commissioner of Patents and Trademarks
to be entitled thereto according to 35 USC .sctn. 122 and the
Commissioner's rules pursuant thereto (including 37 CFR .sctn. 1.14
with particular reference to 8860G 638).
[0494] The assignee of the present application has agreed that if a
culture of the materials on deposit should die or be lost or
destroyed when cultivated under suitable conditions, the materials
will be promptly replaced on notification with another of the same.
Availability of the deposited material is not to be construed as a
license to practice the invention in contravention of the rights
granted under the authority of any government in accordance with
its patent laws.
[0495] The foregoing written specification is considered to be
sufficient to enable one skilled in the art to practice the
invention. The present invention is not to be limited in scope by
the construct deposited, since the deposited embodiment is intended
as a single illustration of certain aspects of the invention and
any constructs that are functionally equivalent are within the
scope of this invention. The deposit of material herein does not
constitute an admission that the written description herein
contained is inadequate to enable the practice of any aspect of the
invention, including the best mode thereof, nor is it to be
construed as limiting the scope of the claims to the specific
illustrations that it represents. Indeed, various modifications of
the invention in addition to those shown and described herein will
become apparent to those skilled in the art from the foregoing
description and fall within the scope of the appended claims.
Sequence CWU 1
1
2 1 870 DNA Homo Sapien 1 ctcgccctca aatgggaacg ctggcctggg
actaaagcat agaccaccag 50 gctgagtatc ctgacctgag tcatccccag
ggatcaggag cctccagcag 100 ggaaccttcc attatattct tcaagcaact
tacagctgca ccgacagttg 150 cgatgaaagt tctaatctct tccctcctcc
tgttgctgcc actaatgctg 200 atgtccatgg tctctagcag cctgaatcca
ggggtcgcca gaggccacag 250 ggaccgaggc caggcttcta ggagatggct
ccaggaaggc ggccaagaat 300 gtgagtgcaa agattggttc ctgagagccc
cgagaagaaa attcatgaca 350 gtgtctgggc tgccaaagaa gcagtgcccc
tgtgatcatt tcaagggcaa 400 tgtgaagaaa acaagacacc aaaggcacca
cagaaagcca aacaagcatt 450 ccagagcctg ccagcaattt ctcaaacaat
gtcagctaag aagctttgct 500 ctgcctttgt aggagctctg agcgcccact
cttccaatta aacattctca 550 gccaagaaga cagtgagcac acctaccaga
cactcttctt ctcccacctc 600 actctcccac tgtacccacc cctaaatcat
tccagtgctc tcaaaaagca 650 tgtttttcaa gatcattttg tttgttgctc
tctctagtgt cttcttctct 700 cgtcagtctt agcctgtgcc ctccccttac
ccaggcttag gcttaattac 750 ctgaaagatt ccaggaaact gtagcttcct
agctagtgtc atttaacctt 800 aaatgcaatc aggaaagtag caaacagaag
tcaataaata tttttaaatg 850 tcaaaaaaaa aaaaaaaaaa 870 2 119 PRT Homo
Sapien 2 Met Lys Val Leu Ile Ser Ser Leu Leu Leu Leu Leu Pro Leu
Met 1 5 10 15 Leu Met Ser Met Val Ser Ser Ser Leu Asn Pro Gly Val
Ala Arg 20 25 30 Gly His Arg Asp Arg Gly Gln Ala Ser Arg Arg Trp
Leu Gln Glu 35 40 45 Gly Gly Gln Glu Cys Glu Cys Lys Asp Trp Phe
Leu Arg Ala Pro 50 55 60 Arg Arg Lys Phe Met Thr Val Ser Gly Leu
Pro Lys Lys Gln Cys 65 70 75 Pro Cys Asp His Phe Lys Gly Asn Val
Lys Lys Thr Arg His Gln 80 85 90 Arg His His Arg Lys Pro Asn Lys
His Ser Arg Ala Cys Gln Gln 95 100 105 Phe Leu Lys Gln Cys Gln Leu
Arg Ser Phe Ala Leu Pro Leu 110 115
* * * * *
References